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"Bring me a fig from the banyan tree. " 
"Here is one, father. " 
"Open it. " 
"Here it is cut open. " 
"What do you see ?" 
"Very tiny seeds, father. " 
"Cut open one of them. " 
IIHere, it is cut open. II 
"What do you see ?" 
"Nothing father. " 
"My dear boy ! This nothing which you do not perceive. 
That huge tree has sprung up from it. 
My dear boy, you must believe! 
This very nothing is self to all that exists. 
That is reality. That is self. 
And that you are, my son!" 
Chandogya Upanishad 
Voor Govinda, Papa, Mama en Mark 
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Part I 
General introduction 

Chapter 1 Introduction 
1.1 Macrophage fuuctions 
The human body has an extensive and specialized cellular network to defend against 
invading microorganisms, and to prevent the development and spread of neoplastic 
disease. The mononuclear phagocytic cells are important secretory cells that, through 
their receptors and secretory products, have a central and essential role in the initiation 
and maintenance of many immunologic and inflammatory processes. The secretory 
products are listed in Table l.1 [1]. The mononuclear phagocyte system [monocytes 
and macrophages (M.p)] is complex, representing a heterogeneous group of cells found 
in organs and tissues throughout the body. All these mononuclear phagocytic cells are 
derived from a stem cell in the bone marrow [1,2]. 
Table 1.1 Secretory products of macrophages [1]. 
- Bioactive lipids 
- Cytokines 
- Complement components 
- Coagulation factors 
- Enzymes 
neutral proteases 
lipases 
glucosaminidase 
lysosomal acid hydrolases 
deaminase 
- Inhibitors of enzymes and cytokines 
- Proteins of extracelluar matrix or cell adhesion 
- Bioactive oligopeptides 
- Sterol hormones 
- Purine and pyrimidine products 
- Reactive oxygen intermediates 
- Reactive nitrogen intermediates 
Inflammation is a multifunctional process, with both local and systemic features. The 
primary inflammatory response, the acute phase, is the migration of neutrophils, M.p 
and other leucocytes to the site of inflammation. Besides neutrophils, M.p also mediate 
the influx of leucocytes to the inflammatory site by generating chemotactic factors and 
providing a non-specific defence by ph ago- and pinocytosis combined with oxygen 
radical production and the release of lysosomal enzymes. In steady-state, M.p are also 
the key effector cells in the elimination of intracellular microorganisms, other 
pathogens, senescent cells and other waste products. 
During the inflammatory reaction, besides the non-specific response, M.p are also 
involved in initiating and maintaining the specific response. They regulate the cellular 
immune response by the recognition, processing and presentation of the antigen to 
lymphocytes. By modulating the lymphocyte functions with their secretory mediators, 
they are positively involved in the humoral immune response. Further, M.p mediate 
tumor cytotoxity through direct cell-cell contact, inhibit the tumor cell division and 
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lyse antibody-coated tumor cells with their secretory products. During the 
inflammatory response, as well as in steady-state, M¢ are involved in the regulation 
of the growth of committed haematopoietic progenitor cells by producing numerous 
homeopathic growth factors and providing a mechanical framework together with other 
stroma cells. Besides local effects, the inflammatory mediators also have systemical 
effects as they have access to the circulation and exert action at distant organs. 
The most important mediators produced by M¢ to regulate the specific response are 
eicosanoids and cytokines. Eicosanoids are biological active lipids and cytokines are 
polypeptides with a regulatory function [4-6]. 
1.2 Aim of the work 
The aim of this series of investigations was to obtain more insight in the actions of 
inflammatory mediators synthesized by human macrophages (M¢). Information 
presently available on M¢ and their inflammatory mediators have been obtained 
mainly from animals. The exact inflammatory mediator production by human M¢ and 
their mediator interactions still have to be characterized. 
1.2.1 Construction of the thesis 
Chapter 2 provides background information on M¢ and their inflammatory mediators 
for a better understanding of the series of experiments performed. 
In these experiments the production and interactions of inflammatory mediators by 
human peritoneal M¢ are characterized. Chapter 3 presents the investigation in which 
eicosanoid and cytokine production was studied in vitro using cells obtained from the 
rat peritoneal cavity during inflammatory response. All investigations following this 
experiment were performed using human M¢, which M¢ were obtained from a sterile 
chronic inflammation site: the peritoneal cavity of patients with accumulation of ascitic 
fluid. In Chapter 4, the influence of cellular maturation and activation on the 
eicosanoid production of density-defined human peritoneal M¢ is described. 
Subsequently the profile, levels and interactions of eicosanoids and cytokines from 
human M¢ are characterized and presented in Chapter 5, 6 and 7. 
As M¢ are predominantly present in ascites, the levels of eicosanoids, cytokines and 
ICAM-l, which plays a crucial role in the adhesion and migration of inflammatory 
cells, were measured in the ascitic fluid to correlate disease related patterns with these 
mediators for either diagnostic or prognostic purposes. These two studies are described 
in Chapter 8 and 9. 
M¢ have a central role in the initiation and maintenance of inflammatory diseases and, 
as shown in Chapters 5 and 7, the inflammatory mediator production of human M¢ 
differ, in part, from M¢ of other species. With the insight obtained on the production 
of inflammatory mediators by human peritoneal M¢ and the interactions of these 
mediators with each other, human peritoneal M¢ could be used as an in vitro model 
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to characterize the interactions of anti-inflammatory drugs with human M1>. 
Non-selective drugs are very effective in inflammatory diseases; however, they may 
have a considerable risk of side effects and potential complications with prolonged 
systemic use. Selective inhibition and neutralization by therapeutics are currently being 
developed to overcome these risks. Their effects in vivo could be more predictable 
when also tested in vitro using human M1>. For this reason the role of M1> and their 
mediators in several inflammatory diseases are described and the differential effects 
of non-selective and selective acting therapeutics using an in vitro model of human 
peritoneal M1>, are discussed in Chapter 10. 
1.3 References 
1. Nathan CF. Secretory products of macrophages. 1. Clin. Invest. 1987;79:319-326. 
2. Van Furth R, Cohn ZA. The origin and kinetics of mononuclear phagocytes. 1. Exp. Med. 
1968; 128:415-433. 
3. Volkman A, Gowans 1L. The origin of macrophages from bone marrow in the rat. Br. 1. 
Path. 1965;46:62-70. 
4. Papadimitriou 1M, Ashman RB. Macrophages: current vieuws on their differentiation, 
structure, and function. Ultrastruct. Patho!. 1989;13:343-372. 
5. Weiss L. Cell and tissue biology; a textbook of histology. 6th ed. Baltimore, Munich: Urban 
and Schwarzenberg. 1988;173-188. 
6. Auger MJ. Ross JA. The biology of the macrophage. In: Lewis CE, McGee O'D (eds). The 
natural immune system. The Macrophage. Oxford, New York, Tokyo: IRL Press. 1993;2-74. 
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Chapter 2 The mononuclear phagocyte system and its inflammatory 
mediators 
2.1 Mononuclear phagocyte heterogeneity 
The mononuclear phagocytes are a heterogeneous type of cells with both phenotypical 
and functional properties. A distinction can be made between inter- and intrapopulation 
heterogeneity. Interpopulation heterogeneity refers to differences between macrophage 
(M1» populations located at different anatomical sites as summarized in Table 2.1 
(Chapter I). whereas intrapopulation heterogeneity evidently refers to differences 
within the mononuclear phagocyte population from one particular morphological 
location [1-3]. 
Table 2.1 Cells of the mononuclear phagocytic system [II. 
Macrophages Location 
- Committed stem cells - Bone marrow 
- Monoblasts - Bone marrow 
- Promonocytes - Bone marrow 
- Monocytes - Bone marrow and blood 
- Macrophages 
Kupffer cells - Liver 
Alveolar macrophages - Lung 
Free and fixed macrophages - Spleen, lymph nodes,bone marrow, 
thymus, mucosa-associated 
lymphoid tissues, gastrointestinal 
tract, genitourinary tact, endocrine 
organs, colostrum 
Histiocytes - Connective tissue 
Pleural and peritoneal - Serous cavities 
macrophages 
Microgliacytes - Central nervous system 
Osteoclasts - Bone tissue 
Synovial type A - Joints 
- Epithelioid cells - Inflamed tissues 
- Multinucleated giant cells - Inflamed tissues 
The development of the various mononuclear phagocytes can be considered to consist 
of multiple processes which all are under tight regulatory control. The steps that 
contribute to phagocyte development are proliferation, maturation, and differentiation 
of progenitor cells as well as functional activation, mostly of mature cells. These 
processes can be defined as follows. Proliferation is the replication of cells giving rise 
to daughter cells that express characteristics similar to those of their parental cells. 
Maturation is the process of cells acquiring features typical of cells in later stages of 
development and losing aspects of earlier stages. Differentiation is a specific type of 
maturation by which diversity is generated. Both maturation and differentiation are, 
in principal. irreversible. In contrast, activation is a reversible process by which cells 
are driven to express particular functions or by which the performance of existing 
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functions is enhanced [i-3]. Figure 2.i presents a scheme of distinctive processes 
invoived in mononuclear phagocyte development [I]. 
Figure 2.1 A scheme of distinctive processes involved in mononuclear phagocyte development. P = 
proliferation; M = maturation; D = differentiation, A = activation; de-A = deactivation [1}. 
Table 2.2 Schematic representation of peroxidase activity of human mononuclear phagocytes in 
culture, in co-expression with the differentiation antigen RFD7 [5]. 
Localisation of Monoblast Pro- Monocyte Macrophage 
peroxidase activity monocyte 
Endoplasmatic + + 
-
± 
reticulum 
Nuclear envelope + + 
-
± 
Golgi apparatus + + 
- -
Lysosomal granules + + + 
-
RFm + 
- - -
Variabie phenotypic characteristics include size, morphology, intracellular enzymes and 
secreted substances (Table l.i) as well as surface receptors. Many of these features 
can be used as markers to distinguish between deveiopment stages. Peroxidase activity 
patterns can, for example, be used to distinguish the developmental stages of 
mononuclear phagocytes. With electron microscopy the iocalisation of peroxidase 
activity can be detected. This peroxidase activity pattern has been important in 
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classifying the activation and developmental stages of mononuclear phagocytes. Besides 
the animal system, these studies have also been performed in human mononuclear cells 
[4,5]. The monoclonal antibodies against mononuclear phagocytes (mice and human) 
have facilitated the identification and functional investigation of the various cell surface 
molecules present, and have shown that the mononuclear phagocyte system is far more 
complex and heterogeneous than was previously thought [1-3]. 
Table 2.2 shows that during differentiation (6-day period in vitro) the peroxidase 
activity of human monocytes disappears, parallel with the expression of the 
differentiation antigen RFD7 on the cell surface [5]. 
2.2 Development of monocytes 
The monocyte in the peripheral blood is derived from a stem cell in the bone marrow 
[6,7] by passing through different stages. The pluripotent haemopoietic stem cells 
(PHSC) self-generate and generate different progenitor cells [8]. One of them, the 
granulocyte/macrophage colony forming cell (GM-CFC) will form the macrophage and 
granulocyte lineage. In the macrophage lineage, GM-CFC will give rise to the 
restricted macrophage colony-forming cells (M-CFC) [9]. The M-CFC will generate 
the monoblast, which divides into two promonocytes [10,11]. The promonocyte will 
divide once, leading to two bone marrow monocytes [12]. These bone marrow 
monocytes, with a generation time of about 24 hours for mice will not divide further, 
and leave the bone marrow compartment and enter the blood stream [6]. 
The blood monocytes will distribute over a circulating and marginating pool [13] and 
stay there with a half-disappearance time of 17.4 hours in mice [14]; subsequently they 
migrate through the vascular wall into the tissues and do not return into the peripheral 
blood stream [6]. 
During an acute inflammatory reaction the number of monocytes increases at the site 
of the inflammation [6,14]. This is due to the decreased cell cycle time of the 
promonocytes, leading to an enhanced influx of monocytes into the peripheral blood 
compartment and a decreased half-disappearance time (10 hours in mice), leading to 
an increased efflux of monocytes out of the peripheral blood compartment [14]. 
Studies on the origin of mononuclear phagocytes and kinetics were mainly performed 
in mice. Kinetical studies and phenotypical studies on mononuclear phagocytes of other 
animal species gave similar results [rat (7, 15); rabbit (16); guinea pig (17,18)]. With 
bone marrow transplantation studies it was demonstrated that human Mq, also originate 
from the bone marrow [19-21]. A few kinetical studies have been done on human 
mononuclear phagocytes. One study demonstrated that in healthy human the half-
disappearance time of monocytes out of the peripheral blood compartment was 71 
hours [22], whereas another study demonstrated that this half-disappearance time for 
healthy human was 8.4 hours. In patients with acute or chronic inflammation this 
monocyte turnover did not change [23]. 
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2.3 Trans-endothelial migration of monocytes 
Transendothelial migration is a multistep process in which three families of adhesion 
receptors are involved. The initial attachment of leucocytes to a vessel wall ("rolling") 
is mediated by selectins, present on endothelium and leucocytes. The roIling process 
is arrested by the activation of integrin and immunoglobin superfamily proteins and 
leads to firm attachment of the leucocytes, followed by shape changes and migration 
through the endothelium. Figure 2.2 shows the steps involved in the binding and trans-
endothelial migration of leucocytes [24-26]. 
Medintors of inflammation Mediators of inflammation 
{(\ _Endothelial cell ~ adhesion molecules 
Figure 2.2 The subsequent phases of the migration of monocytes through vascular endothelium [27J. 
The selectins consist primarily of L-selectin, E-selectin and P-selectin. The 
immunoglobulin superfamily include the intercellular adhesion molecule I ([CAM· I) 
and the vascular cell adhesion molecule 1 (VCAM-l). The integrins include the 
specifically lymphocyte-function-associated molecule 1 (LFA-l) and the very-late-
antigen 4 (VLA-4). The functions and specificities are shown in Table 2.3 [24-26]. 
rCAM -1 is one of the adhesion molecules which has a crucial role in transendothelial 
migration in inflammation. rCAM-I is a single-chain membrane-bound glycoprotein 
that is encoded by genes of the super immunoglobulin family and consists of five 
extracellulair domains, a transmembrane portion and a cytoplasmatic tail. rCAM-I is 
a ligand for LFA-I, which is only expressed on leucocytes [26,28]. rCAM-I is 
expressed on endothelial cells, but also on a wide variety of other cells, including 
fibroblasts, epithelial cells, mucosal cells, human melanoma cell lines, lymphocytes 
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and monocytes [26,29,30]. Expression ofICAM-l on different types of cells and the 
binding capacity of monocytes to macrovascular endothelial cells in vitro, is 
upregulated by cytokines such as interleukin 1 (IL-l), tumor necrosis factor a (TNF-
a), interferon -y (IFN--y) [29,31,32] and also by the chemoattractants like leukotriene 
B, (LTB,) and complement factor 5a (C5a) [33]. These chemoaltractants increase the 
speed of migration and control the orientation and movement of the monocytes in a 
specific direction. 
Table 2.3 Adhesion molecules involved in leucocyte binding to endothelium [24-26}. 
Adhesion Tissue distribution Implicated in: 
Molecule 
Selectins 
L-selectin - Allieucocytes, varying density - Leucocyte rolling 
P-selectin - Megakaryocytes, platelets, - Leucocyte rolling 
endothelium - Lymph node homing 
E-selectin - Cytokine-activated endothelium 
Integrins 
LFA-! - Leucocytes - Firm adhesion 
VLA-4 - Leucocytes - Homing to inflamed 
tissue 
Immunoglobulin 
Superfamily 
ICAM-! - Widespread constituve, - Transendothel ial 
cytokine inducible migration 
VCAM-! - Endothelium, epithelium, - Transendothelial 
macrophage, dendritic celIs, migration 
cytokine inducible 
2.4 Development of macrophages 
In normal, non-inflammatory situations, blood monocytes will differentiate through 
exudate M.p and exudate-resident M.p into resident tissue M.p [4,34] forming the 
various pools of local tissue M.p. In the steady state resident M.p will occur both freely 
as well as fixed in the tissue of most organs, each organ containing its own 
characteristic resident M.p populations [35,36]. 
Under steady-state conditions the monocytes replace the resident M.p. The lifespan of 
tissue M.p is not known exactly, but studies of bone marrow chimeras and repopulation 
kinetics following M.p depletion indicate a turnover time in the order of weeks in mice 
[37] and months in man [19,21]. Some studies suggest that the steady-state M.p 
populations are only maintained by local proliferation [38-40]. Others suggest that 
besides the replacement of resident M.p by monocytes, there is only a small number 
« 5 %) of non-resident M.p which have not completed their cell division and they 
divide further locally [37,41]. 
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During immunological stress conditions (acute and chronic) relatively larger numbers 
of monocytes enter the tissues and accumulate as responsive M.p. The local production 
of M.p does not play an important role in this increase [42-44]. 
2.5 Macrophage activation 
The monocytes which migrate during immunological stress to the inflammatory area 
have a large and diverse potential for further development. It is not clear why these 
monocytes are more responsive to induction than resident tissue M.p, but probably this 
is because they interact with a larger variety of inflammatory mediators which are not 
present, or present in a lower concentration under conditions when there is no 
inflammation. The development state of the monocytes and the adherence at the 
inflammation site could also be of importance. These inflammatory monocytes are the 
young responsive M.p which probably have the potential for being activated in 
numerOUS different ways by inductive and suppressive signals, as put forward by the 
macrophage activation model presented in Figure 2.3 [45]. Each state represents the 
enhancement of one or mOre functions and the suppression of others [45,46]. 
~M~ activated 
~forF4 
or or 
Y B + H 
X lrA or F 
~~~~~~~ ~XOryJ~AorB~C~~~ 
M ~ activated 
for F5 X 
M ~ activated 
for F1 and F2 lRespons,ve MO ~ReStlng tissue ~MO 
M 121 activated 
for F2 and F3 
Figure 2.3 Model of macrophage activation. Responsive macrophages can develop in a large number 
of ways for complex functions (FI-FS), by receiving inductive signals (A-H) and/or suppressive 
signals (X-Z) [45]. 
This model of macrophage activation for multiple functions is based on the earlier 
developed model of M.p activation for tumor cytolysis, shown in Figure 2.4: 
Responsive M.p get "primed" by IFN--y and "fully activated" by lipopolysaccharide 
(LPS). In each state certain markers appear or disappear and certain functions are 
turned off Or on [47]. 
12 
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Responsive M~ Primed M,p Activated M~ 
Capacities J, . Ia ++++ Ia ++ 
TFR ++++ TFR • TFR· 
LFA·l ~ LFA·l ++++ LFA·l ++++ 
Secretion CP and Secretion of CP and Secretion of CP and 
TNF-a· TNF+-O!- TNF-a ++++ 
Secretion ROi - Secretion of ROi + + + Secretion of ROI + + + 
Bind tumor cells - Bind tumor cells Bind tumor cells 
++++ ++++ 
Functions Elevated chemotaxis Elevated cbemotaxis and Elevated Chemotaxis 
and phagocytosis pbagocytis and phagocytosis 
Proliferate Do not proliferate Do not proliferate 
Microbicidal Microbicidal 
Present antigen Kill tumor cells 
Figure 2.4 Early developed macrophage activating model for tumor cytolysis. Interferon-), (IFN-)') 
primes the macrophage and lipopolysaccharide (LPS) converts it to the fully activated form. The 
capacities and functions of the ?lacrophage varies with the stage of activation [47]. 
2.6 Modulators of macrophage activation 
The extracellular signals which can regulate M</> activation are a wide range of 
cytokines (e.g. interferons, interleukins, colony stimulating factors and growth factors), 
eicosanoids and mediators which are not produced by cells such as LPS. Eicosanoids 
are biological active lipids, mainly produced by cells participating in the inflammatory 
responses. They interact with specific membrane receptors. Cytokines are soluble 
polypeptides which modulate cellular functions through interaction with specific 
membrane receptors. By initiating signal transduction, the eicosanoid- and cytokine-
receptor complexes will alter the cell function. In section 2.8 the characteristics of the 
eicosanoids and cytokines will be described. 
Lipopolysaccharide (IPS): LPS (or endotoxin) provides a potent and pleiotropic 
stimulus for mononuclear cells. It stimulates the release of pro-inflammatory cytokines 
like IL-l, IL-6, TNF-a, and also the release ofIL-l receptor antagonist (lL-lra) and 
eicosanoids. It increases the adherence to endothelium and increases the respiratory 
burst activity [48,49]. 
LPS, a complex glycolipid, is the major component of the outermost membrane of 
Gram-negative bacteria. Structurally, LPS consists of a variable polysaccharide domain 
covalently bound to a diglucosamine based acylated phospholipid, lipid A. Lipid A 
domain is highly conserved and is responsible for most of the biological effects of LPS 
[50]. 
LPS binding protein (LBP) is a 60-kD acute phase protein present in sera [51] and 
synthesized in the liver [52]. It acts as an opsonin [53,54] as it binds to the lipid A 
moiety ofLPS [55], the LPS-LBP complex then binds to the receptor CDI4, a 55-kD 
glycoprotein, on mononuclear cells [56]. This binding leads to enhanced activation of 
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the mononuclear cells to produce mediators. Not known is whether the binding of the 
complex to CDI4 alone is sufficient enough to induce production of mediators, or that 
CD 14 does not issue signals but instead enables LPS to activate a second receptor. 
LPS may activate also certain receptors directly, without help from LBP or CDI4 [57]. 
lnteiferon-r (IFN-r): IFN-r is a cytokine [(20-25 kDa) 58] that is known as a factor 
that elicits the inflammatory responses of LPS on Mq, [59]; however, this depends on 
the underlying activating state of the Mq, [60]. IFN-r is a product of T-lymphocytes 
and natural killer cells, that alters the function of M¢ by interacting with a specific 
surface receptor on Mq, [61]. 
Calcium: Calcium ionophore A23187 activates Mq, by inducing a rapid calcium influx. 
[62]. 
2.7 Signal transduction mechanism 
Signal transduction: Binding of agonists, the extracellular signal, to specific receptors 
on the outer surface of the lipid bilayer cell membrane usually causes activation of G-
proteins on the inner surface of the cell membrane. G-proteins are a class of proteins 
that couple temporarily activation of receptors to either activation or inhibition of other 
effectors, e.g. activation of adenylyl cyclase, phospholipase C (PLC), cyclic 
3' ,5' guanosine monophosphate (cGMP), phosphodiesterase and calcium and potassium 
channels, leading to the generation of second messengers, respectively cyclic 3' ,5' 
adenosine monophosphate (cAMP), 1,2 diacylglycerol (DAG) and inositol 1,4,5-
triphosphate (IP,), cGMP and mobilization of Ca2+ [63]. 
These second messengers are able to activate a subgroup of protein kinases: the 
serine/threonine kinases. The other subgroup, the tyrosine kinases, are activated 
directly by their receptors. The protein kinases are enzymes which are part of the 
mechanism which regulate the cellular functions by phosphorylation. Phosphorylation 
alters the biological properties of the phosphorylated enzymes [64]. 
Protein phosphatases, dephosphorylating enzymes, are also involved in cellular 
regulation; however, the knowledge about their role in vivo is still premature [64,65]. 
Table 2.4 presents a summary of the protein kinases and protein phosphatases. 
Phosphoinositide (PI) metabolism: The PI metabolism is an important source of second 
messengers. PLC phosphorylates phosphatidylinositol 4,5-biphosphate (PIP,) into IP, 
and DAG. Both products are second messengers. 
IP, will stimulate an intracellular Ca2+ influx from the endoplasmatic reticulum [66,67] 
and also elicits extracellular Ca2+ by activating Ca'+ release-activated channels and 
second-messenger-operated channels. There are also Ca2+ channels which are activated 
by other second messengers (e.g. Ca2+ and inositol 1,3,4,5-tetra phosphate (IP4», G-
proteins or directly by a receptor [68]. 
14 
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The other second messenger released by the PI metabolism, DAG, in combination with 
Ca2 + will activate protein kinase C (PKC). PKC is a serine/threonine kinase that was 
first characterized by Nishizuki as a Ca2+ and DAG dependent enzyme [66,67]. PKC 
is now known to be a large family of proteins with at least 12 isotypes. Besides the 
PKCs which are Ca2+ and DAG dependent, there is a group of PKCs which does not 
depend on Ca2 +, and another PKC group which depends neither on DAG nor Ca2+. 
Most probably, activation of individual PKC isotypes will lead to the phosphorylation 
of unique substrates [69]. 
Table 2.4 Protein kinases and protein phosphatases [64]. 
Enzymes Regulates 
Serine/Threonine Kinases 
Cyclic AMP-dependent protein kinase cAMP 
(type I and II) 
Cyclic GMP-dependent protein kinase cGMP 
Phosphorylase kinase Ca2 +/calmodulin 
Myosin light-chain kinase Ca2 + Icalmodulin 
Ca2+ /calmodulin kinase I, III Ca2 + Icalmodulin 
Ca2 + /calmodulin kinase II Ca2+ Icalmodulin 
Protein kinase C CaH Iphospholipid 
Casein kinase II Polyamine 
Casein kinase I Unknown 
Glycogen synthase kinase 3 Unknown 
Tyrosine Kinase 
Insulin receptor kinase Insulin 
PDGF receptor kinase PDGF 
EGF receptor kinase EGF 
Oncogen production Unknown 
Serine/Threonine Phosphatases 
Protein phosphatase-l Inhibitor 1,2 
ATP/Mg-dependent phosphatase Glycogen synthase kinase 3; 
Inhibitor 1,2 
Protein phosphatase-2A Polyamines/G-substrate 
Protein phosphatase-2B Ca2 + /calmodulin 
Protein phosphatase-2C Mg2+ 
Tyrosine Phosphatase ? 
Phosphatidyl choline (PC) metabolism: PI is not the only source for DAG. In recent 
years it has become clear that PC is an important source for DAG at a relatively later 
phase. PC can be hydrolized by PLC directly into DAG or PC is hydrolized by 
phospholipase D (PLD) into phosphatic acid [(PA), 70], which is then converted by 
phosphatic acid phosphomonoesterase into DAG. This DAG then gives then probably 
sustained activation of PKC, which is essential for subsequent responses such as cell 
proliferation and differentiation [71]. PA and its metabolic product (lysoPA) may also 
be activators ofPKC, PLC and PLD [72]. Phospholipase A2 (PLA2) hydrolizes PC into 
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free fatty acids and lysoPC. Cis unsaturated fatty acids and lysoPC enhance the DAG-
dependent activation of PKC [71]. Figure 2.5 presents a schematic diagram of events 
following receptor activation by an external stimulus. 
The M¢ modulators: The transductional mechanism induced by lFN--y and LPS have 
been intensively studied. IFN--y triggers the signalling cascade by activating tyrosine 
kinases. This will induce a rise in intracellular levels of Ca'+, raising the potential 
function of PKC, without initiating the phosphorylation [73] and they will also induce 
a set of immediate early genes [74]. 
LPS will initiate the rapid hydrolysis of PIP, by PLC, activating PKC [73]. 
Extracelluar calcium influx, induced by calcium ionophore, can directly activate 
calcium dependent enzymes [62]. 
Signal pathway after phosphorylation: The ionic changes (e.g. rCa +] increase or 
Na + IH+ exchange) generated by the second messengers and the activated protein 
kinases and phosphatases will covalent modify regulatory proteins and enhance binding 
of nuclear regulatory factors, leading to the regulation at transcriptional and translation 
level of specific genes. Protein products of immediate-early genes in combination with 
ionic changes and modified proteins will lead to execution of rapid functions. The 
rapid response will lead to the initiation of chemotaxis, secretion of metabolites of 
arachidonic acid, neutral proteases, lysosomal hydrolases and radical oxygen 
intermediates (ROI). The protein products of the later appearing genes, also in 
combination with ionic changes and modificated proteins, can lead to enhanced 
potential for execution of complex functions. The long-term responses will include 
development changes [45]. 
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Figure 2.5 A schematic diagram of events following receptor activation by an external stimulus. See 
text for details and abbrevations used (PKA = protein kinase A). 
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2.8 Mediator production by macrophages 
Important secretory products of the Mq" which are key mediators of immunity and 
inflammation, are the eicosanoids and cytokines. 
2.8.1 Eicosanoids 
Production: The eicosanoids are biological active lipids. They are not stored in cellular 
"pools", but are synthesized directly from free 20-carbon essential fatty acid-precursors 
(dihomo-'Y-liolenic acid, arachidonic acid (AA), 5,8, 11,14, 17-eicosapentaenic acid). 
These free fatty acid-precursors become available when the cell membrane is disturbed 
and certain enzymes are activated. In man, AA is the most abundant precursor, and 
is in large amounts esterified to phospholipids [PC and phosphatidylethanolamine (PE)] 
and, to a smaller degree, in triacylglycerols in the cell membrane. AA is mainly 
ingested directly from the diet, but it can also be derived from dietary linoleic acid by 
anabolic desaturation and chain elongation. By hydrolysing the phospholipids 
containing the esterified arachidonate by PLA" free nonesterified AA will become 
available. This AA can also become available from the phospholipids by PLC or PLD 
and diacylglycerol lipase, or from the PI by the phosphatidylinositol-specific PLC 
[75,76]. The free nonesterified AA can then, besides efficient reesterfication into 
phospholipids, be further oxidized by two main enzyme systems: the fatty acid 
cyciooxygenase forming the enderoperoxyden (prostanoids) or the lipoxygenases 
forming the hydroperoxy fatty acids (leukotrienes). 
Figure 2.6 shows the eicosanoids formed from AA through the lipoxy- and cycio-
oxygenase pathways. The initial product via the lipoxygenase pathway by 5-
lipoxygenase is the relatively unstable 5-hydroperoxy eicosatetraenoic acid (5-HPETE). 
5-HPETE can be reduced to 5-hydroxy eicosatetraenoate (S-HETE) or converted by 
dehydrase to the labile epoxide leukotriene A4 (LTA4)' LTA4 can be metabolized 
further into two pathways. Hydrolysing ofLTA4 by LTA4 hydrolase yields LTB4 and 
conjugation ofLTA4 with glutathione generates LTC4. Stepwise cleavage of glutamate 
and glycine from LTC4 by 'Y-gluamyltransferase and dipeptidase yields LTD, and 
LTE4, respectively. Via 12- and 15-lipoxygenase the relatively unstable 5- and 12-
HPETE are reduced to 12- and 15-HETE [76-78]. 
The initial product via the cyclooxygenase pathway by prostaglandin endoperoxide 
synthase (POH), is the prostaglandin O2 (POO,). POO, is further oxidized by the same 
enzyme to the precursor of the prostanoids, POH,. POH2 is transformed to POD2 , 
PO~, POF,", POI2 and thromboxane A, (TXA2). POD2 and PO~ by specific 
isomerases or nonenzymatic degradation, POF," by reductase and TXA2 by 
thromboxane synthase. TXA2 is an unstable mediator which hydrolyses spontaneously 
to TXB2 . POI, (unstable) by prostacycline synthase produces from POH2 . POI, is 
hydrolysed quickly to 6-keto-POF la [6kPOF1", 75-77]. 
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Figure 2.6 Eicosanoids formed from arachidonic acid by lipoxy- and cyclooxygenase enzymes 
[75,79]. 
Sources: The inflammatory cells participating in the inflammatory response are the 
main source of a variety of eicosanoids. Tissues (e.g. skin, brain, intestine, kidney, 
heart, lung, spleen and blood vasculature) are also able to synthesize eicosanoids in 
response to a variety of stimuli [76,79]. The eicosanoid production is cell specific, (as 
summarized in Table 2.5) for human cells, but also depending on species origin and 
the type of stimuli which induces the eicosanoid production [80-91]. 
Table 2.5 Eicosanoid production by human cells (*=Table 2.6, *"=reference [80-91]. 
i Cell type LTB, LTC, 5- PGE, PGD, 6k- TXB, 
RETE PGF," 
Macrophages * * * * * * * 
Neutrophils *85/83 *"' *"' *"' *"' 
Eosinophils *" *83/84 
Mast cells *"' *"' *w *w 
Basophils *~H *" 
Endothelial *" *"' *&6187189 
cells 
Platelets *"' *" 
T-Iymphocytes *"" 
Eicosanoid production by M</>: In Table 2.6 [92-125] an overview is given of 
eicosanoid production by resident and activated M</> of different species (human, rat 
and mice), different origin (alveolar, peritoneal, blood monocytes) and stimulated in 
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vitro by different exogenous stimuli [A23187, LPS, zymosan or (phorboI12-myristate 
l3-acetate (TPA)]. The eicosanoid production by MqI is species dependent. 
Besides species, tissue and exogenous stimuli differences, the experiments summarized 
in Table 2.6 also differ in the manner MqI were activated in vivo, the method used for 
the isolation of the cells, the incubation times of the cells in vitro, the concentrations 
of the stimuli, and the way eicosanoids were measured in the supernatant after the 
incubations were performed [high performance liquid chromatography (HPLC) and 
radio-immuno-assays (RIA)]. The concentrations of the eicosanoid production were 
expressed in ng/106 cells, ng/mg cell protein, % of total production, dpm/mg cell 
protein or only dpm/cpm. To compare the results the productions are expressed in 
Table 2.6 as: (I) not detectable: n.d; (2) just detectable but very low production: (+); 
(3) low production: +; (4) high production: + +; and (5) very high production: 
+ + +. A detailed overview of Table 2.6, is given below: 
The 5-lipoxygenase production of human M,p and monocytes: In human peritoneal 
and alveolar MqI (resident and activated) the LTB, and 5-HETE production was very 
high when the cells were stimulated with A23187. Human alveolar MqI produce LTC,; 
however, compared with the LTB4 production of the peritoneal MqI as well as the 
alveolar MqI itself, LTC, production is much lower or not detectable. 
The human blood monocytes also had a very high LTB, production and a high LTC, 
production compared with human MqI, but 5-HETE was not detectable when the 
monocytes were stimulated with A23l87. 
The 5-lipoxygenase production of rat M,p: In contrast to the human peritoneal and 
alveolar MqI, the LTB4 production of resident peritoneal rat MqI were very low when 
stimulated with A23187 or LPS. In in vivo activated and in vitro A23187 stimulated 
peritoneal rat MqI, the LTB, production was not detectable. 5-HETE production was 
also low in resident peritoneal rat MqI, but higher in activated MqI (A23187 
stimulated). LTC, production in resident peritoneal rat MqI (A23l87) was only high 
when the rat was endotoxin tolerant. 
The LTB, and 5-HETE production of resident alveolar rat MqI was higher than the 
production of resident rat peritoneal MqI (A23l87 stimulation). Only activated rat 
Kupffer cells (A23l87) had a very high LTB, and 5-HETE production level. 
The 5-lipoxygenase production of murine M,p: Similar to the rat peritoneal MqI, the 
LTB4 production of resident peritoneal murine MqI was also low (A23187 stimulated). 
The cyc\ooxygenase production of human M</>: In human resident peritoneal MqI 
from continuous ambulatory peritoneal dialysis (CAPD) patients the PGE, and PGI2 
production was very high when these cells were stimulated with LPS. PGI2 , but not 
PGE, production, decreased when these MqI were activated in vivo. 
With A23187 the PGE, production was lower and the PGI2 production of the activated 
peritoneal MqI from CAPD patients was higher, in comparison to the same cells when 
they were stimulated in vitro with LPS. No data were available on the PGE, 
production of resident peritoneal M¢ from CAPO patients stimulated with A23187, the 
PGI, production was low. 
Of resident ascitic M,p only data on eicosanoid production were available of cells 
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stimulated with A23187; PGE2 was not detectable and the PGI, production was low. 
Similar results as the ascitic M¢ were observed with human resident alveolar M¢ 
when they were stimulated with A23l87 or LPS. 
On the contrary, the PGE, production in cultured human blood monocytes was high 
when stimulated with A23187. 
The cyclooxygenase production of rat Mq,: In resident rat peritoneal M¢, PGI, was 
high when stimulated with A23187 and very high when stimulated with LPS. The 
PGE, production of these cells was low when stimulated with A23l87 or LPS. While 
in active rat peritoneal M¢ the PGE, was low to high (depending on the experiment) 
and PGI2 production low, when stimulated with A23187. 
In resident rat alveolar M¢ the prostaglandin production is similar to resident human 
alveolar M¢ when stimulated with A23187. 
In resident rat Kupffer cells the PGE, and PGI2 production was very low, and the 
PGD2 was very high when stimulated with A23l87. In in vivo activated rat Kupffer 
cells PGD2 was also low after A23187 stimulation. In all the other M¢ of different 
species or origin PGD2 production was low, not detectable or not measured. 
The cyclooxygenase production of murine M¢: In resident peritoneal murine M¢ the 
PGE2 and PGI2 production was high when stimulated with LPS, PGI2 was lower when 
the cells were stimulated with A23l87. 
Constitutive and inducible cyclooxygenase (COX): Prostaglandin endoperoxide synthase 
(PGH), the enzyme which exhibits both cyclooxygenase and peroxidase activity, also 
known as COX [126], has two isoforms: COX-l and COX-2. COX-l is encoded by 
a different gene than COX-2 [127,128]. COX-l is constitutively expressed (stomach, 
intestine, kidney, platelets), while COX-2 expression is inducible (10-80 times in 
comparison to expression under normal physiological conditions) in a number of cells 
(e.g. monocytes, M¢, fibroblasts, synovium) by pro-inflammatory stimuli (growth 
factors, cytokines, endotoxin). Under normal conditions there is no expression in the 
gastrointestinal tract [129,130]. 
COX-l and COX-2 are both localized in the endoplasmatic reticulum and nuclear 
membrane. [131]. 
The exact functions of the COX isozymes is not yet known, but recent studies have 
proposed that COX-l is involved in the production of prostaglandins involved in 
cellular "housekeeping functions". These prostaglandins regulate the normal kidney and 
gastric functions and vascular homeostasis. Prostaglandins which are rapidly and 
transiently produced by COX-2 are most probably involved in inflammation and may 
also be involved in regulating cellular proliferation [129]. 
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Mechanism of action: Regulation of the eicosanoid production and action can be 
mediated at different levels as the eicosanoids are released extracelluar and their 
biological effects are receptor-mediated: (I) precursor-incorporation level; (2) 
phospholipid-release level; (3) cyclooxygenase and lipoxygenase enzyme level; and (4) 
receptor level. 
The receptor classification has been based upon the amplication of classical 
pharmacological criteria including: (1) a comparison of the rank order of agonist 
potency; (2) the evaluation of the structure-activity relationships of agonists; (3) the use 
of selective antagonists; (4) radioligand binding analyses; and (5) characterizing of 
transduction processes. The Ieukotriene receptors are classified into LTB4, LTC, and 
LTD4 and the prostanoid receptors are classified into DP, EPI-3, FP, IP and TP 
receptors, as summarized in Table 2.7 [132]. The leukotrienes and prostanoids 
receptors are all G-protein coupled. These G-proteins stimulate or inhibit adenylate 
cyclase, stimulate PLC, PLA" stimulate cGMP-phosphodiesterase, modulate the 
opening ofK+ channels, stimulate Ca'+ mobilization and PKC activation [75,133,134]. 
Table 2.7 Eicosanoid receptors [132]. 
Nomenclature Potency order Predominant 
effectors 
LTB, LTB, > 12r-HETE IP,IDAG 
LTC, LTC.2-LTD,> >LTE, -
LTD, LTD, = L TC.2-L TE, IP,IDAG 
DP PGD, > PGE"PGI"PGF"" TXA, cAMPI 
FP PGF", > PGD, > PGE, > PGI" TXA, IP,/DAG 
IP PGI,> > PGD"PGE"PGF", > TXA, cAMP! 
TP TXA,=PGH,> > PGD"PGE"PGF""PGI, IP,/DAG 
EP, PGE, > PGF""PGI, > PGD"TXA, IP,/DAG 
EP, PGE, > PGF ""PGI, > PGD" TXA, cAMPI 
EP, PGE, > PGF""PGI, > PGD" TXA, cAMP. + IP,/DAG 
Biological properties: The leukotrienes have potent biological actions in a number of 
areas. LTB, is regarded as an important inflammatory mediator in vivo as it primarily 
effects leucocytes (leucotactic), which results in chemotaxis, aggregation, increase of 
vascular permeability, superoxide release and degranulation. The cysteinyI leukotrienes 
(LTC" LTD4, LTE4) primarily affect smooth muscle cells. These leukotrienes have an 
important role in bronchoconstriction, increase microvascular permeability in the 
airways and are able to decrease blood pressure by action on the heart [78,135]. 
Prostanoids exhibit distinct biological effects during inflammation: pro-inflammatory 
such as pain (PGE,), vasodilation and edema formation and inhibition of platelet 
aggregation (PGD2• PGEz, PGI,) , platelet aggregation and vasoconstriction (TXB2) 
[136]. PGEz and PGE analogues have probably also an anti-inflammatory role during 
inflammation via raising cAMP [137]. In 1973 it was already shown that PGE j 
suppresses acute carageenan-induced inflammation and chronic joint inflammation 
characteristic of adjuvant disease in the rat [138]. Different anti-inflammatory actions 
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of PGE, and its analogues are known, such as the inhibition of the TNF-a production 
[139], the inhibitory effect on IL-l expression [140], reduction of granulomas [141] 
and mucosal protective effects [142]. 
Platelet activating factor (PAF): When in inflammatory cells, (e.g. Mq" neutrophils, 
eosinophils, platelets and endothelial cells) in response to different stimuli (e.g. 
A23187, TNF-a, zymosan) PLA2 hydrolyses PC into AA. PAF (1-0-alkyl-2-acetyl-sn-
glycero-3-phosphocholine) can then be formed by acetyltransferase from lyso-PAF. 
There is substantial evidence that PAF has an important role in various physiological 
and pathophysiological episodes, e.g. platelet aggregation, stimulation of neutrophils 
and Mq" acute inflammation, asthma, shock, sepsis and multiple organ failure. 
There are specific PAF receptors on inflammatory cells which are linked to G-proteins. 
When these receptors are activated, they activate PLA, and PLC, inducing the cascade 
of signal transduction mechanism and hereby also stimulating the eicosanoid production 
[143,144]. 
2.8.2 Cytokines 
Cytokines are defined as follows: "Cytokines are regulatory proteins secreted by white 
blood cells and a variety of other cells in the body; the pleiotropic actions of cytokines 
include numerous effects on cells of the immune system and modulation of 
inflammatory responses" [145]. They are a heterogeneous group of proteins with a 
number of characteristics in common: (I) Cytokines are low molecular weight « 80 
kDa) secreted proteins which are often glycolysed; (2) The constitutive production is 
usually low or absent: production is regulated by various inducing stimuli at the level 
of transcription and translation; (3) They are usually produced transiently and locally, 
the action radius is usually short (acting in a paracrine or autocrine, but not in an 
endocrine way; (4) Cytokines are extremely potent, generally acting at picomolar 
concentrations; (5) They interact with high affinity cell surface receptors specific for 
each cytokine or cytokine group; (6) Their cell surface binding ultimately leads to a 
change in the pattern of cellular RNA and protein synthesis, and to altered cell 
behaviour: increase/decrease cell proliferation, change in cell differentiation stage 
and/or change in differentiated functions; (7) Individual cytokines have multiple 
overlapping cell regulatory actions. The response of a cell to a given cytokine is 
dependent on the local concentration of the cytokine, the cell type and other cell 
regulators to which it is concomitantly exposed; (8) Cytokines interact in a network 
firstly by inducing each other, secondly by transmodulating cytokine cell surface 
receptors and thirdly by synergistic, additive or antagonistic interactions on cell 
function [145,146]. 
The cytokine receptors form a superfamily. They are all transmembrane glycoproteins 
made up of an extracelluar amino-terminal ligand binding domain, a short hydrophobic 
transmembrane region and a carboxy-terminal intracellular domain. Several soluble 
receptors have been found. They consist of the extracellular domain and are capable 
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Table 2.8 Characteristic properties of cytokines [M1> ; macrophages; NK ; natural killer cells, 148]. 
Cytokine MW Principal cell Primary type of activity Preeminent effects 
source 
IL-I 17,500 M1> + others Immunoaugmentation Inflammatory, haematopoietic 
IL-2 15,500 T-Iymphocytes + T - and B-cell growth factor Activates T-Iymphocytes and NK cells 
LGL 
IL-3 14,000-28,000 T-Iymphocytes Haematopoietic growth factor Promotes growth of early myeloid 
progenitor cells and 
enhance cytokine production of M1> [151] 
IL-4 20,000 TH-cells T - and B-cell growth factor, promotes IgE Promotes JgE switch and mast cell growth 
I reactions, suppresses cytotoxic and 
inflammatory function of M1> [152] 
IL-5 18,000 T H-cells Stimulates B-cells and eosinophils Promotes JgA switch and eosinophilia 
IL-6 21,000-26,000 Fibroblasts + others Hybridoma growth factor; augments Growth factor for B-cells and polyclonal 
inflammation immunoglobulin production 
fL-7 25,000 Stromal cells L ymphopoietin Generates pre-B- and pre-T -cells and is 
lymphocyte growth factor 
IL-8 8,800 M.p + others Chemoattracts neutrophils and T- Regulates lymphocyte homing and 
lymphocytes neutrophil infiltration 
IL-1O 35,000-40,000 T H-cells, rnonocytes, Immunosuppressant of M¢ function Inhibition T H-cell responses directly and via 
[153] M.p, B-cells M¢, immunostimulatory effects on 
B-cells 
fL-11 Bone marrow Growth factor for IL-6 dependent 
[154] stromal cells plasmacytoma cells, 
functionally related to IL-6 
IL-l3 10,000 T "cells Suppresses cytotoxic and inflammatory Immunostimulatory effects on B-cells 
[152] function and stimulates 
~~ig-en pre~(;!ntin~fllTIction of MtP __ 
-
L 
G-CSF 18,000-22,000 Monocytes + others Myeloid growth factor Generates neutrophils 
M-CSF 18,000-26,000 Monocytes + others Mq, growth factor Generates M1> 
GM-CSF 14,000-38,000 T -lymphocytes + Monomyelocytic growth factor Myelopoiesis 
others 
IFN. 18,000-20,000 Leukocytes Antiviral, antiproliferative, Stimulates Mq, and NK-ceUs, 
IFN, 25,000 Fibroblasts immunomodulating induce cell membrane antigens (eg MHC) 
IFN, 20,000-25,000 T-lymphocytes + 
NK cells 
TNF-a 17,000 Mq,+ Inflammatory, immunoenhancing, Generates vascular thromboses and tumor 
others tumoricidal necrosis I 
TGF, 25,000 Platelets, bone + Fibroplasia, immunosuppresion Involved in wound healing and bone 
others remodeling 
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of ligand-binding. Whether they are actively secreted or represent the degradation 
product of the receptor or cell turnover is uncertain [147]. 
The characteristic properties of the cytokines are presented in Table 2.8 [148]. IL-
lalJl, IL-6 and TNF-a are important pro-inflammatory mediators of the macrophage 
[149]. In Figure 2.7 their overlap is shown [150]. In the next sections the properties 
of these three cytokines will be discussed. 
IL-6 
Antibody 
formation 
Il-1 Inflammation Tumoricidal TNF-a 
activity and 
chaxhexla 
Figure 2.7 Redundancy and specifity in IL-l, IL-6 and TNF-a [1501. 
2.8.2.1 Interleukiu 1 
Interleukin 1 (IL-l) refers to two structurally related polypeptides [(17.5 kDa), 
155,156], IL-la and IL-IJl. IL-l receptor antagonist (IL-lra) is a third structurally 
related interleukin-l which inhibits the activities of IL-la/Jl. All three forms are 
distinct gene products. IL-lra is produced by the same cells that produce IL-la and 
IL-8 [157,158]. 
A wide variety of agents (e.g. microbes, microbial products, inflammatory agents, 
plant lectins and antigens) can induce IL-la and IL-18 production [159]. The second 
messengers involved in the induction of IL-l (a + 8) remains unclear. The leukotriene 
products are most probably involved [160]. IL-la and IL-IJl appear to be under 
separate transcriptional control [161]. Transcription and translation ofIL-I are distinct 
and dissociated processes. Cells (human peripheral blood mononuclear cells) containing 
untranslated IL-l mRNA are "primed", stimuli like LPS [the most common stimulus 
used for IL-l (a + 8)] can rapidly trigger translation [162,163]. 
IL-la and IL-18 are synthesized by both leukocytic as well as nonleukocytic cells, but 
primarily they are a product of monocytes and M</>. Precursor IL-la is fully active and 
remains cell associated. Biological inactive precursor IL-18 is cleaved by IL-18 
converting enzyme into active IL-18 and secreted by the cells [164,165]. IL-l (a + 
8) affects nearly every tissue [149,166]. The active forms of IL-Ia and IL-18 share 
the same biological properties by recognizing and activating the same receptor [167]: 
IL-I receptor type I. So far, no response has been found via the type II IL-I receptor 
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[168]. The exact signal transduction pathway following the binding ofIL-l to the cell 
surface receptor is not yet clear. It is hypothized that activation of a PLC, via coupling 
of IL-I receptor to a G-protein, leads to hydrolyzing of phospholipids, liberating DAG. 
DAG then triggers protein kinases, which in turn phosphorylate multiple target proteins 
[169]. 
Proliferation of a variation of haematopoietic and other cells, regulation of pro-
inflammatory events and mediation of tissue damage in inflammatory disease are 
considered as the main effects of IL-la and IL-IB. 
IL-Ira binds to the same receptor as IL-Ia and IL-IB, but has no activating properties, 
it is a pure receptor antagonist [156]. IL-lra is produced by human monocytes [158] 
and human M¢ [170,171]. The regulation of the ILlra production is differently 
regulated than the IL-IB production in human monocytes [172]. During maturation of 
human monocytes into M¢ in vitro, LPS stimulated IL-IB production is downregulated 
[173], while IL-Ira production is greatly enhanced. Freshly isolated human monocytes 
do not produce IL-Ira unless stimulated with agents such as LPS [172], the enhanced 
IL-lra production of these mature M¢ is then constitutive [173]. 
2.8.2.2 Interleukin 6 
Interleukin 6 (IL-6) is a glycoprotein with a molecular mass in the range 21 to 26 
kDA, which has pleitropic activities that induces differentiation and regulates cell 
growth in a cell type dependent manner. It induces the differentiation of B-cells and 
promotes the growth of haematopoieic progenitor cells and differentiation and/or 
activation of T-cells and M¢. It is also the main regulator of acute phase responses in 
hepatocytes [174]. 
Even though IL-6 is produced by many different cell types including fibroblasts, 
endothelial cells, T and B cells, certain tumors, the monocytic cells are the major 
source [175,176]. Abnormal expression of the IL-6 gene is probably involved in the 
pathogenesis of diseases as IL-6 levels are increased in a variety of diseases, e.g. 
bacterial and parasite infection, viral infections, inflammatory or autoimmune diseases 
[(e.g. rheumatoid arthritis), 177]. 
The exact molecular events leading to the induced IL-6 production remains to be 
clarified [178]; however, it is known that a wide variety of agencies can induce the IL-
6 production such as antigens/mitogens, LPS, IL-I, TNF-a, PAF, TPA, viruses, 
cAMP [179-181]. 
IL-6 binds to a specific cell-surface receptor, the ligand binding chain (gp80), which 
in turn associates with a signal-transducing chain (gpI30). How this IL-6 receptor 
mediated signalling leads to the activation of various transcription factors is not yet 
known [182]. A recent paper shows that probably in the initial step the tyrosine kinase 
pathway is activated and not the protein kinases A (PKA)/PKC or Ca + /calmodulin-
dependent kinases [183]. 
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2.8.2.3 Tumor necrosis factor Ol 
Tumor necrosis faclor a (TNF-a), a 17 kD polypeptide [184], was originally described 
as a factor which is induced by endotoxin and has anticancer activity [185,186]. It is 
clear now that TNF-a is involved in diverse pathological and physiological actions of 
the body. Various cell types are known to produce TNF-a [187], but just as for IL-I 
and IL-6, monocytes and M</> are thought to be the responsible cells which contribute 
mostly to the local and systemic response to bacterial, viral and parasitic organism and 
their products by producing TNF-a [188,189]. An important biological effect ofTNF-
a is probably up-regulation of the immune response. Based on studies in vitro it is 
known that TNF-a directly affects a wide variety of cells, e.g. monocytes/M</>, T- and 
B-cells, eosinophils, neutrophils, fibroblasts and endothelial cells, hereby also inducing 
a wide range of other pro-inflammatory cytokines. In addition, TNF-a is also involved 
in cachexia, is a major mediator of endotoxin-mediated shock, has antibacterial effects, 
is probably involved in autoimmune diseases and is also involved in wound healing 
[187-189]. 
There are two distinct TNF-a receptors (TNF-R): TNF-Rl (P-75) and TNF-R2 (P-5S) 
[190,191]. The specific functions of each receptor is still under debate; it is suggested 
that both receptors are active in signal transduction, TNF-Rl at high TNF-a 
concentrations, signalling a large number of TNF-a activities and TNF-R2 at low 
TNF-a concentrations, only signalling for the proliferation of primary thymocytes and 
T-cells [192]. It was shown with a human epithelial cell line that TNF-a up-regulates 
the expression of TNF-RI but not TNF-R2, and that both receptors mediate, 
independently of each other, different functions [193]. In the signalling transduction 
pathway probably a G-protein and PLA2 are involved [194,195]. 
2.9 Ascites 
The peritoneal cavity is the endothelial one-cell-layer of the viscera. The peritoneal 
cavity normally contains less than 50 ml of fluid. Ascites is the accumulation of free 
fluid and salt in this peritoneal cavity. In sterile ascites peritoneal M</> are 
predominantly present. These cells have migrated from the capillary bed under the 
visceral peritoneum into the ascitic fluid. 
2.9.1 Pathophysiology of ascites 
Ascites results from exudation of fluid either from the surface of the liver or from the 
surfaces of the gut and its mesentry. The different causes are portal hypertension (75 % 
cirrhosis, 5 % cardiac failure), malignancies (10-12 %), infections and others (8 %-10%) 
as summarized in Table 2.9. Once formed, ascitic fluid can exchange with blood 
through an enormous capillary bed under the visceral peritoneum. 
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Table 2.9 Causes of ascites [197]. 
- Portal hypertension 
Cirrhosis 
Hepatic congestion 
Congestive heart failure 
Constrictive pericarditis 
Budd-Chiad syndrome 
Vena-occlusive disease 
Portal vein thrombosis 
- Infections 
Secondary bacterial peritonitis 
Tuberculous peritonitis 
Fungal/parasitic peritonitis 
- Malignancies 
Peritoneal carcinomatosis 
Mesothelioma 
Metastatic liver disease 
Hepatocellular carcinoma 
Other intra-abdominal malignancies 
- Other 
H ypoalbuminaemia 
Leakage from lymphatic tissue 
Pancreas 
Biliary tract 
Renal failure 
Myxoedema 
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Portal hypenension. The liver is literally the crossroads of the body. The portal and 
systemic circulations join here to drain through a common venous outflow. Liver 
cirrhosis is a diffuse process characterized by fibrosis and a conversion of normal 
architecture into structural abnormal nodules. Cirrhosis is a progressive disorder that 
has the potential of leading to portal hypertension and liver failure. Different disorders 
causing cirrhosis are classified as follow: 
- Cirrhosis associated with alcohol abuse (60-70%) 
- Postnecrotic cirrhosis (10-15 %) 
- Biliary cirrhosis: - primary + secondary (10%) 
- Pigment cirrhosis (5 %) 
- Cirrhosis associated with Wilson's disease (rare) 
- cryptogenic cirrhosis (10-15%) 
The pathogenesis of ascites formation in patients with hepatic disorders has not been 
fully clarified. Several theories have explained the initiating event of renal sodium and 
water retention in cirrhosis. The peripheral arterial vasodilation hypothesis proposes 
that cirrhosis leads to peripheral arterial vasodilation as the initial event, resulting in 
a decreased effective plasma volume and the activation of compensating hormonal 
systems causing renal sodium retention. 
Malignancy. Cancers have a propensity for invading blood vessels and may obstruct 
the hepatic vein, producing hepatic vein thrombosis; or they block the portal vein, 
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producing portal hypertension and, as mentioned earlier, portal hypertension leads to 
the formation of ascites. 
Infections. Infection and malignancy, usually cause high protein ascites due to 
increased fluid and lymph production from the peritoneum and increased peritoneum 
permeability of the peritoneal capillaries, at the site of inflammation. Patients with 
ascites and cirrhosis may be complicated with a spontaneous bacterial peritonitis 
without an obvious primary source of infection. It probably reflects the deficient 
opsonic activity of ascitic fluid in these patients. 
Others. Extravasation of pancreatic fluid, bile or lipid-rich lymph into the peritoneal 
cavity may also lead to chronic peritoneal fluid accumulation. 
2.9.2 Treatment of ascites 
When ascites develops in the setting of severe acute liver disease, resolution of ascites 
is likely to follow improvement in liver function. Ascites commonly develops in 
patients with stable or steadily worsening liver function. Therapeutic intervention is 
indicated both to prevent potential complications and to control progressive increase 
in ascites, which may become pronounced enough to cause physical discomfort. Bed 
rest is recommended and the uptake of water and especially salt is restricted. Diuretics 
are instituted when the above mentioned therapy fails to result in diuresis and weight 
loss. 
Large volumes (10 liters in I hour) of ascites are removed by paracentesis in 
combination with concomitant intravenous infusion of albumin in amounts proportional 
to those removed. This is only done to speed the reduction of ascites in patients with 
tense ascites to make them more comfortable, it does not change the relapse or 
survival of the patient. A patient with cirrhosis and developing ascites has only a 40% 
change of being alive 2 years later [196]. Much depends on the major factor in the 
etiology of the fluid retention. 
A minority of patients with advanced cirrhosis have "refractory ascites" and do not 
respond to the therapy. In some patients a side-to-side portacaval shunt may result in 
improvement in ascites or implantation of a plastic peritoneo-venous (Le Veen) shunt 
which has a pressure-sensitive, one-way valve allowing ascitic fluid to flow from the 
abdonimal cavity to the superior vena cava [196-199]. 
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3.1 Summary 
Changes and correlations in cytokine and eicosanoid production by blood monocytes, non-purified and 
purified peritoneal cells during a carrageenin-induced peritonitis were investigated during ten days. 
The cells were isolated and stimulated in vitro. Cytokine and eicosanoid production of the non-purified 
fraction increased steadily during peritonitis. 
During the whole episode of peritonitis the production capacity of granulocytes was very low and 
hardly any effect on the production capacity of macrophages (M¢) was observed. Cytokine and 
eicosanoid production of the non-purified fraction was mainly due to the presence of M~. The 
production capacity of the peripheral blood monocytes was not similar to that of the peritoneal M~, 
Keywords: eicosanoids . peritoneal macrophages . peritonitis. tumor necrosis factor-a 
3.2 Introduction 
Inflammation is the reaction to an injury such as an invasion by infectious agents. The 
blood supply to inflamed area increases, venular permeability increases and leucocytes 
migrate out of venules into the surrounding tissue. 
At the site of an acute inflammation polymorphonuclear granulocytes (PMNs) produce 
large amounts of reactive oxygen intermediates, release a variety of hydrolytic 
enzymes and phagocytose pathogens [I]. By generating of chemotactic factors, the 
migration of mononuclear cells (monocytes/M¢ and lymphocytes) to the site of 
inflammation is stimulated [2,3]. During the chronic phase of the inflammatory 
response, M¢, mononuclear phagocytes derived from blood monocytes [4], 
predominate over PMNs [3]. In addition to acting as a non-specific defence, activated 
M¢ [5,6] will initiate and control the specific defence by presenting processed antigens 
to lymphocytes [7] and by cytotoxity through direct cell-cell contact with tumor cells 
or infected cells [8,9], during which they secrete cytokines and eicosanoids [10,11]. 
These inflammatory mediators also influence and regulate functions of other cells 
participating in the immune response [12,13]. 
Cytokines are proteins with regulatory functions. They can induce other cytokines with 
overlapping effects and form interactive networks with hormones and eicosanoids. M¢ 
are a potent source of wide variety of cytokines [14], whereas granulocytes are 
reported to produce only a limited spectrum of cytokines [15-17]. 
Eicosanoids are bioactive lipids derived from arachidonic acid (AA) by cyclooxygenase 
and lipoxygenase pathways [18,19]. Eicosanoid production is species and tissue 
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dependent and often stimulus dependent [20,21], 
The aim of this paper was to study cytokine (tumor necrosis factor a, TNF-a) and 
eicosanoid (leukotriene B" LTB,; prostaglandin ~, PG~; prostacycline (PGI2 , 
detected as 6-keto-prostaglandin Flo (6kPGFlo) and thromboxane, TXB2) production 
capacity of peritoneal PMNs, M4> and blood monocytes after the induction of a 
peritonitis with a carrageenin solution, a sulphated polygalactan which stimulates cell-
mediated immunity [22], It was of interest to determine whether, during an episode of 
peritonitis, changes occurred in (a) the differentiation of in fluxed cells; (b) the cytokine 
and eicosanoid production capacity of blood monocytes and peritoneal cells; (c) 
interactions between different types of peritoneal cells concerning their production 
capacity; and (d) if there was a correlation between the production of eicosanoids and 
TNF-a by blood monocytes and peritoneal M4>, 
3.3 Materials and methods 
Animals and treatment: Young male Wistar rats (13 weeks, approximately 200 gram, 
six rats per group) were injected intraperitoneally with 2 ml of a carrageenin solution 
(Marine Colloids Inc" USA, I mg/ml) on day 0, Six rats received an injection of 
saline (control group), 
Cell isolation: On day I (that is 24 h after inducing the peritonitis with the carrageenin 
solution), three, seven, and ten peritoneal cells and monocytes from the blood were 
isolated, With each group, cells were also isolated from a control animal, which was 
considered as day 0, 
Blood (± 7 ml) was collected in tubes with Iml EDTA (0,1 M) after decapitation, The 
blood was centrifuged (400xg, 4°C, 10 min) and from the leucocyte layer the 
monocytes were isolated into a 'monocyte' fraction by density gradient centrifugation 
using Percoll (d=1.064 g/ml, Kabi-Pharmacia, Sweden; 400xg, 4°C, 25 min), 
Monocytes were washed three times with phosphate buffer solution (PBS, 400xg, 4°C, 
10 min) and suspended in Dulbecco's modification of Eagle's medium (DMEM + 
HEPES (GIBCO, UK) + penicillin/streptomycin (5x10' U/I / 50 mg/I, Flow Lab, UK) 
+ foetal calf serum (10 % FCS, GIBCO, UK) + L-glutamine (600 mg/I Flow Lab, 
UK), LlO' cells/ml), 
The peritoneal cavities were washed twice with 20 ml PBS (PH 7.4, 4°C, Oxoid, UK), 
The washings per rat were pooled, centrifuged (400xg, 4·C, 10 min) and suspended 
in 5 ml DMEM, 5x1O' cells of this non-purified fraction were kept separate, the rest 
of this 'crude' fraction was separated on Percoll into a 'macrophage' and a 
'granulocyte' fraction, These two purified fractions were washed three times with PBS 
(400xg, 4°C, 10 min) and suspended in DMEM (LlO' cells/ml). 
A small sample of cells of each fraction was stained by Hemacolor (Merck, Germany) 
and the different cell types were counted using a microscope (Zeiss, standard 25, 
Germany), The viability of the cells was determined by trypan blue exclusion, 
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Cell incubation: One million leucocytes per ml DMEM were plated on plastic culture 
dishes (Costar, UK). The cells were triggered for 15 min by calcium ionophore 
A23187 (Calbiochem, USA), 1 I'M final concentration in dimethylsulfoxide (0.1 % 
DMSO, Sigma, USA), 37°C ,7.5 % CO2), Controls were incubated with DMSO (0.1 
%). 
The cells were also incubated for 24 h in the absence or presence oflipopolysaccharide 
(LPS, 10 I'g/ml final concentration in PBS, LPS from E. coli 0111 :B4 in PBS (Sigma, 
USA), 37°C, 7.5 % CO2), As a blank PBS was added. At the end of the incubation 
the supernatant was centrifuged and kept at -80°C until required for analysis. 
Cytokine production: TNF-a production in the samples was determined directly in the 
supernatant by bioassay. For this bioassay the TNF-a sensitive cell line WEHI-164 
was used. The WEHI-164 cells were plated out in 96-wells plates (2x104 cells/50 
I'llwell, Costar, UK) and the samples (50 I'l/well) or the human recombinant TNF-a 
(hr-TNF-a) standards (0.1 - 1000 u/ml hr-TNF-a, 50 I'llwell) were added. After 24 
h incubation (37°C, 7.5 % CO2), MIT (tetrazolium salt, Sigma, USA) was added 
(0.125 mg/well) and after an incubation of 3 h the cells were lysated with buffer (20 
% Sodium Dodecyl Sulphate (SDS) in 50 % N,N-dimethylformamide (DMF), pH 4.7, 
100 I'l/well) for 18 h. The absorbance was measured at 595 nm with an ELISA-reader 
(BIO RAD, model 3550, UK). The TNF-a production by the M<jJ was expressed as 
the cytotoxicity against WEHI-164 cells compared to the blank (DMEM complete) 
(23). 
Eicosanoid production: Eicosanoid production (LTB4 , PGE" TXB, and 6kPGFIo from 
endogenous arachidonate of the samples was determined directly in the supernatant by 
radio immuno assays (RIA, Antibodies were obtained from Advanced Magnetics, 
USA; standards from Sigma, USA; and tritiated antigens from Amersham, UK). 
Cross-reactivities for individual antigens on antibodies were negligible. 
Statistical analysis: Data are expressed as the mean ± standard error of the mean 
(SEM). Data were statistically analyzed with ANOVA followed by the Dunnett test or 
student's t-test. The correlations were determined by Pearson Correlation test. Data 
were considered significant when p < 0.05. 
3.4 Results 
Concentration and differentiation of cells obtainedfrom the peritoneal cavity: Induction 
of peritonitis in rats caused an increase of cells in the peritoneal cavity on day 1. 
The cell count dropped on the following days (Figure 3.1A). A pronounced influx of 
granulocytes was seen on the first day which was followed by an influx of M<jJ, 
resulting in a M<jJ / granulocyte ratio of 4: I from day 3 to 10 (Figure 3.IB). 
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Figure 3.1 Time course (O-to days) of cell number (A) and differentiation of the cells (B) during a 
peritonitis in rats; M¢(e), granulocytes(III); Mean ± SEM; n=6 per group; * = p < 0.05 
macrophages vs. granulocytes. 
Production capacity of cells to generate inflammatory mediators: The inflammatory 
mediator production per million cells stimulated in vitro (LTB,; 15 min A23l87; and 
PGE,., TXB2 , 6kPGF1a, TNF-a; 24 h LPS) by the peritoneal 'crude', 'macrophage' 
and 'granulocyte' fractions and the peripheral blood 'monocyte' fraction is shown in 
Figure 3.2A, 3.2B, 3.2C and 3.2D. 
Cytokine and eicosanoid production by the crude fraction increased steadily during 
peritonitis. TNF-a and TXB2 reached peak levels after 3 days, whereas PGE,. and 
6kPGFIo reached a plateau 7 days after induction of the peritonitis. In comparison with 
levels of other eicosanoids the LTB, production was low before and on the first day 
of the peritonitis and decreased significantly thereafter. By day 10 the production 
capacity returned to the initial level. 
The production pattern of the cells from the macrophage fraction (Figure 3.2B) was 
similar to that of cells from the crude fraction (Figure 3.2A). 
Inflammatory mediators were also produced by the granulocyte fraction (Figure 3.2C), 
although the production capacity of these cells was very low in comparison with cells 
from the crude and macrophage fraction. The pattern of inflammatory mediator 
production of the granulocyte fraction did not significantly change in time. On the 
tenth day after induction of the peritonitis, the concentration of the cells in the 
granulocyte fraction was too low to permit in vitro incubations. 
The capacity of cells from the peripheral blood monocyte fraction to produce 
inflammatory mediators (Figure 3.2D) was at least four times lower in comparison 
with both the crude and macrophage fractions. The production capacity of the cells 
from the monocyte fraction was about the same with or without stimulus. The patterns 
of the TNF-a, PGE, and 6kPGFIo production of cells from the monocyte fraction were 
different from those of the macrophage and crude fraction. After induction of the 
peritonitis the TNF-a production of cells from the monocyte fraction increased 
significantly only on the tenth day, whereas PGE,. and TXB2 reached their highest level 
on the third day. The 6kPGFIa level did not change during the peritonitis. The LTB, 
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production was negligible. 
Correlations between irif/ammatory mediators produced in the same fraction: In the 
crude fraction (Figure 3. 2A) there was a significant positive correlation between the 
production ofPG~ and 6kPGF,• and PG~ and TXB, (r = 0.6365 and r = 0.7145). 
Similar significant correlations were found in the macrophage fraction (Figure 3.2B, 
r = 0.5580 and r = 0.6106). 
In the monocyte fraction (Figure 3.2D) the only significant positive correlation 
between the inflammatory mediators was between PG~ and TXB, (r = 0.8881). 
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Figure 3.2 Production capacity of stimulated 'crude' (A), 'macrophage' (B), 'granulocyte' (C) and 
'monocyte' (D) fraction to produce the eicosanoids LTB,( +), PGE,C'), 6kPGF,.(e), TXB,CB) and 
the cytokine TNF-a("); LTB4 production of 106 cells/ml determined in supernatant after 15 min 1 
J.tM A23187 stimulation. PGEz. TXB2, 6kPGF!c<, TNF-a production of 1(f cells/ml determined in 
supernatant after 24 h 10 Itg/ml LPS stimulation; mean ± SEM; *, #, • = p < 0.05 vs. day 0; n 
= 4-6. 
Correlation between inflammatory mediators in differentfractions: In Figure 3.2A and 
3.2B the patterns of inflammatory mediators produced by the stimulated crude and 
macrophage cell fractions are presented. There was always a significant positive 
correlation between these two fractions. The correlation varied from r = 0.5671 for 
LTB, to r = 0.8586 for TNF-a. (PGE2; r = 0.6254, 6kPGF Io ; r = 0.7536 and TXB2 
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r = 0.7502). This correlation remained significant when we assumed that production 
of the cell inflammation mediators in the crude and macrophage fraction were only 
derived from the M1> (calculated to 100 % M1>; LTB, = 0.4649; PG~ = 0.5855, 
6kPGF1a = 0.5506, TXB2 = 0.7810; and TNF-a = 0.8674). 
There were however some significant differences between the calculated (to 100 % 
M1» production levels of the crude and macrophage fractions. When separate days 
were considered the production levels of the calculated crude fraction in comparison 
with the calculated macrophage fraction was on day 1 lower for PG~ and 6kPGF1a , 
and on day 3 higher for LTB4 , TXB2 and TNF-a (Figure 3.3 A-E). 
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Figure 3.3 Production capacity of the stimulated 'crude' (II) and 'macrophage' fraction Co) (calculated 
to 100% M<I» to produce the eicosanoids LTB, (A), PGE, (B), 6kPGF," (C), TXB, (D) and the 
cytokine TNF-a (E); LTB4 production of 106 cells/ml determined in supernatant after 15 min 1 JlM 
A23187 stimulation. PGE2> TXB2 , 6kPGF1c" TNF-a production of 106 cells/ml determined in 
supernatant after 24 h 10 ,ug/ml LPS stimulation; mean ± SEM ; * = p < 0.05 vs. day 0; # = P 
< 0.05 granulocytes vs. macrophages; n = 4-6. 
Correlation coefficient between irif/ammatory mediators from monocyte and 
macrophage fraction: Only the basal TNF-a production of the cells from the monocyte 
and macrophage fractions, were clearly correlated (r = 0.5421). 
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3.5 Discussion 
Characterization of inflammatory mediators produced by granulocytes and monocytes 
1M</> during induced inflammation in animal models, may be helpful to the 
understanding of inflammatory diseases and their treatment. The present study 
investigated the changes and correlations in cytokine and eicosanoid production 
capacity of peripheral blood monocytes, non-purified (crude fraction) and purified 
(macrophage and granulocyte fraction) peritoneal cells during a carrageenin-induced 
peritonitis in rats. 
In the present study, where an influx of leucocytes into the peritoneum was achieved 
after carrageenin injection, the number ofPMNs increased in the acute phase (day I) 
and thereafter decreased quickly. On day 0, before inducing the peritonitis, there was 
a reasonable number of M</> present in the peritoneal cavity. The number of M</> 
increased from day I until seven days after induction of the peritonitis, resulting in a 
mainly a M</> cell population. Previous histological studies had similar results [24,25], 
although a quantitative and kinetic method showed that both monocytes and PMNs 
from rat migrate rapidly to the inflamed site, the migration of PMNs, however, also 
declined long before the migration of monocytes started to decrease [3). The pattern 
of this migration can be explained with the function of the leucocytes in inflammation. 
In the initial phase both PMN sand M</> are involved in non-specific defence 
mechanisms [1,2). In addition M</> will also initiate and control the specific defence [7-
13). The mechanism of this selective migration is not clear. Leucocyte adhesion to the 
blood vessel endothelium, which is followed by transendothelial migration, is a 
multistep process in which several adhesion molecules are involved [26,27). 
Our experiment showed that the inflammatory mediator production capacity of the non-
purified fraction, which was harvested from the inflamed peritoneal cavity, changed 
with time. The production of inflammatory mediators in the non-purified fraction was 
mainly caused by the presence of M</> during carrageenin-induced peritonitis. This is, 
first of all, based on the significant correlation between the eicosanoid and TNF-a 
production capacity of the macrophage fraction and the crude fraction, these 
correlations hardly changed when it was assumed that these fractions only contained 
M</>. Secondly, the production capacity of the granulocytes appeared to be very low. 
Moreover the production capacity of the granulocyte fraction did not correlate with the 
crude fraction. 
When the production levels of the non-purified fraction was compared with the 
macrophage fraction, assuming that the inflammatory mediators were only produced 
by M</>, it was observed that the production of PGE, and 6kPGF Ia had decreased on 
day I and the production of LTB4 , TXB2 and TNF-a had increased on day 3. The 
results of these effects could be an amplification of the inflammation, due to the 
decrease of anti-inflammatory substances and the subsequent increase of pro-
inflammatory substances. 
The low production capacity of the crude fraction in the acute phase followed by an 
increasing production capacity in the chronic phase could also be explained by 
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presence of the M¢. Blood monocytes and resident M¢ transform from primed into 
active M¢ at the side of the inflammation, after which profound changes occur in 
morphology and function of these cells [4-6]. The M¢ present at day I in the 
peritoneal cavity, probably were not primed in vivo at this time, which could be the 
reason that the eicosanoid and cytokine production capacity of these M¢ were so low 
after stimulation in vitro with LPS. Once these M¢ were primed in vivo, also the new 
recruded monocytes whom migrate into the peritoneal cavity, the production capacity 
of these monocytes/M¢ steadily increased, showing in vitro a differentiated pattern for 
the eicosanoids and TNF-a. This pattern probably depends on the function of the 
metabolite. 
As peripheral blood monocytes transform into peritoneal M¢ [4], the correlation 
between these cells was investigated. The eicosanoid and TNF-a production capacity 
of blood monocytes was not similar to that of M¢ during peritonitis. It was clearly 
shown that through influx and transformation of monocytes into M¢ the synthesis of 
mediators completely changed. 
In conclusion M¢ are the main source of the inflammatory mediators whose production 
is dependent on the episode of the carrageenin-induced peritonitis. Characterisation of 
purified M¢ in vitro in animal and human models will be helpful to the understanding 
of inflammatory diseases and their treatment. Peripheral blood monocytes do not 
reflect mediator production of M¢ present at the inflammatory site. 
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Chapter 4 Eicosanoid production by density-defined human peritoneal 
macrophages during inflammation 
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4.1 Summary 
Density-defined macrophages (M¢) isolated from fluids of patients with liver cirrhosis mainly 
generated the 5-lipoxygenase products leukotriene B4 (L TB4, 16 %) and 5-hydroxy-eicostetranoic acid (5-HETE, 24 %) and the cyclooxygenase products 12-hydroxy-heptadecatrieoic acid (HHT, 22 %) and 
thromboxane B2 (fXBz, 18 %). The synthesis of eicosanoids was linear with the maturity of the M¢ 
subpopuJations, suggesting that eicosanoid production is increased in in-vivo activated Mtb. 
Keywords: ascites . macrophages . subpopulations . eicosanoids 
4.2 Introduction 
During peritonitis a large number of inflammatory cells are present in ascites fluid. 
Ascites obtained from patients with alcoholic liver cirrhosis is a potential source of 
human Mel> (approx. 86 %), which can successfully be used to study various aspects 
of their role in inflammation. It is likely that the mediators produced by these Mel> 
contribute to the observed inflammatory changes. 
In vitro activation of cells obtained from patients has shown that different eicosanoids 
are produced in higher concentrations during peritonitis [I]. 
Subpopulations of peritoneal Mel> could reflect a continuum of functional changes 
induced by cellular maturation, exogenous stimuli or both. Maturation of monocytes 
into Mel> takes place without cell division, but with an increase in cell volume [2]. The 
least mature Mel> are expected to be found in the highest density layer of a density 
gradient and the more mature Mel> in the lower densities [3]. The investigations 
described here were performed to obtain information about the ability of density-
defined subpopulations of human peritoneal Mel> and their ability to synthesize 
eicosanoids. 
4.3 Materials and methods 
Subjects: Peritoneal Mel> were obtained from ascitic fluid of 3 patients with liver 
cirrhosis. 
Cell isolation: Cells were isolated by centrifugation (lOOOxg) and washed with 
phosphate buffered saline (PBS, pH 7.4, Oxoid, UK). The concentrated cell suspension 
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was separated on a Percoll (Kabi-Pharmacia, Sweden) density gradient into six 
subpopulations (0 = non-separated cell suspension, I = 1.035 glml, 2 = 1.041 glml, 
3 = 1.046 glml, 4 = 1.052 g/ml, 5 = 1.064 g/ml, 6 = 1.076 g/ml and 7 = pellet). 
Cell incubation: One million density-defined cells in Dulbecco's minimal essential 
medium (Dulbecco's MEM, Gibco, UK) were labelled with 14C-arachidonic acid (0.1 
I'Ci, Amersham, UK) for 2 min and triggered by the calcium ionophore A23187 (2 
I'M) for 13 min. 3H labelled standards (Amersham, UK) were added and the 
supernatants passed through Sep Pak CIS catridges (Waters Ass., USA). 
Eicosanoid production: Exogenous eicosanoid formation was measured on RP-HPLC 
using a Nucleosil 5CI, column (3x200 mm,Chrompack, The Netherlands). A gradient 
of acetonitrile and 0.2 % triethylamine I 0.12 % trifluoroacetic acid I water (pH 3) 
was used. Cells were stained by Hemacolor (UK) to determine the cell differentiation. 
For each patient, per eicosanoid product, the production of the density defined 
leucocytes was compared with the density defined leucocytes with the highest 
production (= 100 %). The data are expressed as the mean + SD (n = 3), with a 
correction for the number of M¢. 
4.4 Results 
Cell differentiation: When a comparison was made of the morphology of the 
macrophage subpopulations, we found the following: The M¢ with the highest density 
(1.076 g/ml) were small round cells. With a declining density the nucleoplasmatic ratio 
also declined. The M¢ in the lowest density layer (1.035 g/ml) were about the same 
size as the M¢ in the second lightest density (1.041 g/ml), however their structure was 
much more irregular. 
The cell distribution in percentages of total amount of recovered cells on the 
discontinuous gradient (with a cell recovery between 50 and 75 %) was IS ± 2.0 % 
for fraction I, 15 ± 2.1 % for fraction 2, 7 ± 2.4 % for fraction 3, 20 ± 5.6 % for 
fraction 4, 29 ± 2.8 % for fraction 5,7 ± 4.4 % for fraction 6 and 1.7 ± 0.2 % for 
the pellet. 
Each subpopulation contained mainly M¢; 95.5 ± 0.8 % in fraction 1, 94 ± 2.2 % 
in fraction 2, 95.S ± 0.5 % in fraction 3, 91 ± 1.3 % in fraction 4,81 ± 4.1 % in 
fraction 5, 77 ± 5.0 % in fraction 6 and no detectable amounts in the pellet. The non-
separated cell suspension contained S6.3 ± 0.9 % M¢. 
Eicosanoid production: The main lipoxygenase products of one million human 
peritoneal density-defined M¢ from the 3 patients were 5-HETE (24 %), LTB4 (16 %) 
and 15-HETE (7 %). The main cyclooxygenase products were HHT (22 %) and TXB2 
(IS %). In figure 4.1 the relationship between the eicosanoid production in percentages 
of the total formation per substance per patient and the density of the human peritoneal 
macrophage on the average for the 3 patients, is outlined. 
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Figure 4.1 The average of the main eicosanoid production of one mi1lion human peritoneal density-
defined Mcp in percentages (highest production per eicosanoid and per patient is one hundred percent). 
A million human leucocytes were stimulated with A23187; the data are expressed as mean ± SD 
(n=3), with a correction for the number of Mcp. 
4.5 Discussion 
Our preliminary results show that human peritoneal density-defined Me!> also show 
morphological and biochemical heterogeneity, which might correlate with Me!> 
maturation, Cell differentiation presumes that the least human mature Me!> (the small 
round cells) are in the highest density gradient and the more mature Me!> in the lower 
densities (cells with increasing cytoplasm), This has also been suggested for rat and 
human lung alveolar Me!> [3-5], 
The Me!> sUbpopulations synthesize a variety of eicosanoids during inflammation, with 
the lipoxygenase products 5-HETE, LTB, and IS-HETE and the cyclooxygenase 
products HHT and TXB2 as the main eicosanoid products. 
The ability of human peritoneal Me!> to synthesize eicosanoids seem to be density 
dependent. The Me!> subpopulation of the highest density (1,076 g/ml) synthesize the 
least eicosanoids, The Me!> subpopulations of lower densities have a higher level of 
eicosanoid production, The highest level of eicosanoid production is in the second 
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lowest dense macrophage subpopulation (1.041 g/ml). 
Comparing the morphology and biochemical heterogeneity of the MqI subpopulations 
with each other, the following could be concluded: As the eicosanoid production is 
density dependent, we may assume it is depending on the maturity of the MqI. This is 
in agreement with previous findings with human MqI obtained from the peritoneal 
cavity during peritonitis. Freshly recruited MqI produced less eicosanoids than resident 
cells [5]. 
The MqI subpopulation of the lowest density has, compared to the subpopulation of the 
second lowest density a much more irregular shape and also produces less eicosanoids, 
these cells might be "dying". 
The experiments described here confirm the idea that a relationship between the pattern 
and the abilities of human peritoneal density-defined MqI to produce eicosanoids exists. 
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5.1 Summary 
Ascites is a readily available source of human macrophages (Mcp). which can be used to study Mrp 
functions in vitro. We characterized the mediators of inflammation produced by human peritoneal Mcp 
(hp-MrjJ) obtained from patients with portal hypertension and ascites. 
The production of the cytokines interleukin 1 f) (IL-lfi), interleukin 6 (IL-6) and tumor necrosis factor 
a (TNF-a) was found to be lipopolysaccharide (LPS) concentration dependent (0 - 10 I'g/ml) with a 
maximal production at 10 {lg/ml and also dependent on the time of exposure to the stimulus (0 - 36 
h). IL-16, IL-6 and TNF-O:' production after LPS administration reached a plateau at 24 h. 
In vitro stimulation for 24 h with LPS does not influence the eicosanoid production from endogenous 
arachidonate. Thirteen min of exposure of the cells to the calcium ionophore A23187 gives an 
significant increase in eicosanoid production from both exogenous and endogenous arachidonate. The 
main eicosanoids produced are the 5-lipoxygenase products leukotriene B4 (L TB4) and 5-hydroxy-
eicosatetraenoic acid (5-RETE). The increase in production of the other eicosanoids are not 
significant. 
The eicosanoid production depends on the stimulus concentration. The optimal A23187 concentration 
is 1 J,LM. 
Oxygen radical production was measured in the M¢ by a tlowcytometric method. The fluorescence 
intensity ofphorbol12-myristate 13-acetate (TPA) stimulated and dihydro-rhodamine 123 (DRR 123) 
loaded hp-M¢ increases significantly after 15 min. 
We conclude that LPS stimulation of hp-M¢ from liver disease results in similar production of IL-lfi, 
IL-6 and TNF-a, but that the profile of the eicosanoid production of these M¢ stimulated with LPS 
and A23187 differs from M¢ of other origin and species. 
Key Words: human peritoneal macrophages . eicosanoids . interleukin III . 
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5.2 Introduction 
M¢ are of central importance in the initiation and regulation of non-specific and 
specific immune responses. They take part as active phagocytic cells, serve as antigen 
presenting cells (APC) for T-lymphocytes and are a major source of a wide range of 
inflammatory products including eicosanoids and cytokines in different types of 
immune responses (e.g. host defence against microorganism, antitumor and chronic 
inflammation). 
When monocytes or tissue M¢ are stimulated, both develop into active M¢. Profound 
changes then occur in morphology and function. Major changes are: increase in size, 
more complex and numerous surface folds and an increase in the numbers of vacuoles, 
lysosomes, phagosomes and endoplasmatic reticular elements. The adhesiveness and 
expression of Ia antigens increases. The M¢ become more sensitive for agents which 
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trigger oxygen radicals and they secrete a large range of products including enzymes, 
coagulation factors, proteins of complement system, factors regulating cell activities 
and proliferation, bioactive lipids, nucleotide metabolites and reactive oxygen 
metabolites [1,2]. 
In vivo M¢ activation appears to be mediated andlor modulated by microbial pathogens 
and their products, lipid mediators and cytokines [3,4]. in vitro activation can be 
initiated by a variety of agents, including A23187 [5], LPS [6,7] or cytokines [8,9]. 
The cytokines IL-I [10], IL-6 [II] and TNF-a [12] are important M¢ cytokine 
products when stimulated with LPS [7], which is one of the most potent stimuli of M¢ 
[13]. 
Arachidonic acid (AA) can be metabolized to biologically active eicosanoids. The 
cyclooxygenase pathway generates the prostanoids and the 5-lipoxygenase pathway 
produces leukotriene LTB4 and 5-HETE [14,15]. Eicosanoids exhibit distinct biological 
effects [16-19]. Like the cytokines they have an important function in controlling the 
immune reaction. A23187 is one of the most potent stimuli of eicosanoid production 
[5,20,21]. 
The respiratory burst is a characteristic feature of phagocytes. The production and 
release of radical oxygen intermediates (ROI) by M¢ plays a major role in several of 
the effector functions of these cells. Oxygen radicals are of critical importance for 
antibacterial defence. They are also involved in tumoricidal activities, in suppression 
of lymphocyte proliferation [22,23] and have been implicated as important mediators 
of tissue damage in inflammation [24,25]. Oxygen radicals may be involved in a 
positive feedback mechanism of inflammation; superoxide anion (0,") can induce IL-I 
production in monocytes and polymorphonuclear leucocytes (PMNs) [26]. 
We have previously isolated human peritoneal M¢ (hp-M¢) from ascitic fluid, obtained 
from patients with liver cirrhosis to investigate various aspects of their metabolism and 
the role of M¢ in inflammation [27,28]. The aim of this study is to analyze the profile 
of eicosanoid production, the levels of cytokine production and the respiratory burst 
activity in this type of hp-M¢, regarding the potential influence of liver disease on 
these parameters, in comparison with other types of M¢. 
5.3 Materials and methods 
Subjects: The hp-M¢ were obtained from aSCItIc fluid of 12 patients with liver 
cirrhosis, 2 patients with congestive heart failure, I patient with primary sclerosing 
cholangitis, I patient with malignant mesothelioma and I patient with the Budd-Chiari 
syndrome (Table 5.1). None of the patients were on drugs which have been reported 
to influence the lipoxygenase and cyclooxygenase enzymes. 
Cell isolation: The hp-cells were isolated by centrifugation of the ascitic fluid at 
400xg (4°C) and washed with phosphate buffered saline (PBS, pH 7.4, 4°C, Oxoid, 
UK). The concentrated hp-cell suspension was separated on Percoll (d = 1.064 glml, 
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Table 5.1 List of patients with ascites (n = 17). 
I Number m/f - age Diagnosis I 
1. male - 68 biliary liver cirrhosis 
2. male - 65 congestive heart failure 
3. female - 50 alcoholic hepatitis and liver cirrhosis 
4. female -72 alcoholic liver cirrhosis 
5. male - 69 alcoholic liver cirrhosis 
6. female - 41 alcoholic liver cirrhosis 
7. female - 65 alcoholic liver cirrhosis 
8. male - 69 congestive heart failure 
9. female - 38 Budd- Chiari syndrome 
10. male - 46 alcoholic liver cirrhosis 
I!. male - 65 cryptogenic liver cirrhosis 
12. male - 59 alcoholic liver cirrhosis 
13. male - 60 alcoholic liver cirrhosis 
14. male - 39 primary sclerosing 
cholangitis 
15. female - 42 alcoholic liver cirrhosis 
16. male - 39 alcoholic liver cirrhosis 
17. male - 82 malignant mesothelioma 
Kabi-Pharmacia, Sweden). A small sample of cells was stained by Hemacolor 
(Merck, Germany) and the different cell types were counted under a microscope (Zeiss, 
standard 25, Germany). The viability of the cells was tested by trypan blue exclusion. 
Cytokine production: For the measurement of the cytokine production one million 
leucocytes per ml RPMI complete [RPMI-1640 + HEPES (GIBCO, UK) + penicillin 
/streptomycin (5x10' u/I / 50 mg/I, Flow Lab, UK) + foetal calf serum (10 % FCS, 
GIBCO, UK) + L-glutamine (600 mg/I Flow Lab, UK)] were plated on plastic culture 
dishes (Costar, UK). The cells were stimulated with the addition of increasing 
concentrations of lipopolysaccharide (0 - 10 "g/ml, 36 h, LPS from E. coli 0111 :B4 
in PBS, Sigma, USA) or incubated in the absence or presence of LPS (10 "g/ml) for 
an increasing time period (0 - 36 h, 3rC, 7.5 % CO2), As blanc PBS was added. The 
net cytokine production is the production with LPS minus blanc of cells incubated for 
the same period of time. At the end of the incubation the supernatant was filtered (0.22 
"m, Millipore, France) and kept at -70°C till analyzing. IL-IJl and IL-6 production in 
the supernatant of the samples were measured by ELISA (IL-IJl: Medgenix, Belgium, 
IL-6: Hycult, Holland). TNF-a production of the samples was determined with a 
bioassay and partly by ELISA (Cistron, USA). For this bioassay the TNF-a sensitive 
cell line WEHI-164 was used. The WEHI-164 cells were plated out in 96-wells plates 
(2xlO' cells/50 Ill/well, Costar, UK) and the samples (50 Ill/well) or the human 
recombinant TNF-a (hr-TNF-a) standards (0.1 - 1000 u/ml hr-TNF-a, 50 Ill/well) 
were added. After 24 h of incubation (3rC, 7.5 % CO,), MIT (Tetrazolium salt, 
Sigma, USA) was added (0.125 mg/well) and after an incubation of3 h the cells were 
lysed with buffer (20 % Sodium Dodecyl Sulphate (SDS) in 50 % N,N-
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dimethylformamide (DMF), pH 4.7, 100 I'l/well) during 18 h The absorbance was 
measured at 595 nm with an ELISA-reader (BIO RAD, model 3550, UK). The TNF-a 
production by hp-M¢ is expressed as the cytotoxicity against WEHI-164 cells 
compared to blanc (RPMI complete) (29). 
Eicosanoid production: For the measurement of eicosanoid production from exogenous 
arachidonate, lxlO' leucocytes per ml PBS (+ Ca2 +, pH 7.4, Oxoid, UK) in 
polypropylene tubes (Greiner, The Netherlands) were labelled with 14C_AA (0.125 I'Ci, 
55.7 mCi/mmol, Amersham, UK) for two min and triggered by A23187 (0 - 5 I'M 
final concentration in dimethylsulfoxide (DMSO, Sigma, USA) for 13 min at 3rC. 
Controls were incubated with DMSO. 'H-Iabelled standards consisting of 6-keto-
prostaglandin Flo (6kPGFlo), PGE" LTB" 12-HETE and 15-HETE (approximately 
0.01 I'Ci of each eicosanoid, Amersham, UK) were added for recovery calculations 
and as retention time markers. The supernatants were then passed through Sep Pak Cl8 
cartridges (Waters Ass., USA) and eluted with methanol, dried and dissolved in 200 
1'1 methanol. Eicosanoid formation was measured on RP-HPLC using a Nucleosil5Cl8 
column (3x200 mm, Chrompak, The Netherlands). 100 1'1 sample was injected onto 
the column. As eluens a gradient of acetonitrile and 0.2 % triethylamine / 0.132 % 
trifluoracetic acid / water (pH > > 3) was used. The eicosanoid formation is 
expressed as the mean percentage of total formation of the most common metabolites 
per patient. 
In these samples, both A23187 stimulated and non-stimulated, eicosanoid production 
from endogenous arachidonate was measured (LTB4, PGE" thromboxane (TXB,) and 
6kPGFlo)' In the cytokine samples (24 h, 10 I'g/ml LPS in RPMI) also the eicosanoid 
production from endogenous arachidonate was measured by radio immuno assays 
(RIA; Antibodies were obtained from Advanced Magnetics, USA and standards from 
Sigma, USA). The exogenous eicosanoid production is given as net production. This 
is the production of the cells with A23187 minus control values. 
Respiratory burst activity: ROI production was measured with DHR 123 (Molecular 
probes, USA). The stock solution was 1 mg/ml in N,N-dimethylformamide (Sigma, 
USA); further dilution was performed with PBS. DHR 123 is oxidized intracellularly 
to fluorescent rhodamine 123 (RI23) by hydrogen peroxide. 
Leucocytes (0.25xlO'/ml) were incubated in RPMI in polypropylene tubes with 
increasing concentrations of TPA (0 - 1000 ng/ml, TPA diluted in DMSO:PBS = 
1:10, Sigma, USA, 10 min, 37°C, blanc is 10 % DMSO) directly followed by 
incubations with increasing concentrations ofDHR 123 (0 - 100 ng/ml, 15 min, 3rC). 
In the time experiments TPA and DHR 123 were added to the cells at the same time 
and incubated for an increasing time period (0 - 1 hour, 100 ng/ml TPA, 333 ng/ml 
DHR 123, 37"C). Samples were put on ice straight after the incubations. The 
fluorescence intensity [mean channel number (MCN)] was measured with a 
fluorescence activating cell scanner (FACS, Becton Dickinson Immunocytometry 
Systems, USA). Rl23 is detected as Fluorescence 1 (green; 500-530 nm) (30,31). 
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5000 cells per sample were measured. The data were evaluated with the FACS SCAN 
program system (Becton Dickinson Immunocytometry Systems, USA). The net ROI 
production is the fluorescence intensity (in MCN) oflhe TPA stimulated and DHR 123 
loaded cells, minus the fluorescence intensity (in MCN) of the non stimulated cells 
which were also loaded with DHR 123 and incubated for the same period of time. 
Statistical analysis: The data are expressed as the mean + standard error of the mean 
(SEM). Data were statistically analyzed with Anova followed by the Student T-test or 
the student T-test only; data were considered significant when p < 0.05. 
5.4 Results 
Cell differentiation: The Percoll separated cell suspension was microscopically 
examined and the following composition of cells was found: 94.6 ± 1.2 % Mol>, 4.0 
± 1.1 % lymphocytes and 1.2 ± 0.4 % granulocytes (n=17). The viability of the 
cells was 86 ± 1.3 % (range: 94.2 - 75.8). 
Cytokine production: To determine LPS concentration for optimal IL-lll, IL-6 and 
TNF-a production, hp-MoI> were stimulated with increasing concentrations of LPS (0-
10 pg/ml) for 36 h as shown in Figure 5.1. The highest production was with the 
highest LPS concentration used. All subsequent experiments were performed with 10 
I'g/ml LPS. 
The time dependent net IL-IJl, IL-6 and TNF-a production from 0 to 36 h with LPS 
is shown in Figure 5.2. The maximal net cytokine production for all three cytokines 
was reached at 24. 
The IL-lll (n=16), IL-6 (n=1O) and TNF-a (n=1O/17) production without or after 
stimulation with 10 pg/ml LPS for 24 h is shown in Table 5.2. LPS stimulation 
resulted in a significant increase in the production of each cytokine. 
Mol> from 6 out of 16 patients had no IL-lll production without LPS, all patients had 
IL-6 production without LPS stimulation and 6 out of 10 patients had no TNF-a 
production without LPS. 
Table 5.2 Cytokine production by hp-M¢. IL-lfi, IL-6 and TNF-c< generation by 10' hp-M¢/ml 
stimulated for 24 h with 10 {Lg/ml LPS. Data are expressed as mean ± SEM and statistically analyzed 
by Student T-test. 
I PRODUCT II CONTROL I LPS I n I 
IL-16 (ng/ml) 3.0 ±1.2 8.7 ± 1.5 * 16 
IL-6 (ng/ml) 6.1 ± 1.4 32.6 ± 7.1 * 10 
TNF-c< (ng/ml) 0.1 ± 0.1 2.7 ± 1.1 * 10 
TNF-c< y(% killing) 21.6 + 5.1 47.7 ± 3.9 * 17 
* p < 0.05 (increase vs controls). n = number of patients. 
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Figure 5.1 Interleukin Ifi (n=3, ng/ml, left figure), interleukin 6 (n=2, ng/ml, middle figure) and 
tumor necrosis factor a (n=2, % killing, right figure) production by hp-M¢ (1Q6/ml) stimulated with 
an increasing concentration LPS; 0 - 10 j.tg/ml. The results are shown separately per patient (III, .. , 
. ), 
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Figure 5.2 The time dependency of net interleukin 16 (n=2, ng/mI, left figure), interleukin 6 (n=3, 
fig/ml, middle figure) and tumor necrosis factor a (% killing, n= 3, right figure) production ofhp-M¢ 
(1O'/ml) stimulated with 10 ~g/ml LPS, The cells were stimulated for 0 - 36 h. The results are shown 
separately per patient (Iilil, ., A). 
Eicosanoid production: First the A23187 concentration was determined (0 - 5 ",M) 
which yielded the most eicosanoid production. Figure 5.3 (top and middle) shows the 
LTB4 and 5-HETE production from added 14C_AA (exogenous production) and Figure 
5.3 (bottom) the endogenous LTB4 production as measured by RIA of 3 patients, The 
optimal concentration is I - 2 ",M, Consequently all following experiments were 
performed with I ",M A23187. 
All eicosanoids formed from exogenous arachidonate by hp-M¢ after A23187 
stimulation are listed in Table 5,3A. The main net eicosanoids were the 5-lipoxygenase 
products LTB4 and 5-HETE, the minor net eicosanoids were the cyclooxygenase 
products hydroxy-heptadecatrieoic acid (HHT) and TXB2 , Other eicosanoids were less 
then 1.5 % of 14C_AA which was converted per product. 
To investigate if eicosanoid production from exogenous and endogenous arachidonate 
were related to each other, four eicosanoids were measured in the same samples by 
RIA, as in which 14C_AA conversion was determined by HPLC (Table 5.3B). 
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Figure 5.3 Eicosanoid formation from exogenous (left figure; 5-HETE, middle figure; LTB4, % of 
total formation per patient) and endogenous arachidonate (right figure; LTB4, ng/ml) production of 
hp-M<J> (lO'/ml). Cells were prelabeled with "C-AA (2 min), triggered with 1 I'M A23187 for 13 min 
and 3H labelled standards were added afterwards. The results of three patients are shown separately; 
(0,.,.). 
Table 5.3A Eicosanoid production from exogenous arachidonate by hp-Mq... Profile of eicosanoid 
production from exogenous 14C-arachidonic acid in l(f hp-Mq../ml after A23187 stimulation (l{LM, 
13 min, expressed as percentages of total formation per patient). 
NET EXOGENOUS LIPOXYGENASE NET EXOGENOUS 
PRODUCTS CYCLOOXYOENASE n 
A23187 (%) PRODUCTS A23187 (%) 
LTB4 32.1 ± 3.9 * 6kPOF," 0.5 ± 0.3 5 
5-HETE 57.2 ± 3.9 * TXB, 2.6 ± 1.3 5 
di-HETE 1.4 ± 0.4 HHT 4.3 ± 1.6 5 
12-HETE 0.3 ± 0.2 POF", 0.9 ± 0.5 5 
15-HETE 0.7 ± 0.3 POE, 0.1 ± 0.04 5 
POD, 0.1±0.1 5 
* p < 0.05 (increase vs controls). 
The main eicosanoid was also a 5-lipoxygenase product (LTB4). Cyc100xygenase 
production did not increase significantly with A23187. 
Furthermore eicosanoid production from endogenous arachidonate was measured in the 
same samples as in which the cytokine production was measured (24 h LPS). LPS did 
not influence significantly eicosanoid production from endogenous arachidonate over 
24 h as measured by RIA (Table 5.4). 
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Table 5.3B Eicosanoid production from endogenous eicosanoid by hp~M¢. Eicosanoid production 
from endogenous arachidonate in 106 hp-M¢lml with and without A23187 stimulation (1 JlM, 13 min, 
expressed as ng/ml) , 
CONTROL A23187 n 
(ng/ml) (ng/ml) 
L1POXYGENASE PRODUCT 
LTB, 
1.0 + 0.3 7.6 + 1.7 * II 
CYCLO-
OXYGENASE PRODUCTS 
PGE, 0.1 ± 0.1 0.24 ± 0.1 11 
TXB, 1.8 ± 0.2 1.8 ± 0.3 5 
6kPGF'a 0.4 + 0.4 0.4 + 0.3 5 
* p < 0.05 (increase vs controls). 
Table 5.4 Eicosanoid production from endogenous arachidonate by hp-M¢. Eicosanoid production 
from endogenous arachidonate in 106 hp-M¢/ml with LPS (10 ttl/ml, 24 h, expressed as ng/ml). LPS 
stimulation does not significantly (p < 0.05) stimulate the eicosanoid production (vs. controls). 
IbOXYGENASE PRODUCTS :: 
OL LPS 0 
) (og/ml) 
1.2 + 0.3 LTB, 1.0 + 0.2 16 
CYCLO-
OXYGENASE PRODUCTS 
PGE, 1.7 ± 0.3 2.1 ± 0.2 16 
TXB, 3.4 ± 0.3 3.2 ± 0.2 5 
6kPGF'a 2.7 + 0.3 3.1 + 0.3 5 
Respiratory burst: To measure the respiratory burst activity of the hp-M¢, the method 
published by Emmendorffer et aJ. using DHR 123 for human neutrophils (31) was 
modified for peritoneal M¢. The optimal net formation of ROI loaded with DHR 123 
(0 - 1000 ng/ml, 10 min) and stimulated with TPA (0 - 1000 ng/ml, 15 min) is given 
in Figure 5.4 (top left and top right). All subsequent experiments were performed with 
100 ng/ml TPA and 333 ng/ml DHR 123. 
To check whether this method depended on the cell activity, the ROT production 
wasalso measured in cells (n =4) which were kept on ice during the stimulation and 
loading (10 + 15 min). In Figure 5.4 (left bottom) the temperature dependency for the 
ROI production at 4'C (n =4) and 37'C (n = 10) is shown. There was nO significant 
ROI production increase at 4'C, but TPA increased the net ROI production 
significantly at 37'C. The respiratory burst activity dependence on the time of stimulus 
is shown in Figure 5.4 (bottom right). The ROI production was significantly different 
after 15 min of stimulation. DHR 123 and TPA were given at the same time now. 
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Figure 5.4 The radical oxygen intermediates (ROI) of hp-M.p (0.25xlO"/ml) was mea5ured with 
dihydrorhodamine 123 (DHR 123). Left top figure shows the dependency of net ROI production on 
phorbol 12-myristate 13-acetate (TPA) concentration (0 - 1000 nglml, 10 min TPA + IS min 333 
nglml DHR 123, 37'C, n=3). Right top figure shows the dependency of net ROI production on DHR 
123 concentration (0 - 1000 nglml, 10 min 100 nglml TPA + IS min DHR 123, 37"C, n=3). The 
results of three patients are shown separately; (m, ., JI.). Left bottom figure shows the spontaneous 
(open bar) and TPA-stimulated (closed bar) respiratory burst activity at 4°C (n=4) versus 37°C 
(n= 10) (10 min blanc or 100 nglml TPA + 15 min 333 nglml DHR 123). In these 3 graphs the ROI 
production is given in mean channel number (MCN). Data are expressed as mean ± SEM and 
statistically significant (*) when p < 0.05 vs. controls (spontaneous respiratory burst). Right bottom 
figure shows the stimulus time dependency (n=3). Blanc (0) or TPA (8) and DHR 123 were given 
at the same time (t= 0 - I hr, 100 nglml TPA, 333 nglml DHR 123, 37'C, n=3). The ROI 
production is expressed as % increase of maximal increase (= 100 %) per patient with TPA. Data 
are expressed as mean ± SEM and statistically significant (*) when p < 0.05 vs. controls (t ::;; 0 h). 
5,5 Discussion 
Aim: In previous experiments we have shown that ascites is a good source of hp-M¢ 
which can be used to study eicosanoid production by human M¢ [27,28,32]. These 
M¢ can be used as a model for testing the effects of anti-inflammatory drugs on the 
eicosanoid production in vitro, as we have shown previously with drugs such as 
Malotilate [33] and E6080 [34]. 
By gaining more information on the inter-relationships between the inflammatory 
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mediators, such as eicosanoids, cytokines and oxygen radicals of the hp-M¢ we expect 
to expand our ex vivo anti-inflammatory drug testing model with human inflammatory 
cells. 
The aim of this study was to characterize in addition to the eicosanoid production other 
cell functions of hp-M¢ including cytokine production and respiratory burst activity. 
Results: We investigated the cytokine production ofhp-M¢ stimulated with LPS as this 
is an important stimulus for M¢ in vivo [7,13]. 
The eicosanoid production was determined both with LPS and A23187 as this stimulus 
is known to be a potent trigger for lipoxygenase products derived from M¢ [5,20,21]. 
The experiments showed that the production of the cytokines IL-IJl, IL-6 and TNF-O! 
was LPS concentration dependent and also dependent on the time of exposure to the 
stimulus. 
LPS stimulation influenced the net IL-IJl, IL-6 and TNF-O! production significantly, 
but did not have an appreciable effect on the eicosanoid production from endogenous 
arachidonate. 
A short stimulation with A23187 gave a significant increase in lipoxygenase products 
from exogenous and endogenous arachidonate. The eicosanoid production from 
exogenous and endogenous arachidonate depended on the A23187 concentration. 
Production of measurable amounts of ROJ in vitro of the hp-M¢ can be triggered by 
TPA. With the lowest concentration of the stimulating agent the ROl production was 
maximal, higher concentrations of TPA did not change the level of production. The 
measurement of ROI production was DHR 123 concentration dependent. Beyond 333 
nglml the ROI production slightly decreased, the DHR 123 concentration was no 
longer a limiting factor. 
With optimal concentrations of TPA and DHR 123 the net respiratory burst activity 
increased significantly. When stimulus and DHR 123 were given at same time, the 
increase was significant after 15 min. 
Comparison of cytoldne and eicosanoid production in M¢ from different species and/or 
origin: Similar kinetics as we had found for LPS induced cytokine production have 
been previously reported for human alveolar M¢ [35-37] hp-M¢ obtained from 
continuous ambulatory peritoneal dialysis (CAPD) patients [38,39], a murine 
macrophage cell line [40] and murine peritoneal M¢ [41-43]. 
In all these observations the cytokine production increased with increasing LPS 
concentration with a maximum in the range 1 - 10 I'g/ml LPS. Human alveolar M¢ 
had with LPS a maximal IL-lJl (0 - 42 hand lL-6 (0 - 72 h) production by 24 h [a 
slight increase at 72 h for lL-6), 35,36]. 
The IL-I production of the murine macrophage cell line P388DI (0 - 18 h) and murine 
peritoneal M¢ (Alderey Park, 0 - 24 h) increased in time with LPS [40,42]. Peritoneal 
M¢ from C3H/HEN and C3HIHEJ mice had with LPS (0 - 72 h) a maximal II-I 
production at 24 h [41]. The IL-6 production was maximal between 8 - 12 h for the 
murine macrophage cell line [40]. 
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TNF-a production of Mq, of other origin or species usually reached a maximal level 
at an earlier time then our hp-Mq,. TNF-a (0 - 42 h) production of human alveolar Mq, 
peaked between 4 - 8 h [35]. The murine macrophage cell line stimulated with LPS 
reached a plateau at 2 h [40]. Rat peritoneal Mq, reached a maximum at 6 h [44] and 
guinea pig peritoneal Mq, around 8 h [45]. 
In our experiments LTB4 and 5-HETE were the main eicosanoids formed (89 %), 
when the Mq, were stimulated with A23187. In normal bovine alveolar Mq, A23187 
stimulated the release of both the cyclooxygenase and Jipoxygenase products [21], also 
in resident mouse peritoneal Mq, [46,47]. Rat peritoneal Mq, and rat Kupffer cells 
mainly synthesized cyclooxygenase products after A23187 stimulation [32]. 
In alveolar Mq, from healthy volunteers, exogenous arachidonic acid was 
predominantly metabolized via the 5-lipoxygenase pathway [20,48,49], but also 
cyclooxygenase products were formed, when stimulated with A23187 [20,49]. 
Leukotrienes are known to mediate inflammatory reactions. LTB, is an important 
chemotactic agent for leucocytes [16], generates superoxide anion in neutrophils [17], 
whereas the sulfidopeptide leukotrienes (LTC" LTD, and LTE4) primarily affect 
smooth muscle contraction, increase vascular permeability [18] and promotes 
lysosomal enzymes [19]. 
Specific inhibition of the enzyme 5-lipoxygenase has therapeutical potential in a variety 
of inflammatory conditions shown by different animal models and clinical trials [50-52] 
and as mentioned before we have tested the drugs Malotilate [33] and E6080 [34] on 
the eicosanoid production in our in vitro model. 
The pattern of eicosanoid metabolism depends on the stimulus applied [20,21,48], as 
well as the maturity of the cell [49], site of origin of macrophage and the species [32]. 
In relation to this, in vivo priming might be another important point for influencing the 
eicosanoid and cytokine profile when the cells are stimulated in vitro. Cytokines and 
eicosanoids regulate also their own and each other's release in vivo and in vitro [53-
55]. The exact interaction of these mediators involved in human macrophage 
inflammation still has to be investigated. 
Comparison of cytokine and eicosanoid production in hp-Mq, from liver cirrhosis and 
CAPD patients: The high cytokine production of our hp-Mq, with LPS was probably 
due to priming of the cells in vivo. The patients, where the cells were isolated from, 
have a chronic inflammation. Peritoneal Mq, obtained from CAPD patients during 
peritonitis and compared to Mq, obtained from the same type of patients during a 
infection free period, stimulated with LPS in vitro, released significantly more IL-IB 
and TNF-a [39,56] whereas their prostacyclin release (measured as 6kPGF 1a , without 
and with LPS) had declined sharply [38]. 
The TNF-a bioactivity of the liver cirrhosis Mq, seems lower then Mq, of CAPD 
patients with peritonitis, however TNF-a was measured by different bioassays. 
Although the methods are comparable the % killing is higher with the 3H-thymidine 
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Table 5.5 Comparison of cytokine and Prostaglandin synthesis by human peritoneal macrophages from 
liver cirrhosis and continuous ambulatory peritoneal dialysis (CAPD) patients without and with 
peritonitis. Compared are the eicosanoid and cytokine synthesis without stimulus (24 h PBS = blancs) 
and with stimulus (24 h LPS = LPS), LPS = 5 Jlg/ml CAPD hp-M¢ (10' cells/ml) and 10 "g/ml with 
liver cirrhosis hp-Mcp (106 cells/m!), n = number of patients. 
Liver Cirrhosis (this study) CAPD [38,39,56] 
n 
Control n Peritonitis n 
IL-IB blancs 3.0 ± 1.2 16 0.3 ± 0.1 9 0.2 ± 0.1 8 
(ng/ml) 
LPS 8.7 ± 1.5 1.0 ± 0.2 6.6 ± 2.8 
TNF-c< blancs 21.6 ± 5.1 17 4.3 ± 5.1 21 12.9 ± 4.1 12 
(% 
LPS 47.7 ± 3.9 15.8 ± 6.5 61.9 ± 7.7 
killing) 
TNF-c< blancs 0.1 ± 0.1 10 1.0 ± 0.3 12 1.0 ± 0.3 12 
(ng/ml) 
LPS 2.7 ± 1.I 2.6 ± 0.4 9.3 ± 4.3 
6kPOF," blancs 2.7 ± 0.3 5 19.1 ± 3.6 10 3.4 ± 1.4 10 
(ng/ml) 
LPS 3.1 ± 0.3 21.4 ± 4.3 4.0 ± 1.2 
. 
POE, blancs 1.7 ± 0.3 5 15.1 ± 2.7 10 9.4 ± 2.6 10 
(ng/ml) 
LPS 2.1 ± 0.2 27.4 ± 4.5 31.0 ± 4.4 
incorporation cytostatic assay compared to the MIT tetrazolium cytotoxic assay [29]. 
Therefore the TNF-a bioactivity of hp-M¢ from liver cirrhosis patients compared to 
M¢ from CAPD patients with peritonitis could be in the same range. The 
concentrations ofTNF-a measured by ELISA in supernatants of liver cirrhosis patients 
however showed a TNF-a production comparable to M¢ from CAPD patients without 
peritonitis. 
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A pronounced difference between the M¢ from liver cirrhosis and the M¢ of CAPD 
patients with peritonitis was observed in the PGE2 production. The PGE, release of 
human peritonitis M¢ without LPS was initially much higher then the hp-M¢ in our 
observations. Furthermore a significant increase in PGE, production in response to 
LPS was seen (no difference compared to infection-free M¢ of CAPD patients). 
In conclusion the M¢ of liver cirrhosis patients have striking features with M¢ from 
CAPD patients with peritonitis (see Table 5.5). 
Oxygen radical production: In response to TPA the ability to generate oxygen radicals 
was enhanced. TPA stimulates the intracellularly and extracellularly respiratory burst 
of phagocytes [57,58]. The flow cytometric method we have used here reflects the total 
production of H20, inside single, stimulated, cells. DHR 123 is oxidized by a 
hydrogen peroxide and peroxidase dependent system. This method with DHR 123 
seemed to be a highly sensitive indicator for the respiratory burst [59-6l]. In 
comparison with human monocytes and neutrophils the respiratory burst of monocyte-
derived M¢ was very low when measured with the luminol-amplified 
chemiluminescence assay [61], which measures intra- and extracellular H20 2 and 0 2-
[58]. We were able to measure with DHR 123 a clear increase in the respiratory burst 
activity, when the M¢ were stimulated with TPA. Our results were similar to Banati 
[30] whom measured the respiratory burst of rat peritoneal M¢ with DHR 123. The 
M¢ exhibit spontaneous respiratory burst activity already before stimulation and after 
stimulation the fluorescence intensity had increased about a factor 3, our ROI 
production (in MCN) increased a factor 2.4. 
Conclusion: Ascitic fluid is an easily available source of large quantities of hp-M¢. In 
this study we have characterized the eicosanoid and cytokine production and 
respiratory burst activity of human M¢ isolated from peritoneal ascitic fluid. The IL-
IB, IL-6 and TNF-a kinetics ofhp-M¢ stimulated with LPS is similar to that of human 
lung M¢, peritoneal M¢ of CAPD patients and peritoneal M¢ of other species. The 
cytokine production is LPS concentration dependent and dependent on the time of 
exposure to LPS. The profile of eicosanoid production depends on both the species 
origin, location and the stimulus applied. LPS did not effect the eicosanoid production 
from endogenous arachidonate of the hp-M¢, while a stimulation with A23187 both 
increased the Jipoxygenase production from exogenous and endogenous arachidonate. 
The M¢ of liver cirrhosis patients have striking features with M¢ from CAPD patients 
with peritonitis, probably due to priming of the M¢ in vivo. 
With optimal concentrations of TPA and DHR 123 the net respiratory burst activity 
in the hp-M¢ increased significantly. Whether a relation exists between formation of 
cytokines and eicosanoids and the respiratory burst activity of the hp-M¢ still has to 
be examined. 
Characterization of hp-M¢ function show that ascites may be a promising source of 
M¢ to set up a model for testing the effects of anti-inflammatory drugs in vitro on 
different types of inflammatory mediators produced by human M¢. 
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Chapter 6 Effect of a novel 5-lipoxygenase inhibitor, E6080 on the 
eicosanoid production of human peritoneal macrophages 
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1 Dept. of Pharmacology, Erasmus University, Rotterdam and 'Dept. of Internal 
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6.1 Summary 
This study was performed to determine the selectivity of the 5-lipoxygenase inhibitor 6-Hydroxy-2-(4-
sulfamoylbenzylamino)-4,5,7-trimethylbenzothiazole hydrochloride (E6080) on the in vitro eicosanoid 
metabolism in human peritoneal cells of patients with ascites. The ICso for E6080 on the formation 
of the 5-Jipoxygenase products leukotriene B4 (LTB4) and 5-hydroxy-eicosatetraenoic acid (5-HETE) 
was respectively 3.7 ~M and 1.7 ~M. The production of the other lipxygenase (8-, 12-, IS-RETE) 
and cyclooxygenase products [hydroxy-heptadecatrieoic acid CHHT), 6-keto-prostaglandin F I", 
(6kPGP,.), thromboxane B, (TXB,), PGP"" PGE, and PGD,) were not significantly inhibited in the 
dose range we have studied (0.3,uM - 30 J.tM). E6080 is specific and equipotent to most of the known 
potent 5-lipoxygenase inhibitors. 
Keywords: E6080. 5-lipoxygenase inhibitor. arachidonic acid metabolism. human 
peritoneal cells 
6.2 Introduction 
One potential approach for the treatment of chronic inflammatory diseases is to 
suppress the release of inflammatory mediators. 
Eicosanoids are among the most important inflammatory mediators and modulators of 
both the initial and late phase of the inflammatory reaction. 
Leukotrienes, a group of 5-lipoxygenase products belonging to the eicosanoids, have 
marked effects on the neutrophil migration, neutrophil and monocyte aggregation, 
release of lysosomal enzymes, capillary permeability, induction of pain and smooth 
muscle contraction [1,2]. Different animal models and clinical trials have shown that 
drugs which block leukotriene synthesis by specific inhibition of the enzyme 5-
lipoxygenase, have therapeutic potential in a variety of inflammatory conditions such 
as inflammatory bowel disease [3], rheumatoid arthritis [4], anaphylaxis [5,6,7], 
asthma [8,9,10], endotoxic shock [II] and edema and pleurism [12,13]. 
Several5-lipoxygenase blockers have been described, of varying specificity. Recently 
Tsunoda et. aI. reported that the new compound E6080 suppressed anaphylaxis and 
bronchospasm in animal models, probably by blocking leukotriene synthesis [5,8]. To 
determine whether this compound is indeed a specific and potent 5-lipoxygenase 
blocker and also effective in human cells, we examined its effects on the pattern of 
eicosanoid production by human peritoneal cells. We compared our findings on 
specificity and potency with those reported for other 5-lipoxygenase blockers. 
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6.3 Materials and methods 
Subjects: Peritoneal cells were obtained from ascites of five patients with portal 
hypertension (5 patients). None of the patients were on drugs which have been 
reported to influence the lipoxygenase and cyclooxygenase enzymes. 
Cell isolation: The human peritoneal cells were isolated by centrifugation of the ascitic 
fluid at 400xg (4°C) and washed with phosphate buffered saline (PBS. pH 7.4, 4°C, 
Oxoid, UK). A small sample of the cells were stained by Hemacolor (UK) and the 
different cell types were counted under a microscope (Zeiss, standard 25, Germany). 
Incubation: One million peritoneal cells suspended in Dulbecco's minimal essential 
medium (Dulbecco's MEM, Gibco, UK) were incubated for two min with 6-Hydroxy-
2-(4-sulfamoylbenzylamino)-4,5,7-trimethyl-benzo thiazole hydrochloride (E6080, Eisai 
Co., Japan; dose range: 0.3 I'M - 30 I'M), labelled with 14C-arachidonic acid (0.125 
I'Ci, 55.7 mCi/mmol, Amersham, UK) for two min and triggered by the calcium 
ionophore A23187 (2 I'M, final concentration) for 13 min at 37°C. 3H labelled 
standards consisting of 6kPGF'a, PGE" LTB" 12-HETE and IS-HETE (approx. 0.01 
I'Ci of each eicosanoid, Amersham, UK) were added for recovery calculations and as 
retention time markers. The supernatants were then passed through Sep Pak C" 
cartridges (Waters Ass., USA) and eluated with methanol, dried and dissolved in 200 
1'1 methanol. 
Eicosanoid production: Exogenous eicosanoid formation was measured on RP-HPLC 
using a Nucleosil 5C" column (3x200 mm, Chrompack, The Netherlands). 100 1'1 
sample was injected onto the column. As eluens a gradient of acetonitrile and 0.2 % 
triethylamine I 0.12% trifluoracetic acid I water (> > pH 3) was used. 
Statistical analysis: The data are expressed as the mealY + standard error of the mean 
(SEM, n=5). The IC,o values were calculated by BMDP software module for non-
linear curve-fitting [14]. The curve was fitted to a four parameter logistic function 
[15]. 
6.4 Results 
Cell differentiation: Microscopically the following cells were found: 77 + 10.4 % 
macrophages (MY), 16 + 11.3% Neutrophils, 7 ± 5.0 % lymphocytes and 0.1 + 0.1 
% eosinophils. 
Eicosanoid production: Figure 6.1 shows the main lipoxygenase products formed by 
human peritoneal cells consisting ofLTB, (16.7 %), 5-HETE (15.6 %) and 15-HETE 
(4.5 %). The minor lipoxygenase products were 8-HETE (1.3 %) and 12-HETE (1.0 
%). The main cyclooxygenase products were HHT (20.0 %), 6kPGF'a (19.6 %) and 
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TXB2 (6.2 %) and as minor cyclooxygenase products PGF2• (3.1 %), PG~ (2.4 %) 
and PGD2 (l.8 %) were formed. 
Eicosanoid inhibition: In figure 6.2 the influence of E6080 on the production of the 
most common eicosanoid products of the human peritoneal cells, is presented. E6080 
inhibited, in a concentration range of 0.1 I'M -30.0 I'M, the 5-lipoxygenase products 
LTB4 and 5-HETE in a selective manner. The Ie" values for LTB4 and 5-HETE were 
respectively 3.7 and l.7 I'M. The production of the other lipoxygenase and 
cyc\ooxygenase products was not significantly inhibited in the dose range studied. 
30 
c 
.~ 
"  ~ 15 
0: ;( 
fi i@' 
'" o ;;;:: / " .<,.<Q~ .<,.'v A,,'v -A,,~ A~ 0~~o+<Q'" t- 0~"'o 0~" 0Q " 
'v -l-~ ~~ ~~ ~~- $ .<,. ~ q ~ ~ 
~'b,\q;,,',jQ<i 
Figure 6.1 Arachidonic acid metabolites formed by peritoneal cel1s of patients with ascites, expressed 
as the mean percentage of total formation of the most common metabolites ± SEM (n = 5). 
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Figure 6.2 Effect of E6080 on the formation of the 5-1ipoxygenase products LTB4 and 5-HETE (IA), 
the other lipoxygenase products, 8-HETE, 12-HETE and IS-HETE (IB) and cyc100xygenase products, 
6kPGF,", TXB, and HHT (IC), PGF,", PGE, and PGD, (ID) in human peritoneal cells. Each point 
represents the mean ± SEM (n = 5). Control = 100 % of metabolite formation. 
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The effects of E6080 on 5-, 12- and 15-lipoxygenase and cyclooxygenase are 
summarized in table 6, I and compared with reported IC,o values for the following 
drugs: A64077, AA861, MK861, BWA137C and CGS 8515. 
Table 6.1 Comparison of the potencies and selectivities of some novel5-lipoxygel1ase inhibitors and 
E6080 in vitro (REF = reference; > > = higher then; n,d.= not detected). 
IC,o {J.tM) 
DRUG REF LTB, 5-HETE 12/IS-LO CO 
E6080 
ill vitro this paper 3.7 1.7 > > 30 > > 30 
in vivo 8 approx 1 n.d. n.d. n.d. 
A64077 4,16 0.16 - 2 0.53 > > 100 4.8 - 25 
AA861 12,16,23 0.08-0.8 0.01-0.8 100 (12-W) 15 
MK-886 9,19 0.0025-1.1 0.003-0.013 > > 1.1 > > 1.1 
BW A137C 24 0.1 - 0.8 n.d. 2.2 - 15 22 - 32.4 
CGS 8515 13 0.1-3.8 0.02-1.0 »3012- 60 - 340 
LO 
> > 50015-
LO 
6.5 Discussion 
Human peritoneal M.p (hp-M.p) are an easily available source of inflammatory cells, 
which can be used to test new drugs for the effects on inflammatory mediators and 
may be a first choice model for anti-inflammatory drugs tested in vitro before clinical 
studies are started. 
E6080 proved to be a potent 5-lipoxygenase inhibitor in human peritoneal cells (M.p, 
neutrophile granulocytes, eosinophils and lymphocytes) with an IC,o between 1.7 - 3.7 
I'M. 
According to Tsunoda et. al. the IC,o of E6080 on LTB, production in an antigen 
inhalation sensitized guinea pig model, measured in broncho alveolar lavage fluid, was 
approximately 1 I'M [8]. This suggest that the IC,o values of E6080 found in vitro for 
human peritoneal cells for 5-lipoxynase, are similar to those found in vivo in the 
anaphylactic shock animal model. 
E6080 is an orally active 5-lipoxygenase inhibitor [8] which we have shown now by 
examining overall eicosanoid production, to be specific. E6080 inhibits, in a 
concentration range from 0.1 to 30 I'M, the 5-lipoxygenase products LTB, and 5-
HETE in a selective manner without effecting the other lipoxygenase and 
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cyclooxygenase products. 
Potent specific 5-lipoxygenase inhibitors for clinical use are not available as yet, 
although clinical trials with some novel 5-lipoxygenase inhibitors are at present 
performed. 
A-64077 (Zileuton) seems to be a useful oral 5-lipoxygenase inhibitor. In vitro in 
different models the IC" value is quite low [4,16]. In clinical trials in patients with 
ulcerative colitis A-M077 caused a significant fall in the median LTB4 levels [3], and 
in other clinical trials it ameliorated the asthmatic response to cold, dry air [17] and 
attenuated allergen-induced nasal congestion and the release of5-lipoxygenase products 
in nasal-rinse [7]. However, results in atopic asthma have been disappointing [10]. 
MK-886 seems to be a very potent and specific 5-lipoxygenase inhibitor (So far as 
known the only 5-lipoxygenase inhibitor through a new mechanism: 5-lipoxygenase 
activating protein (FLAP) [IS]) for human PMNLs in vitro [9,19], orally active in 
different animal models [9,20,21], which is now undergoing clinical trials [22]. 
AA861, as shown in table I, has marked lower IC" values for LTB4 and 5-HETE then 
those obtained for E6080 [12,16,23]. However, AA861 is orally less effective when 
compared with E6080 on bronchospasm in actively sensitized conscious guinea pigs 
[S] and protection ofPAF-induced death in mice [5]. The difference between in vitro 
and in vivo results might be due to poor bioavailability [S]. 
Other more or less equipotent 5-lipoxygenase inhibitors are the following substances: 
BW A4C and BW A137C [24], given orally, been found to be effective in a bronchial 
anaphylaxis anaesthezided guinea pig model [6], and CGS 8515 inhibits inflammatory 
response in carrageen-induced pleurisy, sponge inflammation in rats [13] and endotoxic 
shock in rats [11]. 
E60S0 is equipotent to most of the known 5-lipoxygenase inhibitors. We have shown 
that it is effective in human peritonealleucocytes. E60S0 is a promising 5-lipoxygenase 
blocker for clinical use as it is very selective in the wide dose range we have used. 
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Chapter 7 Interactions between cytokines and eicosanoids: a study 
using human peritoneal macrophages 
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7.1 Summary 
To examine the interactions between the main pro-inflammatory'cytokines and eicosanoids produced 
by human inflammatory cells, human peritoneal macrophages (hp-M¢) were isolated from ascitic fluid 
of patients with portal hypertension. Interactions between interleukin 18 (lL-l/l), interleukin 6 (IL-6), 
tumor necrosis factor ex (TNF-a), leukotriene B4 (LTB4) and prostaglandin E2 (PG~) were studied by 
addition or inhibition of several cytokines and eicosanoids: Human recombinant IL-IB (hrIL-l13) 
addition, LTB4 addition and 5-lipoxygenase inhibition (6-Hydroxy-2-(4-sulfamoyJbenzylamino)-4,5,7-
trimethylbenzothiazole hydrochloride; E6080), PGE2 addition and cyclooxygenase inhibition (indomethacin). 
In hp-Mq., hrIL-lfi stimulated the LTB4 production, while the PGE2 production was inhibited. HrIL-lB 
had no significant effect on IL-6 production in hp-Mq.,. LTB4 did not regulate IL-lfi and IL-6 
production. Increasing PGE2 down regulated the TNF-O' production, but did not effect the IL-lfi and 
IL-6 production. 
Key words: human peritoneal macrophages . eicosanoids . cytokines . interactions 
7.2 Introduction 
It is known that M¢ are a principal source of inflammatory mediators such as 
cytokines and eicosanoids, and that many differences exist both in their production of 
and interactions between mediators depending on the species origin, tissue origin, 
stimulus and cell maturity. These differences must be considered when in vitro systems 
are used as models for human inflammatory diseases. 
In previous studies we have characterized the production of the cytokines IL-IJl, IL-6 
and TNF-a and the lipoxygenase and cyclooxygenase products by hp-M¢ isolated from 
ascitic fluid of patients with portal hypertension [I]. The cytokines IL-I [2], IL-6 [3], 
and TNF-a [4] are important pro-inflammatory cytokine products of M¢ upon 
stimulation with lipopolysaccharide [(LPS), 5]. The cytokine release of hp-M¢ was 
time and dose LPS dependent. The IL-IJl, IL-6 and TNF-a had similar kinetic plots 
in hp-M¢ [I] human lung M¢ [6], peritoneal MY (p-M¢) of continuous ambulatory 
peritoneal dialysis (CAPD) patients [7] and p-M¢ of other species [8]. In contrast, the 
eicosanoid profile in M¢ seems to be more dependent on the species origin, on the 
tissue from which the M¢ were derived [9] and the stimulus applied [10]. Thus rat p-
M¢ synthesize mainly cyclooxygenase products [9] and mice p-M¢ synthesize both 
cyclo- and lipoxygenase products when the cells are stimulated by calcium ionophore 
[11]. In hp-M¢ a stimulation with calcium ionophore increased the lipoxygenase 
products [I]. Usually peripheral blood monocytes of healthy donors or resident p-M¢ 
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from rats or mice are used to study interactions between cytokines and eicosanoids. 
However peripheral blood monocytes differ from mature M¢ and have different 
profiles of inflammatory mediators [12]. Resident M¢ also differ from activated M¢, 
as. in vivo priming also influences the profile of inflammatory mediators produced by 
the hp-M¢ [7]. IL-l is known to stimulate 5-lipoxygenase [13] and PGE, production 
[14,15], leukotrienes are known to be involved in the regulation of IL-I production 
[16,17] and interactions between IL-l and IL-6 have been reported [18,19]. All these 
experiments have been performed with cells derived from different species and/or 
tissues or different cell types. 
As differences exist in the production of inflammatory mediators, it is expected that 
the interactions between eicosanoids and cytokines also depends on the species origin, 
tissue origin, stimulus applied and cell maturity. Following the above concept, we have 
attempted to characterize in vitro the interactions between IL-lll, IL-6, TNF-ex, LTB4 
and PGE" the major pro-inflammatory cytokines and eicosanoids of hp-M¢. 
7.3 Materials and methods 
Subjects: The hp-M¢ were obtained from ascitic fluid of 6 patients (= n, 5 males and 
I female, age 39 - 82 years) with ascites, due to portal hypertension, undergoing 
therapeutic paracentesis. Patients were mainly on drugs such as diuretics which have 
not been reported to affect cytokine and eicosanoid production. 
Cell isolation: The hp-cells were isolated from the ascitic fluid by centrifugation at 
400xg (4°C) and washed with phosphate buffered saline (PBS, pH 7.4, 4°C, Oxoid, 
UK). After that the concentrated hp-cell suspension was separated on Percoll (d = 
1.064 g/ml, Kabi-Phannacia, Sweden). To establish the hp-cell purity a small sample 
of cells was stained by Hemacolor (Merck, Germany) and the different cell types were 
counted under a light microscope. The following composition of cells was found: 92.5 
± 2.4% M¢, 6.1 ± 2.2 % lymphocytes and 1.5 ± 0.7 % granulocytes (number of 
patients (n) = 6). The viability of the hp-cells was tested by trypan blue exclusion 
method. The viability of the cells was 84.1 ± 1.9 % (range: 78.5 - 90.6). 
Cell incubation: Cells were plated on plastic culture dishes (Costar, UK) at a density 
of 10' celI/ml in RPMI medium [RPMI-I640 supplied with HEPES (25 mM, GIBCO, 
UK), penicillin/streptomycin (5xlO' U/I / 50 mg/I, Flow Lab, UK), foetal calf serum 
(10 % FCS, GIBCO, UK) and L-glutamine (600 mg/I Flow Lab, UK)]. The cells were 
first incubated for 10 min with different mediators and inhibitors of inflammatory 
mediators (3rC, 7.5 % CO,): LTB4 (Sigma, USA), a 5-lipoxygenase inhibitor E6080 
(Eisai Co., 43 Japan), PGE, (Sigma, USA), Indomethacin (Merck Sharp and Dohme, 
NL), hrlL-ill (British Bio-technology, UK). 
Thereafter cells were incubated in the absence or presence of a final concentration of 
10 I'g/ml LPS in PBS (PBS; 10 % final concentration, Sigma, USA, 3rC, 7.5 % 
CO2) for 24 h or stimulated by a final concentration of 1 I'M calcium ionophore 
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A23187 in dimethyl sulfoxide (DMSO; 0.1 % final concentration, Sigma, USA, 37'C, 
7.5 % CO2) for 15 min. At the end of the incubation the supernatant was filtered (0.22 
/Lm, Millipore, France) and kept at -80°C till analyzing. Cell viability was not 
influenced by increasing concentrations of hrlL-lB, LTB4, E6080, PGE,. and 
indomethacin in comparison to controls (24 h incubations). 
Cytokine analysis: The cytokine production was measured in the supernatant of the 
samples incubated for 24 h without or with 10 /Lg/ml LPS. IL-IB, IL-6 and TNF-a 
products were measured by ELISA (IL-IB: Medgenix, Belgium, sensitivity = 2 pg/ml. 
IL-6: Hycyte, The Netherlands, sensitivity = 2 pg/ml; TNF-a: Cistron Biotechnology, 
USA, sensitivity = 10 pg/ml). 
Eicosanoid production: LTB, and PGE,. production from endogenous arachidonate was 
measured in supernatant of the samples stimulated with A23187 or LPS by radio 
immuno assays (RIA's; antibodies were obtained from Advanced Magnetics, USA, 
tritiated antigens from Amersham, UK and standards from Sigma, USA). Cross 
reactivities for individual antigens on antibodies were negligible. 
Statistical analysis: The data are expressed as the mean ± standard error of the mean 
(SEM). Data were statistically analyzed with ANOVA followed by Dunnett's test, or 
only the Student's T -test or Wilcoxon-test. The non-parametric Wilcoxon-test was used 
for statistical analysis as the range of the production between the patients was fairly 
wide. This lack of homogeneity was nonpermissive for the student's T-test. The 
correlations were determined by Pearson's Correlation test. Data were considered 
significant when p < 0.05. 
7.4 Results 
Cytokine and eicosanoid production of hp-Mq,: To determine the basal cytokine and 
eicosanoid production of the hp-Mq" the cells were incubated in vitro without and with 
l/LM A23187 for 15 min (Table 7.IA) and without and with 10 /Lg/ml LPS for 24 h 
(Table 7.1B). The LTB4 and PGE2 production of the hp-Mq, were low after 15 min of 
incubation without stimulus. Only the LTB, production increased with A23187 
stimulation. 24 h of incubation without or with LPS did not influence the LTB, 
production. The PGE2 production was 10 fold higher when the cells were incubated 
without stimulus for 24 h and further increased twofold when the cells were stimulated 
with LPS. Hp-Mq, produced the cytokines IL-IB, IL-6 and TNF-a when they were 
incubated without stimulus for 24 h. The production of these cytokines increased then 
significantly when the hp-Mq, were stimulated in vitro with LPS. 
The interactions between cytokines and eicosanoids were studied by addition or 
inhibition of several mediators: hrlL-IB addition, LTB, addition and 5-lipoxygenase 
inhibition (E6080), PGE,. addition and cyclooxygenase inhibition (indomethacin). The 
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results are presented in percentages, control is set as 100 % (Tabel 7.1 gives the 
production of controls in pg or ng per mil. 
Table 7.1 (A) PGE, and LTB, production (pg/ml) by 10' hp-M¢!ml stimulated for 15 min with I ~M 
A23187 (Control is 15 min incubation with DMSO). (8) LTB" PGE" IL-16, TNF-<> (pg/ml) and IL-6 
production (ng/ml) by 10' hp-M<J>lml stimulated for 24 h with 10 ~g/ml LPS (Control is 24 h 
incubation with PBS). Data are expressed as mean ± SEM and statistically analyzed by Wilcoxon-test 
(JV), * = p < 0.05 (increase vs control), n = number of patients, fiS = not significant. 
Table 7 IA 
PRODUCT CONTROL 
LTB, (pg/ml) 652 ± 416 
PGE, IPg/ml) 52 + 26.3 
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PRODUCT CONTROL 
LTB, (pg/ml) 611 ± 125 
PGE, (pg/ml) 692 ± 167 
IL-16 (pg/ml) 825 ± 417 
TNF-<> (pg/ml) 195 ± 81 
IL-6 (ng/ml) 8 + 2.0 
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Figure 7.1 The effects of hrIL-16 (0.33 - 33 ng/ml) 
on the production of (A) LTB, (15 min DMSO), (8) 
PGE, (24 h LPS) and (C) IL-6 (24 h PBS) of 1.10' 
hp-M<J> Iml. Data [% change (100 % = control)] are 
expressed as mean ± SEM and statistically analyzed 
by ANOVA followed by Dunnett's test, * = p < 
0.05 (increase vs control), number of patients = 5. 
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Addition of hrIL-Ij3: As the 24 h incubation without or with stimulus did not influence 
the LTB4 production of the hp-M¢ (Table 7 .lE), we only studied the effect of hrIL-IJl 
on the LTB4 production when the cells were incubated for 15 min without or with 
A23187. LTB4 production was dose dependently increased when the cells were 
incubated for 15 min without A23187 and with hrIL-IJl (Figure 7.IA). PGE2 
production was stimulated by LPS (Table 7 .lE). This production was dose dependently 
decreased by hrIL-IJl (Figure 7.lE). HrIL-IJl (24 h without LPS) did not significantly 
affect IL-6 production in hp-M¢ (Figure 7.1C). 
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Figure 7.2 The effect of LTB, (0.33 - 33.3 ng/ml) on 
(A) the PGE, production (24 h LPS) of 1.1 0' hp-M<J> 
1m!. The effect of E6080 (0.33 - 33 I'M) on the 
production of (8) LTB, (15 min A23187) and (C) 
PGE, (24 h LPS) of 1.10' hp-M<t> 1m!. Data [% 
change (100 % = control)] are expressed as mean ± 
SEM and statistically analyzed by ANOVA followed 
by Dunnett's test, * = p < 0.05 (increase vs 
control), number of patients = 6, 
LTB4 addition and 5-lipoxygenase inhibition: PGE, production increased significantly 
when the hp-M¢ were incubated for 24 h with LPS (Table 7.1B). Adding LTB, to hp-
M¢ followed by incubations of the cells for 24 h without (D.33 - 33.3 ng/ml LTB4: 92 
± 7.D %; 86 ± 15.1 %; 86 ± 8.3 %; 64 ± 8.7 %; 91 ± 15.2 %, n = 6) or with 
LPS (Figure 7.2A) did not have significant effects on PGE, production. As expected 
the 5-lipoxygenase inhibitor E6D8D significantly reduced A23187 stimulated LTB4 
production (IC,o value of approx. 0.2 I'M, Figure 7.2B). Although LPS (24 h) did not 
stimulate the LTB4 production, E6D8D also inhibited without or with LPS (24 h) the 
LTB4 production dose dependently (0.33 - 33.3 I'M E6D8D: 79 ± 9.D %; 80 ± 12.6 
%; 39 ± 6.1 % (p<D.D5); 31 ± 9.1 % (p<O.OS); 38 ± 14.3 % (p<D.D5), IC,o 
value of approx. 2.S I'M, n = 3). E6D8D also inhibited the LPS stimulated PGE, 
production dose dependently (IC,o value of approx. 25 I'M, Figure 7.2C), although 
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E6080 did not significantly affect the LPS stimulated IL-IB (0.33 . 33.3 I'M E6080: 
89 ± 6.3 %; 77 ± 8.7 %; 79 ± 7.7 %; 67 ± 13.0 %; 56 ± 14.8 %, n = 6) and IL-
6 production (0.33 - 33.3 I'M E6080: 109 ± 10 %; 109 ± 11 %; 118 ± 11 %; 110 
± 9 %; 122 ± 16 %, n = 6) at concentrations which significantly inhibited the LTB4 
production. 
PGE, addition and cyclooxygenase inhibition: Exogenous PG~ dose dependently 
reduced LPS stimulated TNF-a production by hp-M¢ (Figure 7.3), although 
exogenous PG~ did not significantly affect LPS stimulated IL-IB (0.33·33.3 ng/ml 
PG~: 99 ± 7.6 %, III ± 9 %; 99 ± 7.5 %; 95 ± 5.1 %; 94 ± 5.4 %, n = 6) or 
IL-6 production (0.33 - 33.3 ng/ml PG~: 101 ± 11 %; 111 ± 13 %; 105 ± II %; 
114 ± 8 %; 105 ± 10 %, n = 6). Indomethacin in combination with LPS stimulation 
(24 h) almost completely inhibited the PG~ production at the lowest dose (0.33 - 33.3 
I'M indomethacin: 5 ± 1.3 %; 5 ± 1.3%; 5 ± 11.3 %; 11 ± 4.9 %; 5 ± 1.1 %, 
n = 6). Indomethacin did not significantly affect LPS stimulated TNF-a production, 
although there was an increase (3.3 - 33.3 I'M indomethacin: 206 ± 80 %; 246 ± 51 
%, n = 6), neither directly the LPS stimulated (24 h) IL-IB (0.33 - 33.3 I'M 
indomethacin: 103 ± 8 %; 129 ± 28 %; 104 ± 9 %; ll8 ± 11 %; 122 ± 16 %, n 
= 6) and IL·6 production (0.33 - 33.3 I'M indomethacin: 86 ± 7.5; 87 ± 6.8; 95 ± 
5.9; 91 ± 8.8; 96 ± 10.7, n = 6). 
150 
75 
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7.5 Discussion 
o 3.3 33.3 
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Figure 7.3 The effect ofPGE, (0.33 - 33.3 ng/ml) on 
TNF-O! production (24 h LPS) of 1.10' hp-M<I> 1m!. 
Data [% change (100 % = control)] are expressed as 
mean ± SEM and statistically analyzed by ANOY A 
followed by Dunnett's test, * = p < 0.05 (increase 
vs control), number of patients = 6. 
It is well established that the profile of eicosanoid production of M¢ depends on the 
species origin, tissue origin and the stimulus applied. We expected that the profile of 
interactions between inflammatory mediators such as the cytokines and eicosanoids 
would also vary. We observed the following interactions: 
Interaction between hrIL-IfJ and LTB, and PGE,: Two forms ofIL-l exist: IL-Ia and 
IL-1B. Precursor IL-la is fully active and remains cell associated. Biological inactive 
precursor IL-IB is cleaved by IL·IB converting enzyme into active IL·lB and secreted 
by the cells [20]. To study the interactions of IL-l with the eicosanoids and other 
cytokines, hrIL-lB was used because IL-IB is mainly found outside the cells. Our 
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results indicate that exogenous hrIL-lll had reverse effects on the production of several 
eicosanoids by the hp-M</>: An increase of LTB4 and a decrease of PGE, production. 
This is in contrast with cells of other species origin and or tissue origin (e.g. murine 
lymphoma cells, human neutrophils, monocytes from healthy donors, human dermal 
fibroblasts), in which LTB4 and PGE, production were stimulated [21,13-15]. In 
murine resident peritoneal M</> PGE, production was only stimulated at a low dose of 
IL-lll [22]. 
Influence of lip oxygenase inhibition on IL-IJ3 and PGE,: It has been reported that LTs 
are involved in the regulation of IL-l production by activated murine peritoneal 
macrophages and human blood monocytes, based on studies with dual inhibitors of 5-
lipoxygenase and cyclo-oxygenase [16,17]. A study with specific 5-lipoxygenase 
inhibitors showed that at concentrations which completely inhibited LT synthesis the 
IL-l production of activated murine peritoneal macrophages [23] and human peripheral 
blood monocytes of healthy donors [(IL-Ill), 24] was not reduced. Our study confirms 
this finding using the 5-lipoxygenase inhibitor E6080 in human peritoneal inflammatory 
cells. This 5-lipoxygenase inhibition had no significant effect on IL-Ill and IL-6 
production at concentrations which significantly inhibited the LTB, production after 
LPS stimulation. We conclude that LTB4 does not regulate IL-lll and IL-6 production 
in hp-M</>. In our study the 5-lipoxygenase inhibitor had no effect on LPS stimulated 
PGE, production at low concentrations « 3.3 I"M) but at higher concentrations PGE, 
production was significantly inhibited. This could be explained by the fact that this was 
achieved directly with lower LTB4 concentrations (In 24 h. incubations LTB4 was also 
inhibited by E6080 (.?:. 3.3 I"M», another possibility is that this effect was through a 
non selective inhibition of the cyclooxygenase enzyme, although in earlier findings it 
was shown that E6080 was a specific 5-lipoxygenase inhibitor when macrophages were 
stimulated with A23187 and the exogenous eicosanoid production was measured by 
HPLC [25]. 
Effect of PGE, on TNF-a: In our studies PGE, (2:. 3.3 ng/ml) down-regulated the 
TNF-a production of hp-M</>. This was reported before only in different animal 
models: Activated murine peritoneal M</> [26], resident peritoneal rat M</> and murine 
cell lines [27]. The decreased PGE, concentration [5 % of the LPS stimulated control 
level (1345 ng/ml)] did not significantly effect the TNF-a production by hp-M</>, 
however the trend was an increase in TNF-a production. It seems that PGE, only 
significantly inhibits TNF-a production of hp-M</> when it has reached a certain level. 
Probably this level was not reached when the hp-M</> were only incubated with LPS 
for 24 h, otherwise indomethacin would have given a significant increase in the LPS 
stimulated TNF-a production. 
Influence of IL-IJ3 on IL-6: In our studies hrIL-IJl did not significantly influence IL-6 
production by hp-M</>, although in human monocytes of healthy volunteers hriL-IB 
induced IL-6 production was seen [19]. Cell maturity is probably responsible for this 
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difference between monocytes and macrophages, as in two other studies hrIL-IB was 
shown to stimulate IL-6 synthesis in human blood monocytes, but not in monocyte-
derived macrophages and human alveolar macrophages [12,28]. Also species origin 
al)d tissue origin of the cells probably effects the interaction between IL-I Band IL-6 
production. RIL-l was able to induce IL-6 in vivo in mice [29] and hrIL-lB induced 
IL-6 production in human endothelial and smooth muscle cells [20]. 
Conclusion: There are differences between the interactions of cytokine and eicosanoid 
production by hp-M1> and M1> of other species origin, but also similarities. In 
inflammatory processes the regulation of the sequential release of pro- and anti-
inflammatory mediators could be important for the outcome of the disease. For our 
understanding of inflammatory diseases and their treatment, in vitro investigations with 
inflammatory cells are very important, although results obtained from incubations with 
cells from other species, tissue origin or maturity should be interpreted with caution, 
as this study shows these cells differ from human cells in their profile of interactions 
between and their production of cytokines and eicosanoids. When human inflammatory 
diseases are to be studied, hp-M1> isolated from ascitic fluid are therefore suitable cells 
to examine the interactions between cytokines and lipid inflammatory mediators. 
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Levels of inflammatory mediators in ascitic fluid 

Chapter 8 Levels of soluble intercellular adhesion molecule 1, 
eicosanoids and cytokines in ascites of patients with liver 
cirrhosis, peritoneal cancer and spontaneons bacterial 
peritonitis 
W.M. Pruimboom', D.J. Bae', A.P.M. van Dijkl, LM. Garrelds', C.J.A.M. Tak', 
I.L. Bonta', J .H.P. Wilson' and F.J. Zijlstra' 
lDept. of Pharmacology, Erasmus University, Rotterdam and 'Dept. of Internal 
Medicine II, University Hospital Dijkzigt Rotterdam, The Netherlands 
8.1 Summary 
The levels of the eicosanoids leukotriene B4 (L TB4), prostaglandin E2 (POE;). prostacycline (POI;) and 
thromboxane B2 (TXB2), the cytokines interleukin III (IL-ll1), interleukin 6 (IL-6) and tumor necrosis 
factor a (TNF-a) and soluble intercellular adhesion molecule 1 (sleAM-I) were measured in ascites 
and plasma samples of patients with liver cirrhosis (53), peritoneal cancer (26) and spontaneous 
bacterial peritonitis (SBP; 10) to assess their value as a possible diagnostic and prognostic parameter 
in the course of the disease, Soluble ICAM-l, of the eicosanoids PG~ and LTB4 and the protein 
concentration in ascites were all significantly elevated in ascites of patients with peritoneal cancer in 
comparison to ascites of patients with liver cirrhosis, In ascites of patients with SBP, IL-6 
concentration was significantly elevated and the protein concentration was significantly lower in 
comparison to the other two groups, None of these parameters however seems to be of practical use 
as a diagnostic parameter, as there is an overlap between all the levels of these mediators in ascites 
of liver cirrhosis, peritoneal cancer and spontaneous bacterial peritonitis group, Soluble ICAM-l levels 
were much higher in plasma compared to ascites, contrary to IL-6 levels which were much higher in 
ascites than in plasma, Soluble ICAM-l in ascites correlated with sICAM-l in plasma (r = 0.6926, 
P = 0.0001). Soluble ICAM-I, IL-6 and the number of polymorphonuclear cells (PMNs) in peritoneal 
fluid correlated during episodes of infection in patients with a peritonitis. For this reason sICAM-l 
and IL-6 could be of prognostic value for patients with a peritonitis. 
Keywords: Soluble ICAM-l . interleukin 6 . ascites. liver cirrhosis. peritoneal 
cancer. spontaneous bacterial peritonitis 
8.2 Introduction 
Ascites is the accumulation of fluid in the peritoneal cavity. The main causes of ascites 
are liver cirrhosis, malignancies involving the peritoneum and inflammatory processes. 
Early diagnosis of the probable cause of the ascites is useful for guiding further 
investigation and treatment [I]. Ascites may be complicated by bacterial infection, a 
condition known as spontaneous bacterial peritonitis (SBP). SBP has a high mortality 
unless diagnosed and treated at an early stage [2]. Ascites of all causes contains 
inflammatory cells, mainly macrophages (M.p), which produce inflammatory 
mediators. As the pattern of mediators produced by inflammatory cells depends in part 
on the stimulus and on the stage of inflammation, we decided to measure a wide 
variety of inflammatory mediators or products of inflammation to determine whether 
the different causes of ascites were associated with specific patterns of inflammatory 
mediators in ascites. Based on prior work in which we characterized production Of 
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inflammatory mediators by human peritoneal Met> [(hp-Mq,), 3] we measured 
arachidonic acid products, several pro-inflammatory cytokines, and an adhesion 
molecule. The lipoxygenase product LTB4 [4] and the cyclooxygenase products PGEz, 
1;XA, and PGI, [detected as 6-keto-prostaglandin Fla (6kPGFla), 5] were measured as 
these are products of hp-Mq, [3]. We also measured the pro-inflammatory cytokines 
IL-IJl, IL-6 and TNF-a [6,7], which are also produced by hp-Mq, [3]. 
In addition we measured the sICAM-1. ICAM-I plays a crucial role in the adhesion 
and migration of inflammatory cells. ICAM-l is a single-chain membrane-bound 
glycoprotein [8] which is expressed on endothelial and other cells [8-10]. Expression 
ofICAM-l is upregulated by the cytokines IL-I, TNF-a, interferon 'Y (IFN-'Y) ([9-12] 
and also by the chemoattractants LTB, and C5a [13]. Expression ofICAM-I on tissue 
leads to the release of a soluble form into the circulation. The biological function of 
this soluble form of ICAM -I is not yet clear and little is known about the relation 
between expression of ICAM-l on tissue and its soluble form. Soluble isoforms of 
adhesion molecules can be found in the circulation of normal humans [14]. 
Although there are publications on IL-6 and TNF-a in ascites, especially during SBP 
[15-18], we are not aware of reports on ascitic eicosanoid and ascitic sICAM-llevels. 
Soluble ICAM-I in plasma or serum [14,19-24] and the cytokines IL-I, IL-6 and TNF-
a in plasma, serum or ascites [15,16,22,25-29] have been found to be elevated in 
patients with different diseases including malignancies and liver cirrhosis. Therefore 
we measured the levels of sICAM-I, the representative eicosanoids LTB4, PGEz, PGI, 
and TXB, and the pro-inflammatory cytokines IL-IJl, IL-6 and TNF-a in ascites of 
patients with liver cirrhosis, peritoneal cancer and SBP to increase our understanding 
of inflammatory mediators involved in peritoneal inflammation, to determine if these 
mediators showed a specific disease related pattern and whether this pattern could be 
of diagnostic and prognostic value. 
Simultaneously we measured the same parameters in blood samples of these patients 
to determine if there was a close correlation between ascites and plasma values. 
8.3 Patients and methods 
Patients: Eighty nine ascites samples were obtained. Some patients were drained 
several times in the period we collected the samples. Usually there was a time period 
of several weeks in between (totally 63 patients were drained). These samples were 
divided into 3 groups: The liver cirrhosis group [number of samples = 53, sex 
(male/female (m/f) = 33/20, age (range) = 58 (27-82)], the peritoneal cancer group 
[number of samples = 26, sex (mlf) = 18/8, age (range) = 61 (37-81)] and the SBP 
group [number of samples = 10, sex (m/f) = 7/3, age (range) = 48 (22-59)]. 
A patient with ascites was classified as having SBP if the number of PMNs was higher 
then O.25xlO' cells/I in the ascites and the bacterial culture of the ascitic fluid was 
positive or in case of the culture was negative, the PMNs count in the ascites should 
be higher then 0.5xlO' cells/I (Bac et al., 1993a). A patient with renal failure on 
continuous ambulatory peritoneal dialysis (CAPD) was classified as having a peritonitis 
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if the number of PMNs is higher then O.lOxlO' cellsll in the dialysates and the 
bacterial culture is positive (Vas, 1989). 
In the liver cirrhosis group there were 29 samples obtained from patients with 
alcoholic liver cirrhosis, 13 samples from patients with hepatitis B or C virus induced 
cirrhosis, 3 samples from partients with primary biliary cirrhosis or sclerosing 
cholangitis, 5 samples from patients with Budd Chiari and 3 samples from patients 
with other diseases. 
Of the malignancy related ascites group all patients had metastized disease. Eight 
samples were obtained from patients with colon carcinoma, 7 samples from patients 
with pancreatic carcinoma, 3 samples from patients with liver carcinoma, 2 samples 
from patients with peritoneal mesothelioma, 2 samples from patients with gastric 
carcinoma, I sample from a patient with lung carcinoma, 1 sample from a patient with 
a sarcoma and 2 samples from patients with an unknown primary source. 
In the SBP group 4 samples were obtained from a patient with hepatitis B virus 
induced cirrhosis and this patient had a Staphylococcus epidermidis infection in the 
ascites (PMNs number varied between 0.5xlO' and 4.2x10' cells/I), 3 samples were 
obtained from a patient with a pancreas carcinoma and a portal vein thrombosis and 
this patient had a Klebsiella infection in the ascites (PMNs number varied between 
0.6x10' and 15.6x10' cells/I), 2 samples were obtained from patients with liver 
cirrhosis, one of these patients had an Escherichia coli infection in the ascites (4.3xlQ' 
PMNs/I), the other patient had a Streptococcus mitis infection in the blood, the ascitic 
culture of this patient was negative (7.8xlO' PMNs/1 in ascites). One sample was 
obtained from a patient with an acute liver failure and an Escherichia coli infection in 
the ascites (lO.5xlO'PMNs/I). 
In 34 of these patients with ascites, blood (24 samples from the liver cirrhosis group, 
6 samples from the cancer group and 4 samples from the SBP group) was collected in 
EDTA-tubes on the same day or the day after ascites drainage. Blood was also 
obtained from 17 healthy volunteers [sex (m/t) = 12/5, age (range) = 29 (23-40)]. 
Additionaly from two CAPD patients [sex (m/t) = 111, age (range) = 49 (41 - 57)] 
the drained dialysates were collected during and after an episode of peritoneal bacterial 
infection. The first CAPD patient had a Klebsiella infection. The number of PMNs 
varied between O.lxlO' PMNs/I and 3.8 xlO' PMNs/i. The second CAPD patient had 
Enterococcusfaecalis infection. The number ofPMNs varied between 0.2xlO' PMNs/1 
and 1.4 xlO' PMNs/i. 
Assays: The ascites, dialysates and blood were centrifuged at 1500xg directly after 
withdrawal. The centrifuged ascites, dialysates and plasma were stored at - 80°C until 
they were analysed. Soluble ICAM-I, TNF-c<, IL-I!l and IL-6 were determined in the 
centrifuged ascites and plasma using commercially available ELISA kits (sICAM-l: 
British Biotechnology products, UK, sensitivity = 2.5 ng/m!. TNF-c<: Eurogenetics, 
USA, sensitivity = 10 pg/ml. IL-I!l: Eurogenetics, USA, sensitivity = 2 pg/ml. IL-6: 
Hycult, The Netherlands, sensitivity = 2 pg/ml). 
LTB" PGE" 6kPGFIo and TXB, were determined by radio immuno assays 
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(Antibodies: Advanced Magnetics - USA, 3H-Antigen: Amersham - UK and standards: 
Sigma - USA) in centrifuged ascites and plasma which were passed through Sep Pak 
C18 cartridges (Waters Ass., USA). 
II) the dialysates only sICAM-l and IL-6 were determined. 
Protein concentrations in the ascites and plasma were determined with the pyrogallol-
red-molybdate(IV) method (Instruchemie, The Netherlands). 
Statistical analysis: Data are expressed as the mean ± standard error of the mean 
(SEM). Data were statistically analyzed with ANOV A followed by Student's T -test. 
The correlations were determined by Pearson Correlation test. Data were considered 
significant when p < 0.05. 
8.4 Results 
Soluble ICAM-l, cytokine and eicosanoid concentrations in ascites: Soluble ICAM-I 
concentration was significantly elevated in ascites of patients with peritoneal cancer 
(385 ± 66 ng/ml, n = 26) compared to the concentration of sICAM-l in ascitic fluid 
of patients with liver cirrhosis (151 ± 16 ng/ml, n = 53, p = 0.0000) and SBP (215 
± 27 ng/ml, n = 10, P = 0.0284). There was no significant difference between the 
concentrations in ascites from patients with liver cirrhosis and SBP (Figure 8.1A). 
IL-6 concentration was significantly elevated in ascites of patients with SBP (103 ± 
24 ng/ml, n = 10) compared to the concentration of IL-6 in ascites of patients with 
liver cirrhosis (12 ± 1.8 ng/ml, n = 53, p = 0.0000) and peritoneal cancer (24 ± 5.7 
ng/ml, n = 26, p = 0.0000; Figure 8.1B). 
Ascites protein concentration was significantly lower in SBP (10 ± 1.6 mg/ml, n = 
7, p = 0.0104) compared to the liver cirrhosis group (26 ± 2.4 mg/ml, n = 46) and 
peritoneal cancer group (44 ± 2.6 mg/ml, n = 25, P = 0.0000). Ascites protein 
levels were significantly higher (p = 0.0000) in peritoneal cancer compared to the 
other two groups (Figure S.IC). 
Of the eicosanoids the LTB4 and PGE;, concentrations were significantly higher in 
ascites of patients with peritoneal cancer (n = 26) compared to the liver cirrhosis 
group (n = 47), and ascites LTB4 and 6kPGF1a concentrations of peritoneal cancer 
were significantly increased in comparison to SBP (n = 10, Table 8.1). LTB, 
concentration in ascites of patients with SBP and PGE;, concentration in ascites of 
patients with liver cirrhosis was significantly lower in comparison to the other two 
groups. 
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Figure 8.1 (A) Soluble ICAM-l 
concentration (ng/ml) in ascites of 
patients with ascites due to liver cirrhosis 
(liver, n=53), peritoneal cancer (cancer, 
n=26) and SBP (infection, n= 10). (B) 
Interleukin 6 concentration (ng/ml) in 
ascites of patients with ascites due to 
liver cirrhosis (liver, n=53), peritoneal 
cancer (cancer, n = 26) and SBP 
(infection, n= 10). (C) Protein 
concentration (mg/mO in ascites of 
patients with ascites due to liver cirrhosis 
(liver, n=46), peritoneal cancer (cancer, 
n=25) and SBP (infection, 0=7). * = 
significantly higher compared to the other 
two groups (p < 0.05), ** = 
significantly lower compared to the other 
two groups. 
Table 8.1 Eicosanoid concentration in ascites of patients with liver cirrhosis, peritoneal cancer and 
SBP (Data is mean ± SEM, nd = not detectable, n = number of samples). 
Eicosanoids II ~~)er cirrhosis Peritoneal Cancer (0) 
LTB, 21 ± 5.4 193 ± 67 ** (pg/ml) (47) (26) 
PGE, 27 ± 3.2 * 122 ± 27 *** (pg/mI) (47) (26) 
6kPGF," 145 ± 62 359 ± 110 **** 
(pg/ml) (47) (26) 
TXB, 57 ± 8.1 70 ± 9.4 
(pg/ml) (46) (26) 
* = significantly lower compared to other two groups (p < 0.05). 
** = significantly higher compared to other two groups (p < 0.05). 
*** = significantly higher compared to liver cirrhosis group (p < 0.05). 
**** = significantly higher compared to SBP group (p < 0.05). 
SBP 
(n) 
nd * 
(10) 
79 ± 20.7 
(10) 
113 ± 38 
(10) 
53 ± 3.2 
(8) 
Soluble ICAM-I, cytokine and eicosanoid concentrations in plasma: In Table 8.2 the 
plasma levels of slCAM -I, cytokine and eicosanoid concentrations per patient group 
and controls were compared. No significant differences were seen between the three 
patient groups. Soluble ICAM -1 and IL-6 concentrations in plasma of the patients were 
significantly elevated in comparison to the controls. IL-Ill and TNF-a were not 
detectable in plasma of patients, IL-IIl, IL-6, TNF-a and LTB, were not detectable in 
control plasma. 
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Table 8.2 Soluble ICAM-l, cytokine and eicosanoid concentration in plasma of patients with liver 
cirrhosis, peritoneal cancer and SBP and in plasma of controls (Data is mean ± SEM, n = number 
of samples, nd = not detectable). 
Mediators Liver cirrhosis Peritoneal SBP Plasma control 
(n) Cancer (n) (n) 
(n) 
sICAM-I 781 ± 141 781 ± 367 1204 ± 271 228±24* 
ng/ml (24) (5) (3) (17) 
IL-6 1191 ± 358 420 ± 215 1736 ± 394 nd * 
pg/ml (24) (6) (4) (17) 
IL-16 nd nd nd nd 
pg/ml (17) (6) (4) (17) 
TNF-" nd nd nd nd 
pg/ml (17) (6) (4) (17) 
LTB, 22 ± 16.3 14 ± 14.1 54 ± 54.6 nd 
pg/ml (23) (6) (4) (17) 
PGE, 67 ± 21.1 68 ± 32.1 52 ± 48.0 70 ± 13.0 
pg/ml (23) (6) (4) (16) 
6kPGF" 104 ± 67.4 14 ± 14.3 6.7 ± 4.7 8.8 ± 1.4 
pg/ml (23) (6) (4) (16) 
TXB, 256 ± 126 141 ± 51 127 ± 32 153 ± 67 
pg/ml (17) (6) (2) (14) 
* significantly lower compared to the 3 patients groups (p < 0.05). 
Table 8.3 Soluble ICAM-l, cytokine and eicosanoid concentration in ascites and plasma of patients 
(grouped all together) with liver cirrhosis, peritoneal cancer and SBP (Data is mean ± SEM, n = 
number of samples, nd = not detectable). 
I Mediators metabolites II Ascites (n) I Plasma (n) I 
sICAM-I ng/ml 227 + 24 (89) 820 + 122 (32) * 
IL-6 ng/ml 26 + 4.4 (89) * I + 0.3 (34) 
IL-16 pg/ml 10 + 2.7 (59) nd (25) 
TNF-" pg/ml 65 + 24.4 (78) * nd (24) 
LTB, pg/ml 72 + 22.7 (84) 25 + 13.0 (33) 
PGE, pg/ml 63 + 10.0 (84) 65 + 16.4 (33) 
6kPGF," pg/ml 206 + 50 (84) 76 + 47.3 (33) 
TXB, pg/ml 61 + 5.5 (81) 218 + 86.2 (25) 
* = significantly higher (p < 0.05). 
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Comparison between the sICAM-i, cytokine and eicosanoid concentrations in ascites 
and plasma: As we had only a small number of plasma samples of the peritoneal 
cancer group and the SBP group and there were no significant differences between the 
plasma levels of the three patient groups, all the plasma samples of patients were 
compared with the ascites samples, without subdivision, as calculated and given in 
Table 8.3. There were differences between plasma and ascites values: sICAM-l 
concentration was much higher in plasma, while IL-6 and TNF-a concentrations were 
higher in ascites (Table 8.3). 
There was a good relation between ascites sICAM-I and plasma sICAM-I (r = 0.6926 
and p = 0.0001, n = 27, Figure 8.2); for the other metabolites there was no 
correlation. 
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Figure 8.2 Correlation between sICAM-l in ascites and plasma of patients with ascites due to liver 
cirrhosis, peritoneal cancer and SBP (r = 0.6926, P = 0.0001 and n = 27). 
Soluble ICAM-J and IL-6 concentration during peritonitis: In 2 patients with SBP, 
ascites was drained several times [patient I: 5x (day 0, 25, 28, 32, 38) and patient 2: 
4x (day 0,6, 18,24)] during 5 to 6 weeks. For both these patients sICAM-l and IL-6 
concentrations in ascites changed during this period: Patient I had no SBP on the first 
day (day 0) of drainage (negative culture, O.lxlO' PMNs/I). The sICAM-I and IL-6 
concentrations in the ascites were low (77 ng/ml sICAM-I and I ng/ml IL-6). On day 
25 the patient had a subtotal hepatic resection. After this operation the number of 
PMNs (1.7xlO' PMNs/I), sICAM-I (190 ng/ml) and IL-6 (72 ng/ml) had increased in 
the ascites. A Staphylococcus epidermidis infection was diagnosed on day 28 in the 
ascites (O.5xlO' PMNs/l, 242 ng/ml sICAM-I, 56 ng/ml IL-6). During the peritonitis 
sICAM-1 and IL-6 concentrations peaked at day 32 (316 ng/ml sICAM-I, 119 ng/ml 
IL-6, 4.2xlO' PMNs/I). Antibiotics were given after day 32, after which the sICAM-I 
and IL-6 concentrations decreased (195 ng/ml sICAM-I, 79 ng/ml IL-6, 2.2xlO' 
PMNs/l, Figure 8.3A). 
Patient 2 had a Klebsiella peritonitis on the first day of drainage. In the ascites of this 
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patient the slCAM -I and IL-6 concentrations and the PMN s number were high (351 
ng/ml sICAM-I, 48 ng/mIIL-6, 15.6xlO' PMNs/I). Antibiotics were given for several 
weeks and the sICAM-I concentration decreased to a low level (56 ng/ml). IL-6 
cpncentration slightly increased (day 6, 60 ng/ml), but then also decreased to a very 
low level (0.3 ng/ml). At the same time also the number ofPMNs decreased (3AxIO' 
PMNs/1 on day 6, 0.6xlO' PMNs/1 on day 18). At the last drainage the bacterial 
culture of the ascites was negative and the number of PMNs had further decreased 
(O.5xlO' PMNs/I; Figure 8.3B). 
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Figure 8.3 Soluble ICAM-l (e) and IL-6 (a) concentrations (ng/ml) in ascites of2 patients with SBP. 
(A) Patient 1 had no SBP on day 0 of drainage. The patient was operated on day 25, an 
Staphylococcus epidennidis infection started after this operation. Antibiotics were given after day 32. 
(B) Patient 2 had a SBP on the first day of drainage (Klebsiella infection), During several weeks 
antibiotics were given. At day 24 the patient was infection free. 
The ICAM-I and IL-6 concentrations were also measured in drained dialysates of 2 
CAPD patients during an episode of peritoneal infection (patient 3: 4x (day 0, I, 8, 
13) and patient 4: 6x (day 0, 3, 6, 7, 10, 12). Patient 3 had on day 0 an untreated 
bacterial infection (Klebsiella, 1.4xlO' PMNs/I), the sICAM-I concentration was 3 
ng/ml and the IL-6 concentration 80 ng/m!. On day I antibiotics were given and the 
IL-6 concentration decreased (66 ng/ml), the sICAM-I concentration (6 ng/ml) and the 
number of PMNs (3.8xlO' PMNs/I) increased. On day 8 the sICAM-I concentration 
had only decreased slightly, but the IL-6 concentration (3 ng/ml) and the number of 
PMNs (O.lxlO' PMNs/I) had decreased. On day 13 the patient was free of infection 
(negative culture, < O.lxlO' PMNs/I), sICAM-I was not detectable and the IL-6 
concentration stayed low (3 ng/ml; Figure 8AA). 
Patient 4 had on day 0 a bacterial infection (Enterococcus faecalis, 1.4x1O' PMNs/1) 
and before antibiotics had been given, the sICAM-I concentration was 21 ng/ml and 
the IL-6 concentration 12 ng/m!. On day 3 after antibiotics had been given, IL-6 
concentration increased slightly (13 ng/ml), but sICAM-I concentration (9 ng/ml) and 
also the number of PMNs in the dialysates (0.8xlO' PMNs/I) decreased. Between day 
6 and 10 the infection was still present, but the concentration of sICAM-I and IL-6 
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and the number of PMNs decreased (day 6: 0.9 ng/ml sICAM-I, 0.8 ng/ml IL-6, 
0.5xlO' PMNs/I; day 7: 0 ng/ml sICAM-I, 2 ng/ml IL-6, 0.2xlO' PMNs/I; day 10: 
o ng/ml sICAM-I, 0.9 ng/ml IL-6, O.lxlO' PMNs/I). On day 12 the patient was free 
of infection (negative culture, PMNs < O.lxlO'), sICAM-l was not detectable and the 
IL-6 concentration (0.8 ng/ml) was also low (Figure 8.4B). 
The correlation between sICAM-l, IL-6 and the number of PMNs in the ascites and 
the drained dialysates in those patients with a peritonitis was for sICAM-l and PMNs 
0.7201 (p = 0.0002), for IL-6 and PMNs 0.4454 (p = 0.0378) and for sICAM-l and 
IL-6 0.4800 (p = 0.0238). 
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Figure 8.4 Soluble ICAM-l Ce) and IL-6 Co) concentrations Cng/ml) in drained dialysates of2 CAPD 
patients during an episode of peritoneal infection. (A) Patient 3 had on day 0 a peritonitis (Klebsiella) 
and no antibiotics was given yet. On day 1 antibiotics had been given. On day 13 the patient was 
infection free. (B) Patient 4 had also on day 0 a peritonitis (Enteroccusjaecalis) and no antibiotics was 
given yet. On day 12 the patient was infection free. 
8.5 Discussion 
The present study shows that there are significant differences in the concentrations and 
patterns of inflammatory products in ascites due to different disorders. Soluble ICAM-
1 and the eicosanoids PGEz and LTB4 all clearly differentiated between peritoneal 
cancer and liver cirrhosis: these metabolites were all higher in ascites of patients with 
peritoneal cancer. 
Ascitic sICAM-l and IL-6 also increased during episodes of peritoneal infection in two 
patients with SBP as well as in infected dialysates of two CAPD patients. Soluble 
ICAM-l levels were much higher in plasma than in ascites, in contrast to IL-6 levels 
which were much higher in ascites than in plasma. Soluble ICAM-l in ascites of all 
the patients correlated with sICAM-I in plasma of these patients. The sICAM-I levels 
in plasma of patients were significantly higher than the plasma levels of the controls. 
The cytokines IL-lll and TNF-a were low or not detectable in ascites or plasma of 
patients with liver cirrhosis, peritoneal cancer or SBP. 
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Soluble ICAM-I concentration in ascites and plasma: Although there were significant 
differences in concentrations of sICAM-I in ascites, in the different disorders plasma 
levels of sICAM-I were not significantly different, probably due to the small number 
of plasma samples in the peritoneal cancer group and the SBP group. Other studies 
showed that sIC AM -I levels were elevated in sera of patients with different type of 
diseases in comparison to controls [14,21,22] including acute liver disease [(chronic 
hepatic C virus infection), 24], chronic liver diseases [(Primary biliar cirrhosis and 
primary sclerosing cholangitis), 19] and patients with different forms of cancer 
[20,23]. 
Soluble ICAM-I is probably released more to the blood stream circulation than locally 
within the peritoneal cavity as the srCAM-l levels in plasma of all the patients was 
significantly higher than levels in ascites of all the patients. Adhesion to and 
penetration through the vascular endothelium is a mandatory step for leucocyte 
migration and accumulation at sites of inflammation. De novo or up-regulated 
expression of adhesion molecules on sinusoidal lining cells in inflamed liver biopsy 
specimens indicates that these endothelial cells actively modulate their phenotype in 
response to environmental factors, thus playing a key role in the recruitment of 
leucocytes in acute and chronic liver inflammation [30] and probably leading to the 
release of ICAM-I locally. 
Malignant melanomas are usually surrounded by an heavy inflammatory infiltrate, the 
inflammatory cells often express activation associated markers [31] and the malignant 
melanomas express ICAM-I [32]. An explanation for the significant differences of 
srCAM -I concentration in ascites of the different groups in our study could be that 
cancer cells are also a source of sICAM-1. A study showed that an unstimulated 
human melanoma cell line expressed ICAM -Ion the cell surface but did not release 
significant levels of sICAM-I. Stimulation with TNF-a, IL-I and IFN-'Y, but not IL-6, 
then caused the release of sICAM-I. The same group showed in the same publication 
that in nude mouse models bearing s.c. human melanoma tumours, the serum 
contained human sICAM-I [33]. These two studies show clearly that only the cancer 
cells in these models could have been the source of the soluble form of ICAM-I. In 
humans, cancer cells will most probably be an important source for he release of 
srCAM-llocally into the peritoneal cavity. Assuming that cancer cells are a source of 
sICAM-I, this may provide cancer cells additional escape mechanisms ego ineffective 
recognition of cell surface ICAM-I by cytotoxic lymphocytes or blocking immune 
recognition by the blocking the ligand for rCAM-I, Iymphocyte-function-associated 
antigen I (LFA-I), on the leucocytes [8,34]. 
All our patients with peritoneal cancer had high levels of sICAM-I in the ascites. All 
these patients have late stage cancer, therefore it was not possible to correlate the 
disease progression of these patients with the sICAM-I level in the ascites or plasma 
of these patients. Other studies did show that the levels of srCAM-I in humans 
correlated with liver metastasis in a variety of tumours, and with disease progression 
in melanoma cells [20,23]. 
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fL-Ij3, fL-6 and TNF-Oi concentrations in ascites and plasma: In previous studies we 
have isolated M¢ from ascitic fluid of patients with liver cirrhosis. These M¢ had a 
high IL-6 production capacity [3]. The Il-61evels in the ascites of the patients used for 
this study were always much higher in the peritoneal cavity than in their plasma, 
indicating that IL-6 was produced locally in the peritoneal cavity by M¢. Endothelial 
cells are also able to produce IL-6 [35,36]. IL-IB and TNF-Oi were hardly detectable 
in ascites or plasma of patients with liver cirrhosis, peritoneal cancer and PBS. Other 
reports however show besides IL-6 levels, also elevated IL-l and TNF-Oi plasma levels 
in patients with ascites caused by liver diseases in comparison to controls were found 
[25,27]. In SBP patients, in comparison to non infected patients, elevated TNF-Oi levels 
in ascites [18] and plasma [26] were also found. Similar to our results, one other 
report also describes significant elevated IL-6, but not IL-I or TNF-Oi levels in ascites 
and serum of SBP patients [17]. 
Besides M¢ and endothelium, tumor cells should also be considered as potential 
sources for IL-6. Some tumor cells have been shown to produce IL-6 [37,38]. High 
IL-6 levels may account in different ways for the alterations which are associated with 
malignancy [39]. IL-6 is a potent growth factor for myeloma/plasmacytoma cells and 
its deregulated expression may be involved in the oncogenesis of human multiple 
myelomas [40]. 
The liver is an important site of synthesis and the main clearance organ of circulating 
cytokines. The rapid hepatic clearance of circulating cytokines may normally constitute 
an important mechanism limiting the systemic action of cytokines. Lack of hepatic 
clearance may be one reason for disturbances of the immune system in patients with 
hepatic cirrhosis [41] and probably also patients with liver metastasis. IL-6 is important 
in liver diseases, it induces acute-phase protein synthesis, in particular fibrinogen 
production, in hepatocytes [40]. The high IL-6 production during the bacterial infection 
is probably a direct effect of the bacteria on the macrophages in the 
peritoneum:lipopolysaccharide (LPS), a bacterial membrane component, is known to 
be one of the most potent stimuli of M¢ [42]. Increasing LPS concentrations increases 
the IL-6 production capacity of human peritoneal M¢ in vitro [3]. 
Correlation between IL-6 and sICAM-I: The high sICAM-l and IL-6 levels and low 
IL-IB and TNF-a levels in the patients with ascites could indicate that there is a 
connection between IL-6 and sICAM-I: IL-6 could induce ICAM-l expression and 
also the release of the soluble form. In an auto-immune mouse model ICAM-l was 
newly induced in the hepatic sinusoids of controls by intravenous injection of 
recombinant mouse IL-6 and elevated production of IL-6 by hepatic mononuclear cells 
also correlated with this ICAM-l expression [43]. On the other hand incubation of 
cultured monolayers of endothelial cells with IL-6 did not effect their adhesiveness for 
monocytes [12] and IL-l alB, TNF-Oi and IFN-,), but not IL-6 activate increase the 
permeability of human endothelial cells in vitro [44]. 
It has not been shown previously that both sICAM-l and IL-6 levels in ascites of 
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patients with SBP and in the dialysis fluid of CAPD patients with SBP correlated with 
episodes of infection. Soluble ICAM -I and IL-6levels were high when the patients had 
an infection, decreased when antibiotics were given and were hardly detectable when 
tl)e patients were free of infection. 
Eicosanoids in ascites and plasma: It is not quite clear why the LTB4 production is 
much higher in ascites of the peritoneal cancer group than in the liver cirrhosis group. 
Probably cancer cells in the peritoneal cancer group activate the inflammatory cells to 
produce LTB,. This elevation may in turn stimulate ICAM -1 expression [45]. The 
release of the vasodilating agents PG~ and PGI, [5] could also act as mediators 
involved in the induction of ascites [46]. In patients with a liver disease endothelial 
cells, macrophages and hepatocytes or the disability of the liver to clear these 
vasodilators [47] could be responsible for the PG~ and PGI, production. In patients 
with cancer, the cancer cells itself could also be responsible for the high concentration 
of the PG's in ascites. A number of experimentally induced tumours in animals as well 
as those occurring naturally in humans have been found to produce high amounts of 
PG's and PG~ in particularly [48,49]. 
Conclusion: In conclusion the levels of sICAM-l, the eicosanoids LTB, and PG~ and 
the cytokine IL-6 and the protein concentration in ascites are parameters which showed 
a specific disease related pattern, however for diagnostic use they may not be suitable 
as all the parameters of the 3 different groups, in which we had divided our patients, 
overlapped. However as sICAM-l levels in ascites correlated with sICAM-l levels in 
plasma and both sICAM-I and IL-6 correlated with episodes of infection (in ascites of 
patients with SBP and drained dialysates of CAPD patients with SBP), sICAM-l 
together with IL-6 seem to be parameters which could be of use to monitor for patients 
with SBP. 
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Chapter 9 High interleukin 6 production within the peritoneal cavity 
in decompensated cirrhosis and malignancy-related ascites 
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9.1 Summary 
To assess the diagnostic and prognostic value of interleukin 6 (IL-6), interleukin If3 (IL-lf3), and 
tumor necrosis factor ex (TNF-a) assays in plasma and ascites, we measured these cytokines in 8 
patients with malignancy-related ascites and 32 patients with decompensated cirrhosis. Five patients 
had an episode of bacterial peritonitis (BP) during which period one or more ascitic fluid samples were 
analyzed. IL-6 and TNF-cx were not significantly different between the cirrhotic and malignant two 
groups: ascitic IL-6 13816 ± 15314 vs 28138 ± 23403 pg/ml, plasma IL-6 542 ± 719 vs 559 ± 604 
pg/ml; ascitic TNF-" 19 ± 50 vs 12 ± 31 pg/ml, plasma TNF-" 3,4 ± 8,2 vs 6,1 ± 13,8 pg/ml. 
During an episode of BP there was a significant increase only in ascitic IL-6, (133268 ± 99743 pg/ml) 
which declined after antibiotic treatment. None of the parameters was associated with the 6 months 
survival (11 of the 40 patients died within 6 months). There was a correlation (r = 0.675; p = 0.002) 
between plasma IL-6levels and the Child-Pugh score in patients with liver Cirrhosis, but not with the 
etiology of the liver disorder. Plasma IL-6 levels correlated with immunoglobuline A (Ig A) levels (r 
= 0.649; p = 0.004) but not with eRP, ESR, fibrinogen, Ig M or Ig G. 
11-6 is produced within the peritoneal cavity in hepatic and malignant ascites. There is a sharp increase 
in the local production of IL-6 during an episode of bacterial peritonitis. 
This increase was not detectable for TNF-C'I'. It remains to be assessed what the physiological meaning 
is for this over-production of locally generated cytokines and if this relates to the poor prognosis of 
patients with cirrhosis and infectious disorders. 
Key words: interleukin 6 . tumor necrosis factor 0' . ascites . cirrhosis . malignancy 
9.2 Introduction 
IL-6, also called interferon (32' or hepatocyte-stimulating growth factor, is produced 
by several cell types such as monocytes, fibroblasts and endothelial cells. Monocytes 
seem to be the most important in this process [1,2]. IL-6 acts in concert with other 
cytokines such as IL-I and TNF-O' and leads to a variety of different actions including 
maturation of B cells for immunoglobulin synthesis, and induction of the synthesis of 
acute-phase proteins by hepatocytes [3]. IL-6 appears to be a key member of the IL 
family, however many of the interactions with other Iymphokines are poorly 
understood. Elevated serum levels of different cytokines in chronic liver disease have 
been reported [4,5]. The pattern of cytokine elevation is stage dependant and is only 
moderately affected by the type of liver disease. There are some preliminary reports, 
suggesting high IL-6 production in ascitic fluid during spontaneous bacterial peritonitis 
[6-8], and without peritonitis [9]. A correlation between survival and elevated TNF-O' 
[10] and high serum IL-6 levels [11,12] has been established for patients with alcoholic 
hepatitis. A profound increase of IL-6 and TNF-O' after the onset of septicaemia which 
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lasted much longer in patients with cirrhosis compared to controls may be related to 
the high mortality of infectious complications in cirrhotic patients [13,14]. 
In order to assess the diagnostic and prognostic value of these cytokines, we measured 
plasma as well as ascitic fluid IL-6, TNF-a and IL-liJ in patients with ascites of 
different etiology, including carcinomatous peritonitis and different causes of 
decompensated cirrhosis and portal hypertension. In some patients with an episode of 
SBP cytokines were measured serially in ascitic fluid. Plasma and ascitic fluid IL .. 6, 
TNF-a and IL-liJ levels were compared to clinical data, biochemical measurements, 
diagnosis and prognosis. 
9.3 Material and methods 
Patients: Thirty-two patients with hepatic ascites and 8 patients with malignancy-
related ascites were prospectively studied from June to December 1993. Sixteen 
patients had alcoholic cirrhosis, 7 patients had hepatitis B or C virus induced cirrhosis, 
5 patients had primary biliary cirrhosis (PBC) or sclerosing cholangitis (PSC) and 4 
patients had other another liver disease (auto-immune disease 2x, cryptogenic Ix and 
M Wilson Ix). Of the malignancy-related ascites group all patients had metastasized 
disease (2 patients had pancreatic adenocarcinoma, 2 peritoneal adenocarcinomatosis 
with unknown primary tumor, I gastric carcinoma, I peritoneal mesothelioma, I 
coloncarcinoma and I leiomyosarcoma) . Five patients developed spontaneous BP (SBP) 
during the course of the disease, four patients with cirrhosis and one patient with a 
peritoneal adenocarcinomatosis. For further analysis patients are divided in three 
groups; cirrhosis (n = 28), malignancy-related ascites (n = 7) and bacterial peritonitis 
(n = 5). In 23 out of the 40 patients, plasma samples were available, taken within 24 
h after paracentesis. In those 40 patients a total of 56 ascitic fluid samples were 
available for biochemical analysis, cultures and cytokines assays. If more than one 
sample was analyzed in a patient, the patient's average was used in the statistical 
analysis. Patient characteristics are given in Table 9.1. Survival was assessed during 
a period of six months. 
Cytokine assay: Ascites and blood were obtained under sterile conditions and 
immediately cooled to OoC and centrifuged. Aliquots of cell-free samples were stored 
at -70°C till assay. 11-6 was determined in ascites and plasma by an ELISA (Hycult, 
Uden, The Netherlands) and TNF-a (Eurogenetics, Tessenderlo, Belgium) and IL-liJ 
(Eurogenetics, Tessenderlo, Belgium). The determination threshold for IL-6 was 2 
pg/ml, for TNF-a 10 pg/ml and for IL-liJ 2 pg/ml. 
Blood and ascitic fluid sampling: Blood samples were taken within 24 h after the 
paracentesis was performed. In addition to routine biochemical assessment, plasma C 
reactive protein, IgG, IgM, IgA, and fibrinogen levels were measured. All ascitic fluid 
samples were cultured with bedside inoculation in blood culture bottles. Total protein, 
lactate dehydrogenase, cholesterol, triglycerides and leucocyte count with differential 
108 
High interleukin 6 production ... 
counting was measured in each ascitic fluid sample. In all patients with cirrhosis the 
severity was graded by the Child-Pugh score. Spontaneous bacterial peritonitis was 
defined as a positive ascitic fluid culture with more than 0.25x109 polymorphonuclear 
cellsl1. 
Table 9.1 Clinical and laboratory characteristics of the patients (Mean ± SD). 
Hepatic ascites 
group 1 
Number of patients 28 
Age yrs (mean ± 54 ± 15 
SD) 
Gender M/F l7II1 
Child-Pugh B/C 13/15 
serum bilirubine 84 ± 101 
~molll 
Ascites leucocytes 0.1 ± 0.1 
10' cells II 
Ascites LDH UII 80 + 61' 
Ascites total protein 10 ± 7 
gil 
Ascites cholesterol 0.5 ± 0.4 
mmoll1 
Ascites triglyceride 0.4 ± 0.4 
gil 
Plasma IL-6 pg/ml 542 + 719 
Ascites IL-6 pg/ml 13816 + 15314 
AScites/plasma IL-6 29.2 
ratio 
a: p=O.Ol group 3 versus group 1 and 2 
b : p=O.002 group 2 versus group 1 and 3 
C : p=O.002 group 1 versus group 2 and 3 
d : p=O.004 group 2 versus group 1 and 3 
e : p=O.004 group 2 versus group 1 and 3 
f: p=O.002 group 3 versus group 1 and 2 
Malignant ascites Bacterial peritonitis 
group 2 group 3 
7 5 
58 ± 14 42 ± 17 
6/1 2/3 
2/3 
47 ± 87 122 ± 15& 
0.7 ± 0.7b 8.8 ± 6.5 
295 + 217 274 + 253 
36 ± 9d 11 ± 6 
1.9 ± 0.9' 0.4 ± 0.4 
0.8 ± 0.3 1.1 ±1.8 
559 + 604 1637 + 907 
28138 + 23403 133268 + 99743' 
30.3 56.7 
Statistical analysis: Data are summarized as the mean ± standard deviation (SD). The 
Mann-Whitney U-test was used to compare data between two groups. The Kruskal-
Wallis test was used to compare data between more than 2 groups. Correlations were 
estimated by the Spearman rank correlation coefficient. p-Values (two-tailed) of less 
than 0.05 were considered statistically significant. 
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9.4 Results 
Ascitic fluid IL-6 levels were higher in patients with malignancy-related ascites 
cpmpared to hepatic ascites (28138 ± 23403 pg/ml vs 13816 ± 15314 pg/ml), but 
due to the wide scatter of values this did not reach statistical significancy (p = 0.21). 
However during an episode of SBP there was a marked increase in ascitic fluid IL-6 
levels (133268 ± 99743 pg/ml, p=0.002 when compared to hepatic and malignant 
ascites) while plasma values (1637 ± 907 pg/ml vs 542 ± 719 pg/ml, p = 0.07) were 
barely influenced by this sharp rise in ascitic fluid levels (Figure 9.1). 
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Figure 9.1 Ascitic fluid IL-6levels in hepatic ascites (1), malignant ascites (2) and bacterial peritonitis 
(3). 
In 2 patients ascitic fluid levels were assessed after antibiotic treatment and declining 
values were obtained, finally similar to other patients with hepatic ascites without 
infection. The type of micro-organism causing the ascitic fluid infection (Escherichia 
coli 2x, Klebsiella pneumoniae lx, Staph. Epidermidis lx, and culture-negative Ix) did 
not seem to influence the IL-6 levels. TNF-O' levels were not statisticaly different 
between the patients with hepatic ascites and those with malignant ascites. Ascitic 
TNF-O' 19 ± 50 pg/ml vs 12 ± 31 pg/ml and plasma TNF-O' 3.4 ± 8.2 vs 6.1 ± 
13.8 pg/ml. As TNF-O' was only detectable in plasma in 7 patients and in ascites in 8 
patients, no reliable statistical analysis was possible. Even in the patients with bacterial 
peritonitis and in some terminally ill patients with malignant ascites TNF-O' could not 
be detected in ascites and plasma. IL-I(J was not detected in any ascites or plasma 
samples. 
None of the parameters could differentiate between patients who survived more than 
six months and the eleven patients who died during this period. There was a 
correlation between plasma IL-6 and the Child-Pugh score (r = 0.675; p = 0.002, 
Figure 9.2). 
No relation could be established between the diagnosis of the underlying liver disorder 
(alcoholic, viral or PBC/PSC) and the cytokine profile (Figure 9.3). Plasma IL-6levels 
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Figure 9.2 Correlation between the Child-Pugh score and plasma IL-6levels in patients with cirrhosis. 
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Figure 9.3 Ascitic fluid IL-6 levels in patients with alcoholic (I), viral (2), or PBC/PSC liver disease 
(3). 
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Figure 9.4 Correlation between plasma IL-6 levels and IgA concentration. 
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correlated with serum Ig A levels (r = 0.649; P = 0.004, Figure 9.4) and slightly 
with C reactive protein (r = 0.49; P = 0.04) but not with Ig M (r = 0.30; p = 0.22), 
Ig G (r = 0.34; p = 0.15), and fibrinogen (r = -0.l7; P = 0.53). 
9.5 Discussion 
In this study we found evidence for a high production of IL-6 locally produced within 
the peritoneal cavity. The ascitic fluid levels were 30 times higher than plasma levels 
for hepatic as well as for malignant disease. Apparently, even the presence of sterile 
ascites generates enough inflammation of the peritoneum with an increase of locally 
active monocytes and macrophages to cause these high levels of cytokines. Hepatic 
clearances of locally generated cytokines may be diminished in patients with cirrhosis, 
however lhis mechanism does not seem to be of much importance, as malignant ascites 
with an intact liver function and normal hepatic clearance generates the same high 
ascites/plasma ratio's. More evidence for the local production within the peritoneal 
cavity comes also from the fact that during bacterial inflammation of the ascitic fluid 
ascites levels are about ten times higher, with an ascites/plasma ratio of about 60, 
compared to ascitic fluid levels without infection. Ascites dynamics in patients with 
cirrhosis suggests that there is a continual shift between ascitic fluid and the circulation 
with peritoneal free-water clearances of 4-5 lIhour [15] and a high lymph flow within 
the thoracic duct rich in protein and albumin content [16,17]. Therefore the IL-6 is 
quickly cleared from the circulation as plasma levels are low and not very much 
influenced by the presence of bacterial peritonitis. Indeed the half-life of IL-6 has been 
determined to be only a few minutes [3]. 
High IL-6 synovial fluid levels of patients with rheumatoid arthritis with little activity 
in serum have been demonstrated [18] as well as high cerebrospinal fluid levels in 
patients with acute meningitis, but not in those with chronic or non-infectious neural 
disease [3]. Local production of IL-6 in acute and chronic liver disease has also been 
demonstrated by endothelial, Kuppfer, and infiltrating mononuclear cells in liver tissue, 
expression being more pronounced in areas with most inflammation [19,20]. Many of 
the activities of TNF-a, IL-I, and IL-6 indicate a local rather than a systemic function 
for these cytokines. IL-6 shares many of its biological activities with TNF-a and IL-I, 
and probably all three cytokines act in concert directing inflammatory and 
immunological reaction. For example, IL-I and TNF-a can stimulate IL-6 production, 
but IL-6 suppresses TNF-a and IL-lf3 production [21]. The fact that we did not find 
elevated TNF-a levels in plasma and ascites of most patients does not seem to concur 
with other studies. Most studies describe an increase in ascitic fluid levels during 
bacterial inflammation of both IL-6 and TNF-a [6-8]. Several explanations could be 
given for this discrepancy. First of all there might be a difference in the methodology 
measuring TNF-a [22]. For example Propst et aJ. [6] used an enzyme amplified 
immunoassay (EASIA) which might detect lower levels of TNF-a than the assay we 
used. Zeni et aJ. [7] used a competitive inhibition radioimmunoassay with the use of 
coated monoclonal antibodies to TNF-a, fixed to the inner plastic surface of the tubes. 
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Also Deviere et al. [8] made use of an immunoradiometric assay to measure TNF-a. 
Another explanation for the undetectable levels ofTNF-a levels might be sought in the 
presence of high concentration of soluble TNF receptors in ascites, which might be a 
potential source of interference for immunoassays [23,24]. Van Zee et al. [25] found 
a reduction of TNF-a immunoactivity, as determined by ELISA, when soluble type 
I and type II TNF-a receptors were added to plasma. The same might be applicable 
for IL-l receptor antagonists. The low concentration of IL-l in ascites, even during 
periods of acute bacterial inflammation, was also confirmed in other studies [6,7]. 
Plasma IL-6 levels correlated with the severity of the underlying liver disease, 
indicated by the Child-Pugh score, but not with the etiology of the cirrhosis. This stage 
dependency suggests that porto-systemic shunting or impaired hepatic clearance may 
also contribute to the sustained elevation of endogenous cytokines. Bacterial 
lipopolysaccharide-induced macrophage stimulation due to prolonged endotoxaemia in 
patients with chronic liver disease could be responsible for activation of the cytokine 
cascade. A correlation between serum Ig A levels and IL-6 concentration has been 
described before [26] and seems to represent increased B cell maturation directly 
caused by IL-6. Why this correlation has repeatedly been found only for Ig A levels 
and not for Ig M and Ig G levels is not entirely clear. It might be that B-cells 
producing immunoglobulin Ig A are simply more responsive to the stimulatory effect 
of IL-6. In our findings there is no evidence that this effect was restricted to patients 
with alcoholic liver disease. 
What is the potential pathogenetic role of the cytokine imbalance in patients with 
cirrhosis? 
Although locally produced IL-6 might provide stimulatory signals for the hepatocytes, 
resulting in liver regeneration, excess of cytokines could lead to tissue damage and 
fibrosis [27]. 
Prolonged increased levels of IL-6 and TNF-a after septicaemia have been found in 
cirrhotics and there is some evidence suggesting that increased cytokine levels makes 
the host more susceptable to endotoxaemia [13]. This may be related to the poor 
prognosis of infectious complications during cirrhosis [14]. Furthermore, it does seem 
possible that the very high concentrations of IL-6 locally produced within the 
peritoneal cavity during bacterial peritonitis, is contributing to the decompensation of 
liver disease often found in patients with SBP. 
Finally, we found evidence for high IL-6 production in the ascites in patients with and 
without cirrhosis. Plasma IL-6 levels in patients with cirrhosis are stage-dependant but 
do not correlate with the etiology. Due to the broad scatter of values in plasma as well 
in ascitic fluid, IL-6 can not be used to differentiate between different etiologies of 
ascites in the individual patient. The exact effects of IL-6, whether beneficial or 
harmful to the patient are at present not well understood, therefore it is too early to 
speculate on the therapeutic use of IL-6 antagonists, for example in patients with 
recurrent bacterial infection of the ascitic fluid. 
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Chapter 10 General discussion 
Inflammatory mediators are involved in allergy and acute and chronic inflammatory 
diseases. To treat these type of diseases, the specific role of the inflammatory cells and 
their mediators should be understood. Human peritoneal macrophages (Mq,) obtained 
from ascitic fluid could be used as a human in vitro Mq, model. Our human in vitro 
Mq, model could contribute to understanding the mechanism of human inflammatory 
diseases and the search for therapeutic agents which act as specific inhibitors or 
neutralizers of inflammatory mediators, and thus finally diminish the whole 
inflammatory process. 
To understand the mechanism of human inflammatory diseases care should be taken 
with when using only animal models. When in vitro studies are done, preferably 
human in vitro models should be used. As our studies show, the profile of the 
eicosanoid production of human peritoneal Mq, was not similar to the eicosanoid 
profiles of Mq, from other species. The interactions between the eicosanoids and 
cytokines of human peritoneal Mq, were also different compared with to the 
interactions of eicosanoids and cytokines of Mq, from other species. 
Eicosanoid and cytokine production of human peritoneal Mq,: We measured the 
exogenous eicosanoid profile of the human peritoneal Mq, by high performance liquid 
chromatography (HPLC). These Mq, mainly produced the 5-lipoxygenase products 
leukotriene B, (LTB4) and 5-hydroxy eicosatetraenoic acid (5-HETE) when stimulated 
with calcium ionophore A23187. The levels of the cyclooxygenase products were low 
and did not significantly increase with A23187. Lipopolysaccharide (LPS) did not 
influence the endogenous eicosanoid production at all. 
Our study with rat peritoneal Mq, shows that Mq, produce only cyc100xygenase 
products (Chapter 3). It is not easy to compare the results of human peritoneal Mq, 
with Mq, of different origin and lor species characterized by other groups, as only a 
few eicosanoids are measured per experiment. An overview is given in Table 2.6 in 
the Introduction (Chapter 2). This table shows clearly that human peritoneal Mq" 
isolated from a chronic inflammation site (ascites), differs from resident and activated 
rat and murine Mq" isolated from different locations and stimulated with different 
stimuli. Peritoneal rat Mq, mainly produce cyclooxygenase products. Murine peritoneal 
Mq, produce, besides cyclooxygenase products, also LTC, when stimulated with 
A23187. 
The eicosanoid profile of normal alveolar Mq, and peritoneal Mq, isolated from 
continuous ambulatory peritoneal dyalisis (CAPD) patients with peritonitis stimulated 
with A23187, was very similar to our human peritoneal Mq, isolated from ascitic fluid. 
There were not enough data available on the eicosanoid production of human alveolar 
Mq, activated in vivo and of resident peritoneal Mq, isolated from CAPD patients, to 
make a good comparison with our human peritoneal Mq,. 
The production of the pro-inflammatory cytokines interleukin IJl (IL-IJl), IL-6 and 
tumor necrosis factor O! (TNF-O!) from human peritoneal Mq, is similar to the profile 
of Mq, of other origin and species stimulated with LPS [1-9]. The cytokine production 
increased with increasing LPS concentration and the production level of IL-I Jl and IL-·6 
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reached a plateau around 24 hours. TNF-a always peaked before IL-lB and IL-6. Only 
the TNF-a production from Mq, of other species always peaked at an earlier time than 
the TNF-a production from the human peritoneal Mq, [1,6,ID,II]. 
Eicosanoid and cytokine interaction of human peritoneal Mq,: To understand the 
mechanism of human inflammatory diseases, it should be known how inflammatory 
cells regulate their own and each other's eicosanoid and cytokine production in vivo. 
As a contribution to unravel this complexity, we characterized in vitro the interactions 
between the eicosanoids LTB4 and prostaglandin E, (PGE,) and the cytokines IL-IJl, 
IL-6 and TNF-a of human peritoneal Mq" by the addition and inhibition of several 
eicosanoids and cytokines. 
Human peritoneal Mq, have a positive interaction between IL-IJl and LTB4 , a negative 
interaction between IL-IJl and PGE, and no significant interaction between IL-lJl and 
IL-6. These last two results are in contrast with cells of other species origin and/or 
tissue origin in which IL-IJl stimulated the LTB4, PGE, and IL-6 production [12-16]. 
In human peritoneal Mq, the leukotrienes are not involved in the regulation of IL-IJl 
and IL-6. With dual inhibitors it was reported that leukotrienes are involved in IL-I 
production [17,18]; however, with specific inhibitors similar results as ours were 
obtained for IL-I with activated murine peritoneal Mq, and human peripheral blood 
monocytes of healthy donors were found [19,20]. In our study, when LTB4 was 
selectively inhibited PGE, also decreased. With increasing LTB4 , the PGE, levels did 
not change. 
Increasing PGE, down-regulated the TNF-a production. This has been reported before, 
but only in different animal models. In contrast to Mq, of other species with decreasing 
PGE, no significants effect on the TNF-a production of human peritoneal Mq, were 
seen [21,22]. 
This study shows that the cytokines and eicosanoids influence each other's production 
differently than in Mq, of other species. This could have consequences when 
therapeutics are being developed, which specifically inhibit or neutralize inflammatory 
mediators in disease. They could have different effects in in vitro and in vivo studies 
using inflammatory cells of other species. 
10.1 The human peritoneal macrophage in vitro model 
Decreasing the activity of the pro-inflammatory mediators in disease and achieving 
improvement of these diseases could be done by using different strategies. 
Inflammatory diseases are now treated by drugs which inhibit the mediators non-
selectively: The most important and effective drugs are the glucocorticoids and the 
non-steroidal anti-inflammatory drugs (NSAID). More specific inhibitors and 
neutralizers are in the development stage. 
As Mq, have a central and essential role in the initiation and maintenance of many 
immunologic and inflammatory processes, the effects of specific inhibitors or 
neutralizers can be first tested on Mq" following our human in vitro Mq, model. 
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Our experiments in which the eicosanoid and cytokine pattern of the human peritoneal 
M.p was characterized and the experiments in which the interactions of human 
peritoneal M.p with several eicosanoids and cytokines was studied, have shown that the 
eicosanoid and cytokine production and the interactions of these mediators of human 
peritoneal M.p differ from M.p of other species. Therefore, to study the effects of 
selective inhibitors and neutralizers in vitro On human cells, the usefulness of these 
compounds in vivo will be more predictable and probably lead to a better 
understanding of their mechanisms. 
There are several options for selective inhibition or neutralization of the mediators 
involved in inflammatory diseases: 
(1) Selective inhibition of the leukotrienes with specific 5-Jipoxygenase inhibitors, 
(2) lncreasement of the levels of anti-inflammatory cytokines which inhibit the pro-
inflammatory mediators of the M.p, 
(3) Neutralization of the pro-inflammatory mediators with specific antibodies or 
soluble cytokine receptors against these mediators, 
(4) Receptor blockade of the inflammatory mediators with receptor antibodies or 
receptor antagonists against the receptors of these inflammatory mediators, 
(5) Inhibition of the influx of leucocytes through blocking the adhesion molecules 
on the inflammatory cells and endothelial cells with antibodies. Consequently 
M.p and other inflammatory cells will not migrate through the vessel wall to the 
site of inflammation. 
(6) A combination of different therapies as mentioned above, may lead to a 
synergistic effect. 
The search for specific inhibitors or neutralizers of mediators involved in the 
inflammatory process is still in the elementary stage. Testing has started in several 
animal models and a few clinical trials have been done. Several of these options as 
mentioned above (1-4,6) can be tested in our in vitro model. 
The following section firstly presents a description of several inflammatory diseases 
(asthma, inflammatory bowel disease (IBD) and septic shock) in which M.p and their 
inflammatory mediators have a significant contribution. Then the mechanism of action 
of several drugs which are available for clinical use will be described. Thereafter, a 
description is given of selective inhibitors and neutralizers of inflammatory mediators 
which are currently under investigation, together with a discussion on the use of 
peritoneal M.p. 
10.2 MqI and their inflammatory mediators in diseases 
Asthma: Asthma is a disorder characterized by varying degrees of reversible airway 
obstruction in association with exaggerated airway responsiveness to a wide variety of 
physical and pharmacological agents. Until recently, asthma has been thought of as 
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solely an immunological disorder involving the release of brancho-active mediators 
from mast cells that are triggered by antigen via immunoglobulin E-dependent 
mechanisms. However, allergen mediated bronchospasm is not the fundamental feature 
present in all asthmatics, and is not the basic pathophysiological alteration present in 
all asthmatic diseases. 
It is now widely accepted that asthma is a chronic inflammatory disease. Superimposed 
on this chronic inflammatory state are acute inflammatory episodes, that correspond 
to exacerbations of asthma [23-25]. 
Many different inflammatory cells and their mediators are involved in asthma. Mast 
cells have an important role in initiating the acute responses to allergen and other 
stimuli (exercise, hyperventilation, fog); eosinophils and T-Iymphocytes are more 
important in the chronic inflammatory response. M¢ are probably important in both 
phases. The M¢ are the major cells in the airway lumen, and in broncho-alveolar 
lavages and in biopsies it is found that their number has markedly increased in 
asthmatic patients. Following antigen challenge in vivo they become activated 
(morphological changes) and in vitro it has been shown that they are able to respond 
to antigen by releasing chemo-attractants and pro-inflammatory mediators. 
Mediators such as histamine (derived mast cells), prostaglandins and leukotrienes 
(released from M¢ and mast cells) are important in the acute and subacute 
inflammatory response. They contract airway smooth muscle, increase airway 
hyperresponsiveness, increase microvascular leakage, increase airway mucus secretion 
and attraction of other inflammatory cells. Cytokines playa dominant role in chronic 
inflammation. IL-3, IL-4 and IL-5 secreted by T-Iymphocytes are important for mast 
cells (survival), B-cells (production of Ig E) and eosinophils (differentiation, survival 
and priming), respectively, respectively. Cytokines as IL-l, IL-6 and TNF-a produced 
by the M¢, in combination with the cellular cooperation of the M¢ with the other 
inflammatory cells (e.g. T-Iymphocytes, eosinophils) and endothelial cells, are 
important in the amplification of the inflammatory response [23-31]. 
Inflammatory bowel disease IIBD): This disease encompasses at least two forms of 
intestinal inflammation: ulcerative colitis (UC) and Crahn's disease (CD). The causes 
of these bowel diseases are unknown. They are defined empirically by their typical 
clinical, pathological, radiological, endoscopic and laboratory features. 
The pathogenesis ofIBD can be divided into two stages. The first is the initiating event 
which triggers the inflammatory response, but this event remains unknown. The second 
is the amplification of the inflammatory response which involves the inflammatory 
cells, including M¢, neutrophils, lymphocytes and mast cells [32]. 
It is known that in IBD, the production of pro-inflammatory cytokines as IL-J, IL-8 
and TNF-a, which can be produced by M¢, are increased [33-35]. Also several 
eicosanoid products (IS-HETE, hydroxy-heptadecatrieoic acid (HHT), thromboxane 
(TXB,), PG~ and LTB4), which can be produced by M¢, are present in increased 
amounts in association with IBD [36-38]. Oxygen free radicals generated by 
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neutrophils and MqI may also have a role in tissue injury [32]. 
The incidence of UC is inversely associated with smoking. and clinical relapses have 
been associated with cessation of smoking. Conversely, CD has been directly 
associated with smoking [39,40]. The correlation between smoking and CD could be 
a direct effect of nicotine on the MqI. In CD predominantly MqI and lymphocytes are 
infiltrated, while in UC the lamina propria is densely infiltrated by neutrophils [32]. 
In our human in vitro MqI model we observed that nicotine enhances the IL-6 
production of in vitro LPS stimulated MqI (personal observation). Smoking could 
increase locally the IL-6 levels in patients with CD by affecting the MqI present in the 
lamina propria; however, further investigations have to be performed to clarify the 
mechanism of action. 
Septic shock Circulatory shock from gram negative bacterial sepsis, produces a 
spectrum of pathophysiological alterations including cardiopulmonary, renal, 
haematologic and metabolic dysfunction leading to vascular collapse. 
Many mediators of the pathogenesis of sepsis have been described, e.g. TNF-a, IL-I, 
IL-6, and Iipoxygenase products [41,42]. All these mediators could be products derived 
from MqI, because LPS, the major component of the outermost membrane of gram-
negative bacteria, is a potent stimulus for MqI (see section 2.6). 
A central mediator of sepsis is not known yet, although IL-l and TNF-a have been 
commonly proposed for this role; however, these levels are not in all patients high. 
This is most probably due to differences in the release of endotoxin, local mediator 
production by MqI and the immunological status of the patient. Different methods of 
measurement may also influence the resuIts [43]. 
Usually, the mediators are measured in the blood plasma of the patients. In our study, 
patients with SBP who have a high risk to develop a septic shock had very high levels 
of IL-6 in their ascitic fluid, although the IL-6 levels were much lower in the blood 
(Chapter 8). 
Epithelial damage in sepsis probably results from persistent and repennve 
inflammatory insults, probably locally initiated and controlled by the MqI. These insults 
produce sufficient damage that, down regulation (e.g. cytokine inhibition by PG~, T-
cell inhibition by MqI) of the inflammatory reaction can no longer occur; this may lead 
to a state of metabolic anarchy in which the body can no longer control its own 
inflammatory response [41,44]. 
10.3 Therapy: strategies and application in diseases 
to.3.1.1 Glucocorticosteroids 
Glucocorticosteroids [GCs, e.g. hydrocortisone (cortisol) and cortisone] are hormones 
123 
Chapter 10 
which are synthesized and released by the adrenal cortex when they are needed. 
Synthetic compounds are also available, e.g. Prednisolone (prednisone), 
Methylprednisolone, betamethasone and dexamethasone. 
When given therapeutically, GCs have powerful anti-inflammatory and 
immunosuppressive effects. They inhibit both the early and late manifestations of 
inflammation by reduction of the blood supply, the accumulation of leucocytes at the 
site of inflammation, and by directly effecting Mq, and other inflammatory cells [45]. 
GCs directly affect Mq, by decreasing the function and production of their 
inflammatory mediators [26]. The production of pro-inflammatory cytokines as IL-l, 
IL-6, IL-8 and TNF-a [46], and also IL-4, a cytokine which has inhibitory effects on 
Mq, [(e.g. IL-Ia, TNF-a and PGE, production), 47], are inhibited [48]. GCs also 
inhibit eicosanoid production. It was first thought that GCs inhibit eicosanoids through 
the upregulation of lipocortin I - a calcium and phospholipid binding protein which 
inhibits the activity and synthesis of PLA2 [49]. Recently it has been suggested that 
lipocortin I has a key function in the GCs regulation of inflammatory and immune 
responses, not only by inhibiting the eicosanoid production, but also through other 
mechanisms. It seems that though lipocortin I has no signal sequence for secretion, the 
protein can be secreted by cells and there are receptors forlipocortin I on phagocytes. 
These receptors influence the inflammatory action of the cells by mechanisms 
independent of inhibition of PLA2 activity. Lipocortin I has also, for example, 
inhibitory effects on cytokine induced cell migration and release of reactive induced 
oxygen species. Besides anti-inflammatory effects, lipocortin I also protects the brain 
against damage and has selective effects on the release and actions of several neuro-
endocrine factors. It is possible that, besides lipocortin I, there are other mechanisms 
through which the GCs control the inflammatory and immune response, that will be 
revealed in the future [50,51]. 
In clinical use GCs are used for anti-inflammatory therapy or immunosuppression, for 
example: 
In asthma GCs are the most effective treatment to decrease the number of 
inflammatory cells and the release of inflammatory mediators; they also reduce 
the microvascular permeability and mucus secretion [26,52]. 
In lED GCs are effective for the treatment of mild to severe UC or CD [32]. 
In patients with septic shock GCs did not reduce the mortality [53,54], while 
in animal models they were effective [55,56]. This could be due to the time of 
administration, in animals GCs were administered before LPS, and the balance 
between the toxic effects of the inflammatory mediators and the protective 
actions of these mediators against the infection [46]. 
GCs are usually very effective in the therapy of cytokine and eicosanoid mediated 
pathologies; however, their use is limited, as GCs probably inhibit the synthesis of all 
cytokines and eicosanoids. This leads to a considerable risk of side effects and 
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potential complications when prolonged systemic use is needed [45]. 
10.3.2 Non-steroidal-anti-inl1ammatory drugs 
Non-steroidal-anti-inflammatory drugs (NSAIDs) are divided into different chemical 
classes: salicylic acids (e.g. aspirin), propionic acids (e.g. ibuprofen), acetic acids (e.g. 
indometacin), fenamates, oxicams and pyrazolones. They are anti-inflammatory, have 
anti-analgesic effects and anti-pyretic effects by primarily effecting cyclo-oxygenase 
in the eicosanoid pathway, thus inhibiting the prostanoids [45]. 
By decreasing the generation of PGE, and PGI2 , NSAIDs will reduce in particular the 
vasodilation and erythema. However, not all the anti-inflammatory power appears to 
stem from prostaglandin inhibition, NSAIDs also have the ability to disrupt interactions 
within the cell membranes, in particular signals which are transduced through the G-
proteins e.g. cell-cell adhesion of neutrophils to the blood vessel walls and de-
activation of neutrophils [(e.g. superoxide anion production), 57]. 
Clinical side effects of NSAIDs when used in the long term are stomach irritation, 
gastrointestinal bleeding and ulceration [(prostaglandins are needed to regulate acid 
over production and to synthesize the mucus barrier that prevents its self-digestion), 
58,59]. 
The two isoforms of cyclooxygenase (COX), COX-I and COX-2, are both sensitive 
for NSAIDs, but there are clear pharmacological differences. Recent studies on 
cyclooxygenase (COX-l and COX-2) support the hypothesis that the side effects of 
NSAIDs correlate with their ability to inhibit COX-l (the regulator of normal kidney 
and gastric functions and vascular homeostasis), while the anti-inflammatory 
(therapeutic) effects of these agents are due to their ability to inhibit COX-2 [(pro-
inflammatory functions), 60-63]. 
For example, aspirin and indomethacin are strong inhibitors of COX-I (at anti-
inflammatory dose IC,o COX-I :IC,o COX-2 = 166 and 60 respectively). They are also 
the two NSAIDs that cause the most gastric damage. The NSAIDs diclofenac and 
naproxen inhibit COX-l and COX-2 almost equally (ratio IC,o COX-I:IC,o COX-2 = 
0.7 and 0.6 respevtively). At anti-inflammatory doses they are less ulcerogenic than 
aspirin or indomethacin. BF 389 (ratio IC,o COX-l:IC,o COX-2 = 0.2) and NS 398 
(IC,o COX-2 < 30 nM, no IC,o for COX-I) two experimental drugs, are potent and 
selective COX-2 inhibitors and have little or no gastric ulcerogenicity. 
The development of selective COX-2 inhibitors will probably lead to anti-inflammatory 
drugs without side effects which are associated with the inhibition of COX-I [60-62]. 
The GCs block the synthesis of COX-2 but not of COX-I [63]. 
Blocking of cyclooxygenase diverts arachidonic from PGE, to the lipoxygenase 
products LTB, in the gastric mucosal, this may also contribute to mucosal injury [64]. 
However, BW755C, a dual COX (ratio IC,o COX-I:IC,o COX-I = ± I) and 5-
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lipoxygenase inhibitor, is an experimental anti-inflammatory agent with little or no 
ulcerogenic activity. This is probably due to less inhibition of COX-I at anti-
inflammatory concentrations (as hypothized above) and less production of LTB4 [60]. 
Possibly in vivo with decreasing PGE" TNF-a increases. In our experiments (Chapter 
7) we have shown that in vitro exogenous PGE, can down-regulate the TNF-a 
production of human peritoneal M¢ and there was a trend of increasing TNF-a with 
decreasing PGE,. This increasing TNF-a could also be a source of the side effects 
caused by NSAIDs. 
10.3.3 Neutralization of the effects of pro-inflammatory mediators 
By direct interference with the effects of the key cytokines which sustain the 
inflammation, therapeutic intervention can probably be achieved. The interaction 
between M¢ and the other inflammatory cells will be disturbed (less activation) and 
less pro-inflammatory mediators will then be produced, leading to a decreased influx 
of M¢ and less activation of the M¢ present locally at the inflammation site. This will 
then lead to a decrease of physiological responses. Cytokines and other inflammatory 
mediators which are anti-inflammatory orland have a positive effect on the homeostasis 
will then probably not recover or be disturbed. 
10.3.3.1 5-lipoxygenase inhibitors 
Drugs which only block the 5-lipoxygenase production, also have therapeutic potential. 
The leukotrienes have marked effects on neutrophils and other inflammatory cells. By 
blocking the local 5-lipoxygenase production, less neutrophils and monocytes/M¢ will 
migrate to the site of inflammation and the inflammatory cells will also be less 
activated at the site of inflammation, releasing less inflammatory products. This has 
been shown in different animal models and clinical trials. For example: 
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Asthma: We have shown in vitro that E6080 inhibits specific LTB4 production 
(Chapter 6). Tsunoda et al. have shown that in antigen sensitized guinea pigs, 
E6080 dose dependently inhibited bronchospasm, inhibition of leucocyte 
infiltration and decreased bronchoepithelial damage [65]. In clinical trials, 
specific 5-lipoxygenase inhibitors tended to reduce the symptoms [66,67]. 
Ulcerative colitis: Zileuton, a 5-lipoxygenase inhibitor, has proven effective in 
an experimental model of colitis, showing that leukotrienes play an important 
role in the pathogenesis of IBD [68]. 
Selective 5-lipoxygenase inhibitors have a potential effectiveness in the 
management of UC [28] by decreasing LTB4 in rectal dialysis of patients with 
active UC [36]. 
Septic shock: Selective 5-lipoxygenase inhibitors are able to protect against 
shock. In rat studies it was demonstrated that the initial hypotension induced by 
endotoxin was attenuated by a 5-lipoxygenase inhibitor, probably by directly 
effecting the LTs. Sulfopeptide LTs are potent vasoconstrictors, they probably 
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affect systemic pressure by directly increasing vasculator permeability. Plasma 
immunoreactive 6kPGFIa which was increased in the later phase of endotoxic 
shock was reduced with a 5-lipoxygenase inhibitor, probably by blocking LTC, 
and LTD4 which stimulate prostacyclin synthesis and release from endothelial 
cells [42]. 
The effectiveness of new and existing 5-lipoxygenase inhibitors can be tested in our 
in vitro model, as we have shown with E60S0. The usefulness of these specific 5-
lipoxygenase inhibitors in vivo will then be mOre predictable. 
10.3.3.2 Anti-inflammatory cytokines 
The effects of the pro-inflammatory cytokines can be inhibited by application of the 
proper anti-inflammatory cytokine(s), the inflammatory reaction may then down-
regulated. IL-4, IL-IO and IL-13 suppresses cytotoxic and inflammatory functions of 
Mq,. 
IL-4 has so far only been tried in patients with cancer. Recombinant human IL-
4 had anticancer effects in animal models; however, when tried in patients with 
renal cancer or melanoma, it did not produce meaningful activity [69]. 
Besides Mq" intestinal epithelial cells are also a source of IL-S. In inflammatory IBD 
the source ofIL-S is not yet clear. From studies on epithelial cell lines it became clear 
that IL-4 and IL-IO could not down-regulate the IL-S production. This difference in 
regulation should be taken into account when down-regulation of the IL-8 production 
with 'suppressive' cytokines is warranted [70]. 
Our in vitro model will be very useful to test the effects of anti-inflammatory cytokines 
on the eicosanoid and cytokine production. As we have shown in Chapter 7, there are 
similarities but also differences between eicosanoids and cytokines in comparison to 
Mq, of other species. By studying the effects of natural occurring cytokine inhibitors 
on human Mq" their effect in vivo will be more predictable. Not only will pro-
inflammatory cytokines be influenced, but most probably also several eicosanoids, as 
the cytokines influence the eicosanoid production. 
10.3.3.3 Cytokine antibodies and soluble cytokine receptors 
Inflammatory mediators can be neutralized with specific antibodies or with soluble 
cytokine receptors. 
For example, IL-6 has also pro-inflammatory effects in rheumatoid arthritis. 
Anti-IL-6 monoclonal antibodies resulted in clinical and biological improvement 
of patients with severe rheumatoid arthritis. Further studies are required to 
evaluate the real benefit and the mode of action of this monoclonal antibody 
[71]. 
127 
Chapter 10 
With the measurement of M.p products in the ascitic fluid and plasma of patients with 
ascites due to different etiology, we have shown that IL-6 is very high in patients with 
spontaneous bacterial peritonitis (SBP; Chapters 8 and 9). IL-6 could be used to 
I1jonitor disease activity in patients with SBP. Local treatment with antibodies against 
IL-6, may reduce the risk for the development of septic shock. 
Naturally occurring soluble receptors have been found for a variety of cytokines. These 
soluble cytokine receptors bind to their respective cytokines. The in vivo function of 
soluble receptors is not yet known. When there are soluble cytokines presents, the 
cytokines may bind to the soluble receptors and possibly not to their specific receptors 
on the target cells. In vitro it has been shown that soluble receptors can block cell 
activation [72,73]. 
However, it is also possible that the soluble cytokine receptors (and also the 
autoantibodies) transport the cytokine through the circulation and present it to the cell 
surface receptors and the target cells. The activity of the cytokine is then enhanced as 
it is protected from proteolysis and these soluble receptors act then as a reservoir of 
active or potentially active factors. Enhancing activities have been demonstrated for 
the soluble IL-6 receptor [74]. 
Our in vitro model will be useful to test the effect of inhibiting the effect of IL-l with 
IL-I receptor antagonist (IL-lra). As we have shown in Chapter 7, IL-l increases 
LTB, production and decreases PGE:, production. 
10.3,3.4 Receptor antibodies and receptor antagonists 
Blockade of the receptors to which the inflammatory mediators bind with receptor 
antibodies or receptor antagonists is another possibility. In vivo in a mouse model, it 
was shown that IL-I induced catabolic host changes, associated with inflammation, 
could be blocked with monoclonal antibodies directed against the IL-I receptor [75]. 
IL-lra is a naturally occurring antagonist, so far the only one known, blocking the 
binding of IL-Ia and IL-IB to the IL-I receptor [76]. 
In a rabbit model with immune-mediated bowel inflammation IL-I-ra was a 
potent anti-inflammatory cytokine, preventing acute colitis and the appearance 
of chronic inflammation [77,78]. 
Administration of IL-I ra, after inducing a bacterial sepsis in animals (rats and 
rabbits), also showed significant improvement and survival [79,80] . 
. In an open-label trial in patients with sepsis syndrome or shock, IL-lra 
(continuous infusion) seemed in the initial evaluation to be safe and to provide 
a dose-related survival. Plasma IL-6 was also dose-dependently decreased [81]. 
Our in vitro model will be useful to test the effect of inhibiting the effect of IL-I with 
IL-lra. As we have shown in Chapter 7, IL-I increases LTB, production and decreases 
PGE:, production. 
128 
General discussion 
10.3.3.5 Cellular adhesion molecules antibodies 
Cellular adhesion molecules have an important role in the migration of leucocytes to 
the site of inflammation (see paragraph 2.3). Inhibiting the infiltration of leucocytes 
with specific monoclonal antibodies will have therapeutical potential in acute 
inflammatory events, chronic inflammation and malignancy. This has been shown in 
experimental models of human diseases e.g. Colitis [82] and allergic asthma [83]. 
10.3.3.6 Combinations 
A combination of different therapies mentioned above may have a synergistic effect, 
as the production of inflammatory mediators is a result of a variety of cells which are 
activated by interacting with each other and their mediators. Understanding which 
inflammatory cells and mediators are crucial for the induction of the allergic response 
or inflammation is of prime importance, followed by knowledge on which cells and 
mediators enhance the inflammation. Subsequently a variety of combinations may be 
possible. 
It was shown, for example, that LTD, and PAF receptor antagonists, synergistically 
decrease the antigen-induced airway microvascular leakage in an animal model [84]. 
In asthma and in IBD the possibilities are the blocking of the cell infiltration 
(antibodies to cellular adhesion molecules or inhibition of the chemoattractants, e.g. 
anti-IL-8 monclonal antibody or specific inhibition ofLTB,) combined with antibodies 
or soluble receptors or anti-inflammatory cytokines, decreasing the pro-inflammatory 
cytokines. 
As suggested by Fischer et aI., in patients with septic shock anti-cytokine therapy in 
combination with standard anti-microbial agents in patients with bacterial sepsis may 
be an effective strategy [85]. 
A variety of combinations are possible for inflammatory diseases. Our in vitro Mq, 
model will be of use to study which combination of specific inhibitor(s) and/or 
neutralizers will have a synergistic effect in reducing the inflammatory production by 
Mq,. This could be done in combination with other human cells with which the Mq, 
and their mediators interact during the inflammatory response. This work could then 
contribute to the understanding of the mechanism of human inflammatory diseases and 
help in finding therapeutic agents which act as specific inhibitors and/or neutralizers 
of inflammatory mediators, and will finally abolish the whole inflammatory process. 
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Chapter 11 Summary 
Ascitic fluid is a readily available source of human peritoneal macrophages (hp-Mq,). 
Characterization of the production profile of purified human Mq, in vitro will be 
helpful for our understanding of inflammatory diseases and their treatment. These Mq, 
can then be used as a human in vitro model to characterize the interactions of anti-
inflammatory drugs with Mq,. Mq, are very important in inflammatory diseases, as 
through their receptors and secretory products, they have a central and essential role 
in the initiation and maintenance of immunological and inflammatory processes. 
Chapter 3: Using the carrageenin-induced peritonitis rat model, we have shown that 
in vitro cytokine and eicosanoid production during an episode of inflammation is 
mainly due to the presence of Mq,. The inflammatory mediator production capacity of 
Mq, was dependent on the phase of the peritonitis. The eicosanoid and cytokine 
production in vitro was very low on the first day after inducing the peritonitis (the 
acute phase), then it steadily increased, showing a differentiated pattern in the chronic 
phase. The synthesis pattern of the inflammatory mediators of peripheral blood 
monocytes had completely changed in comparison to monocytes which had migrated 
into the inflamed peritoneum and transformed into peritoneal Mq,. In vivo priming of 
the Mq, leads to a change and a higher eicosanoid and cytokine production capacity of 
the Mq, in vitro. 
Chapter 4: Using hp-Mq" we have shown that the eicosanoid production depended on 
the maturity of the Mq,. Density-defined hp-Mq, showed morphological and 
biochemical heterogeneity. The least mature Mq" the small round Mq" synthesized the 
least eicosanoids. The more mature Mq" the Mq, with more cytoplasm, had a higher 
level of eicosanoid production. Mq, which are more mature, are probably more 
activated in vivo and this activation leads to a higher eicosanoid production capacity 
in vitro. 
Chapter 5: The hp-Mq, were obtained from ascites of patients of varying etiology, 
mainly liver cirrhosis. This is a sterile chronic inflammation site. Lipopolysaccharide 
(LPS) stimulation in vitro resulted in similar production pattern of the pro-
inflammatory cytokines as the LPS stimulated Mq, of other origin and species. 
However, the profile of the eicosanoid production of hp-Mq, stimulated in vitro with 
calcium ionophore A23l87 and LPS differed from A23187 and LPS stimulated Mq, of 
other origin and species. The main eicosanoids produced by the hp-Mq, when 
stimulated in vitro with A23187, were the 5-lipoxygenase products LTB4 and 5-HETE. 
The increase of the cyc100xygenase products was not significant. LPS did not influence 
the eicosanoid production. The production of the pro-inflammatory cytokines 
interleukin III (IL-lll), IL-6 and tumor necrosis factor a (TNF-a) was LPS 
concentration dependent and also depended on the time of exposure to the stimulus. 
The oxygen radical production in these hp-Mq, was measured by a flow cytometric 
method. The production increased significantly, when the hp-Mq, were stimulated with 
phorbol 12-myristate 13-acetate (TPA). 
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Chapters 6 and 7: The interactions between the eicosanoids LTB4 and PG~ and the 
cytokines IL-IB, IL-6 and TNF-O' of hp-M¢, were characterized by the addition and 
inhibition of several of these mediators. The cytokines and eicosanoids influenced each 
O,ther's production. There was a positive interaction between IL-IB and L TB" a 
negative interaction between IL-IB and prostaglandin (PG~) and no significant 
interaction between IL-IB and IL-6. When the LTB4 production was inhibited with the 
specific 5-lipoxygenase inhibitor E6080, the PG~ production decreased. Increasing 
LTB, had no effect on PG~. Increasing PG~ down-regulated the TNF-O' production. 
As we expected, because the profile of eicosanoid production of hp-M¢ was not 
similar to the profiles of M¢ from other origin or species, the profile of interactions 
between the eicosanoids and cytokines of hp-M¢ was partly different compared with 
the profile of eicosanoid and cytokine interactions of M¢ from other origin and 
species. These differences in eicosanoid and cytokine production and interactions 
profiles establish that when mediators in human inflammatory diseases are to be 
studied, care should be taken with animal models. When in vitro studies are done, 
preferably human in vitro models should be used. 
Chapters 8 and 9: M¢ are usually the main inflammatory cells present in ascites of 
patients due to all causes. Corresponding to the pattern of mediators produced by M¢, 
which depends on the stage of activation of the M¢ and the stimulus applied, the 
pattern of the soluble intercellular adhesion molecule 1 (sICAM-I) concentration and 
the eicosanoid LTB, and PG~ concentration, measured directly in ascitic fluid of 
patients, also showed a specific disease related-pattern. The disease-related pattern of 
the different parameters may not be suitable for diagnostic use as the parameters of the 
three different groups (liver cirrhosis, peritoneal cancer, spontaneous bacterial 
peritonitis) overlapped. However, as sICAM-Ilevels in ascites correlated with sIC AM-
I levels in plasma and both slCAM -I and IL-6 correlated with episodes of infection, 
slCAM -I together with IL-6 seem to be parameters which could be of prognostic value 
for patients with spontaneous bacterial peritonitis (SBP). 
Chapter 10: An outline is given of common diseases; asthma, inflammatory bowel 
disease (IBD) and septic shock, in which M¢ and their inflammatory mediators (e.g. 
eicosanoids and pro-inflammatory cytokines) through a co-ordinated cellular co-
operation with other inflammatory cells are involved in the acute and chronic 
inflammation. Besides non-selective working drugs, these diseases may be treated with 
selective acting therapeutics e.g. by selective inhibition of the eicosanoid production, 
by increasing levels of anti-inflammatory cytokines, by neutralizing pro-inflammatory 
cytokines, through receptor blockade of inflammatory mediators, or a combination of 
specific inhibitors andlor neutralizers. 
As human M¢ differ from M¢ of other species, the effects of selective acting 
therapeutics in vivo will be more predictable when tested in vitro using human 
inflammatory cells. Most of these therapeutics can be widely tested to study their effect 
on a variety of mediators involved in the defence mechanism. 
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Ascites yacht is een makkelijk verkrijgbare bran voar humane peritoneale macrofagen 
(hp-Me/». Het in vitro karakteriseren van het productie profiel van humane peritoneale 
Me/> zal zeer nuttig zijn voor het begrijpen van ontstekings ziekten en hun 
behandelingen. Deze Me/> kunnen dan gebruikt worden als een humaan in vitro model 
om de interacties tussen Me/> en ontstekingsremmende geneesmiddelen te bestuderen. 
Me/> zijn zeer belangrijk in ontstekings ziekten, omdat ze door middel van hun 
receptoren en hun uitscheidings producten een centrale en essentiele rol innemen in de 
ontwikkeling en handhaving van immunologische en ontstekingsprocessen. 
Hoofdstuk 3: Gebruikmakend van een carrageenine-geinduceerde peritonitis rat model, 
hebben we laten zien dat de in vitro cytokinen en eicosanoiden productie tijdens het 
ontstekings proces voornamelijk aflcomstig waren van aanwezige Me/>. De 
productiecapaciteit van ontstekingsmediatoren door Me/> was afhankelijk van de fase 
van de peritonitis. De eicosanolden en cytokinen productie was in vitro zeer laag op 
de eerste dag na het induceren van de peritonitis (de acute fase). Daarna nam de 
productiecapaciteit van de ontstekingsmediatoren geleidelijlc toe, waarbij tijdens de 
chronische fase een gedifferentieerd patroon tot stand kwam. 
Het productieprofiel van ontstekingsmediatoren van perifere bloedmonocyten was 
volledig veranderd in vergelijking met monocyten die naar het ontstolcen peritoneum 
waren gemigreerd en tot Me/> waren getransformeerd. In vivo 'priming' van Me/> leidt 
tot verandering en een hogere productie van eicosanoiden en cytokinen door Me/> in 
vitro. 
Hoofdstuk 4: Met hp-Me/> hebben we laten zien dat de eicosanoiden productie 
afhankelijk is van de rijpheid van de Me/>. Dichtheids-gedefineerde humane peritoneale 
Me/> vertonen een morfologische en biochemische heterogeniteit. De minst rijpe Me/>, 
de smalle ronde Me/>, produceerden de minste hoeveelheid eicosanoiden. De meer 
rijpere Me/>, de Me/> met meer cytoplasma, hadden een hogere eicosanoiden productie. 
Me/> die rijper zijn, zijn waarschijnlijk in vivo meer geactiveerd en dit leidt tot een 
hogere eicosanoiden productie capaciteit in vitro. 
Hoofdstuk 5: De hp-Me/> werden verkregen uit ascites van patienten met verschillende 
oorzaken VOar deze aandoening, voornamelijk levercirrose. Ret ontstoken peritoneum 
is een steriele chronische ontstekingsplaats. Lipopolysaccharide (LPS) stimulatie in 
vitro van de hp-Me/>, resulteerde in een vergelijkbaar productiepatroon van ontstekings-
stimulerende cytokinen als de door LPS gestimuleerde Me/> die van andere oorsprong 
en species waren. Echter, het eicosanoiden productie profiel van hp-Me/> die in vitro 
met calcium ionofoor A23187 of LPS werden gestimuleerd, verschilden van met 
A23187 ofLPS gestimuleerde Me/> die van andere oorsprong en species waren. 
De voornaamste eicosanolden, geproduceerd door humane M¢ gestimuleerd in vitro 
met A23187, waren de 5-lipoxygenase producten LTB4 en 5-HETE. De netto productie 
van de cyclooxygenase producten was verwaarloosbaar klein. LPS beinvloedde de 
eicosanoIden productie niet. De productie van de ontstekings-stimulerende cytokinen 
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interleukine IB (IL-IB), IL-6 en tumor necrose factor a (TNF-a) was afuankelijk van 
de concentratie van LPS en ook afuankelijk van de incubatietijd met de stimulus. 
De zuurstof radicaal productie in deze humane peritoneale M</> werd gemeten met 
behulp van een 'flow'cytometrische methode. Wanneer de cellen met 'phorbol 12-
myristate 13 acetate' (TPA) werden gestimuleerd, nam de zuurstof radicaal productie 
van de humane peritoneale M</> significant toe. 
Hoofdstukken 6 en 7: De interacties tussen de eicosanolden LTB4 en PGE, en de 
cytokinen IL-IB, IL-6 en TNF-a van humane peritoneale M</> werden gekarakteriseerd 
door de toevoeging en remming van verschillende mediatoren. De cytokinen en 
eicosanolden be1nvloedde elkaars productie. Er was een positieve interactie tussen IL-
IB en LTB4, een negatieve interactie tussen IL-JB en PGE, en geen interactie tussen 
IL-IB en IL-6. Toen de LTB4 productie werd geremd met behulp van de specifieke 5-
lipoxygenase remmer E6080, nam de PGE, productie ook echter af. Toenemende 
toegevoegde LTB4 had geen effect op PGE, synthese. Toenemende PGE, verlaagde de 
TNF-a productie. 
Zoals we verwachtten, omdat het productie profiel van humane peritoneale M</> 
gevormde eicosanolden anders was dan dat van M</> van andere oorsprong en species, 
verschilden de interacties tussen eicosanolden en cytokinen van humane peritoneale M</> 
gedeeJtelijk van interacties tussen eicosanolden en cytokinen bij M</> van andere 
~ngInes. 
Deze verschillen in eicosanoi'den en cytokinen productie en onderlinge interacties 
bevestigen dat wanneer mediatoren in humane ontstekings ziekten worden bestudeerd, 
zeer voorzichtig met diermodellen moet worden omgegaan. Wanneer in vitro studies 
worden uitgevoerd, verdienen humane in vitro modellen uiteraard de voorkeur. 
Hoofdstukken 8 en 9: In ascites van patienten, veroorzaakt door allerlei aandoeningen, 
zijn M</> meestal de voornaamste aanwezige ontstekingscel1en. Overeenkomstig het 
profiel van mediatoren geproduceerd door M</>, dat afuankelijk is van het activatie 
stadium van de M</> en de toegediende stimulus, vertonen de in ascites gemeten 
concentraties van 'soluble intercellular adhesion molecule I' (sICAM-I) en de 
eicosanolden LTB4 en PGE" specifiek aan ziekten gerelateerde patronen. 
De aan ziekten gerelateerde patronen van de verschillende parameters is waarschijnlijk 
niet geschikt voor diagnostisch gebruik, OIndat aile parameters van de drie 
verschillende groepen, waarin de patienten waren ingedeeld (lever cirrose, peritoneale 
kanker, spontane bacteriele peritonitis (SBP)) overlap vertoonden. Echter, omdat de 
sICAM-1 niveaus in ascites correleerde met sICAM-I niveaus in plasma en zowel 
sICAM-I als IL-6 correleerde met episoden van infectie, zijn sICAM-I en IL-6 
parameters die samen mogelijk prognostische waarde kunnen hebben voor patienten 
met SBP. 
Hoofdstuk 10: In de afsluitende discussie worden als hoofdlijn een aantal veer 
voorkomende ziekten besproken zoals, asthma, darmontstekingen en septische shock, 
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waarin de Me/> en hun ontstekingsmediatoren (eicosanoiden en ontstekingsstimulerende 
cytokinen) door middel van een gecoordineerde cellulaire cooperatie met andere 
ontstekingscellen betrokken zijn bij acute en chronische ontstekings processen. Deze 
ziekten kunnen met behalve niet-selectieve ontstekingsremmende geneesmiddelen, 
waarschijnlijk ook behandeld worden met selectief werkzame therapeutica, bijvoorbeeld 
door middel van selectieve remming van de eicosanoiden productie, het toe laten 
nemen van ontstekingsremmende cytokinen, het neutraliseren van ontstekings-
stimulerende cytokinen, receptorblockade van de ontstekingsmediatoren of een 
combinatie van genoemde stoffen. 
Omdat humane Me/> verschillen van Me/> van andere species, zal het effect van selectief 
werkzame therapeutica in vivo beter voorspelbaar zijn als ze in vitro getest worden met 
gebruikmaking van humane ontstekingscellen. De meeste van deze therapeutica kunnen 
uitgebreid worden getest om hun effect te bestuderen op een verscheidenheid van 
ontstekingsmediatoren, betrokken bij het verdedigingsmechanisme. 
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